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Hypothesis
Insulin dependant diabetes is metabolic disorder associated with vascular
dysfunction. Pregnancy, when occurs in a woman with diabetes, is associated with an
increased risk of vascular complications. Maternal vascular dysfunction may alter the
feto-placental environment and be associated with aberrant placental vascular
development.
Aims
(1) To determine if pregnancy in the insulin dependant (type I) diabetic women is
associated with increased maternal vascular endothelial dysfunction.
(2) To determine if the ultrastructure of the terminal placental villus, the




Insulin dependant diabetes is metabolic disorder associated with vascular endothelial
dysfunction. Pregnancy, in a woman with diabetes, is associated with an increased
risk of maternal vascular complications, such as pre-eclampsia and progression of
microvascular disease. These vascular complications are in part mediated though
inflammatory effects on the vessel wall. Insulin dependent diabetes is also associated
with an increased risk of fetal complications including intrauterine hypoxia and
stillbirth. Maternal vascular dysfunction may alter the feto-placental environment
and be associated with aberrant placental vascular development. We therefore aimed
to determine: (1) if pregnancy in the insulin dependent (type I) diabetic woman is
associated with increased maternal endothelial dysfunction, and (2) if the
ultrastructure of the terminal placental villus, the functional exchange unit, is altered
in these pregnancies.
As an index of maternal vascular function circulating concentrations of defined
endothelial-derived cell adhesion molecules were assessed. An ELISA was used to
quantify the concentrations of these cell adhesion molecules, throughout diabetic and
control pregnancies and in matched non-pregnant women. The circulating
concentrations of the cell adhesion molecules: E-selectin and ICAM-1 were
increased in non-pregnant diabetic subjects compared to non-pregnant controls.
These cell adhesion molecules interact with neutrophils and provide evidence of
endothelial dysfunction in our population of non-pregnant diabetic women. In
contrast, during pregnancy there was no difference in the circulating concentrations
of E-selectin or ICAM-1 between diabetic and control groups. The concentration of
E-selectin was significantly reduced when measured in the pregnant compared to the
non-pregnant diabetic cohorts. Circulating concentrations of von Willebrand factor,
an established index of endothelial dysfunction, were also comparable in diabetic and
control pregnant cohorts. These findings suggest that pregnancy, in our population of
diabetic women, may actually be a time of vascular well-being. We hypothesize that
this is a reflection of the improved glycaemic control achieved by these women
during pregnancy.
The ultrastructure of the terminal placental villi from ten diabetic and control
pregnancies was assessed by three techniques: transmission electron microscopic
determination of cross-sectional architecture, scanning electron microscopy of
specially prepared placental vascular casts and immunohistochemical assessment of
villous stromal composition and cell turnover. The terminal villi of diabetic placentae
were highly comparable to those of control placentae. Specifically we demonstrated
no significant difference on comparison of villous diameter, villous capillary
diameter, cytotrophoblast or syncytiotrophoblast nuclei number, stromal matrix
content or cell turnover. However we demonstrated some small differences in (he
diabetic cases; an increased diffusion distance across the vasculosyncytial
membranes, increased thickness of the cytotrophoblast basal lamina and longer, more
branched terminal capillary loops. The lack of gross placental terminal villous
maldevelopment is likely to reflect the absence of significant maternal vascular
dysfunction in concert with the good glycaemic control demonstrated by our
iv
population of diabetic mothers. We concluded that in these glycaemically controlled
diabetic pregnancies, subtle abnormalities still exist in placental components
intimately involved in nutrient exchange. In combination these findings are not
consistent with significant placental hypoxia, indeed their significance is unclear but
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Type 1 Diabetes Mellitus is the most common medical condition complicating
pregnancy in the United Kingdom, with an incidence of 3.5 per 1000 women. In
Scotland it is estimated that approximately 235 diabetic women with type 1 diabetes
are delivered each year (SIGN publication no.9, 1996). Despite recent advances in
the medical management of diabetes and the obstetric care of pregnant diabetic
women, they and their fetuses still remain at increase risk of complications.
1.1.1 Diabetes
Diabetes is the term given to a range of disorders that have in common a failure of
normal glucose metabolism. This may occur either through a lack of pancreatic
secretion of the hormone or a lack of response (peripheral resistance) to the action of
circulating insulin. The American Diabetes Association (2000) has recently revised
an aetiological classification of diabetes. This replaces an older classification based
on treatment: insulin dependent or non-insulin dependent diabetes, which was
inadequate to describe those patients whose treatment had changed over time to
require insulin. The American classification of diabetes is summarised in table 1.1.
Women with type 1 diabetes form the subject basis of this thesis. Women with other
types of diabetes are not discussed further in detail.
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Table 1.1 Aetiologic Classification of Diabetes




Type 2 diabetes mellitus Insulin resistance with or without varying degrees
of insulin secretory deficiency.
Other specific types of
diabetes
Genetic defects of |3 cell function.
Genetic defects of insulin action.
Disease of the exocrine pancreas.
(i.e. pancreatitis, trauma, neoplasia)
Endocrinopathies.
(i.e. Acromegally, Cushing's Syndrome)
Drug or chemical induced.
Infections.
(congenital rubella, cytomegalovirus)
Unusual forms of immune-mediated diabetes.
Genetic syndromes associated with diabetes.
(i.e. Down's syndrome, Turner's syndrome)
Gestational diabetes
mellitus (GDM)
Diabetes first detected during pregnancy.
Placental hormones antagonise the effects of
insulin.
May represent subclinical type 1 or type 2 diabetes
worsened by the pregnant state.
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1.1.2 Type 1 diabetes mellitus
Type 1 diabetes mellitus is a chronic autoimmune disorder that results in the
destruction of the pancreatic beta islet cells. It is manifest by a lack of insulin
secretion and a disorder of carbohydrate, protein and fat metabolism. The classical
symptoms of the disease, thirst, weight loss and polyuria develop over several weeks
to months, whereas the asymptomatic destruction of the islet cells has occurred over
many months to years.
There is strong evidence of a cell-mediated destruction of the islet cells. T-
lymphocytes infiltrate the islets and cause an islitis. There is also a proposed humoral
attack, which may be triggered by the T-cell attack. Autoantibodies to beta cell and
islet antigens including insulin itself are present in the sera of patients at the time of
diagnosis (Verge et at 1996). Some studies suggest the autoantibodies may inhibit
insulin secretion or assist destruction of the islet cells.
The clinical incidence of diabetes is maximal in childhood with three-quarters of
those affected being diagnosed by 15 years of age. The median age at diagnosis is 12
years. It is therefore interesting that decline in insulin secretion may be demonstrated
for up to 12 years before the onset of clinical disease. At the clinical onset of the
disease less than 10% of the B islet cell mass remains (Shatz 1995).
The diagnosis of diabetes rests upon the finding of elevated plasma glucose levels.
The laboratory definition of diabetes is of a fasting venous plasma blood glucose
greater than 7.8mmol/L and/or a plasma glucose greater than 11.0 mmol/L 2 hours




Glucose metabolism is fundamental to life. Basic metabolic homeostasis requires that
the body should be able to store, produce and expend energy. Intake of carbohydrate,
fat, and protein provides sources of energy. The proportional intake of these
substances and the level of energy expenditure by the body determine whether
energy can be stored as carbohydrate or fat, and protein synthesis can occur
(anabolism), or whether energy is required to be generated from these sources
including protein degradation (catabolism).
The pancreatic hormones insulin and glucagon are the essential regulators of this
process (Gernuth 1998). Insulin is synthesised by the pancreatic islet beta cells. It is
stored in granules so that it can be released rapidly upon beta cell stimulation. Insulin
facilitates the storage of glucose as glycogen in muscle and the liver. It also
facilitates the storage of free fatty acids as triglycerides in adipose tissue, and amino
acids in protein. Glucagon stimulates the mobilisation of glucose from glycogen and
the breakdown of amino acids to form glucose and free fatty acid mobilisation and
ketogenesis to further energy resources. The normal basal levels of insulin and
glucagon maintain fasting glucose levels. After a meal insulin levels and hence
insulin/glucagon ratio rises rapidly. When all the nutrients have been assimilated the
plasma glucose returns to pre-prandial levels and the plasma insulin and
insulin/glucagon ratio promptly return to basal levels, protecting against
hypoglycaemia.
1.1.4 Acute complications of type 1 diabetes mellitus
Lack of insulin action impairs the uptake of glucose by muscle and adipose tissue.
There is also a lack of suppression of hepatic glucose output. This results in severe
hyperglycaemia (Genouth 1973). A high filtered load of glucose in the renal tubules
leads to an osmotic diuresis and dehydration. A compensatory polydypsia occurs. A
lack of insulin activity promotes lipolysis resulting in high levels of circulating free
fatty acid, which promotes their increased uptake into the liver and ketogenesis
resulting in a metabolic acidosis. Ketoacidosis is an acute life threatening
complication of diabetes. Protein breakdown occurs in muscle to sustain
gluconeogenesis. Weight loss therefore includes fat and lean body mass.
Hyperglycaemia also predisposes to infection and can cause blurred vision from lens
swelling.
1.1.5 Chronic complications of type 1 diabetes mellitus
Life span of people with type 1 diabetes is shortened by on average 10-20 years. This
is the consequence of various vascular complications, which may be subdivided into
microvascular and macrovascular pathologies. These complications are also
associated with significant morbidity. There is evidence that these complications may
arise solely due to chronic cellular exposure to hyperglycaemia, however other
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complex metabolic disturbances such as of lipid metabolism are also likely to
contribute, particularly in relation to macrovascular disease. The clinical onset of
these complications is typically seen 10-15 years after the diagnosis of the disease.
1.1.5.1 Microvascular complications
Microvascular diseases include retinopathy with potential loss of vision (Davis 1992)
and nephropathy, which can lead to end stage renal disease (Breyer 1992).
Background retinopathy is the earliest form of retinopathy and occurs in almost all
diabetic subjects with time. The initial pathology is loss of capillary pericytes, which
causes capillary dilatations termed microaneurysms. Leakage of blood from
microaneurysms is seen as dot haemorrhages on the retina and leakage of serum form
hard exudates. These lesions are seen by fundoscopy. The lesions can occur
anywhere on the retina but particularly threaten vision when they occur near the
macula. The capillaries can, with progression of disease, become obstructed causing
retinal ischaemia. Infarcted areas of the retina appear as soft (cotton wool) exudates.
Ischaemia of the retina stimulates neovascularisation. This advanced retinopathy is
termed proliferative retinopathy. In this sinister progression of the disease fragile
new vessels, growing forward into the vitreous, are poorly supported by matrix and
are at risk of rupture. The resulting haemorrhage and subsequent fibrosis, which can
cause tractional retinal detachment, can both result in blindness.
Diabetic nephropathy complicates 35-45% of patients with type 1 diabetes and is
associated with a high mortality. The vascular lesions are characterised by thickening
of the capillary basement membrane, followed by accumulation of mesangial
material throughout the glomerulus. These defects cause a reduction in glomerular
filtration rate, loss of protein through the glomerulus and hypertension.
Microalbinuria (30 - 300 mg albumin/day) may progress to clinical proteinuria (0.5g
protein/day), nephrotic syndrome and eventually end stage renal failure.
Hypertension aggravates progressive renal disease. The incidence of nephropathy
peaks after approximately 15 years of clinical diabetes (Anderson et al 1983).
1.1.5.2 Macrovascular complications
Macrovascular disease can take the form of cardiovascular, peripheral vascular
disease and cerebrovascular disease. Myocardial infarction is a major cause of death
(Gernuth 1995). The histology of the macrovascular disease is similar to the
atherosclerotic lesions seen in non-diabetic subjects. However the disease process is
seen more often and appears to be accelerated in the presence of diabetes.
Epidemiological studies indicate that diabetic subjects have a 3-8 fold increased risk
of premature cardiovascular disease (Bierman 1992).
The vascular lesions demonstrate increased endothelium basement membrane
thickness, also seen in microvascular disease. Proliferation of the basement
membrane results in numerous irregular layers of basal lamina in which lipoprotein
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derived vesicles are trapped (Simionescu 1986). The underlying extracellular matrix
is also expanded (Simionescu 1996) and smooth muscle hypertrophy occurs.
Increased fibronectin and type IV collagen accumulation reduce vascular
compliance. (Heickendorff et al 1994). In the larger vessels adherence and diapedesis
of blood monocytes occurs across the endothelium and lipid loaded macrophages
(foam cells) appear in the hyperplastic matrix. With advancement of the process
calcification occurs under the lipid laden endothelium, the endothelial layer thins and
may be disrupted, exposing the underlying atheromatous plaque, and acutely
increasing the risk of overlying thrombus formation and clinical symptoms.
1.1.6 The aetiology of type 1 diabetes mellitus
The aetiology of type 1 diabetes is yet to be fully determined, however both genetic
and environmental factors pay a role. The prevalence of type 1 insulin dependent
diabetes in the general population is 0.15%. Siblings of diabetics have a 5-15% risk
of developing the disease, and offspring of diabetics have a 4.9% risk. Concordance
in non-identical twins is 50%. This is higher in monozygotic twins but does not
reach 100% (Winter et al 1993). This suggests that it is a susceptibility to diabetes
and not diabetes itself that is inherited, and implicates an interacting aetiological role
for environmental factors.
1.1.6.1 The genetic basis of diabetes
The family studies do not support a Mendelian inheritance of type 1 diabetes, nor has
a single gene defect been implicated (Schatz 1995). It is proposed that genetic
susceptibility to type 1 diabetes is linked to several genes. As type 1 diabetes is an
autoimmune disease the genes studied first were those within the major
histocompatibilty (HLA) complex located on the short arm of chromosome 6.
Genetic association and linkage studies show siblings with diabetes share entire HLA
haplotypes (Raffel 1997). DR3 and DR4 are susceptibility alleles that appear to
operate synergistically (Schatz et al 1995). The DR2 allele decreases the risk of
diabetes and dominates the susceptibility effect of DR3 and DR4. The HLA-DQ
locus also is associated with an increased risk of diabetes. To date studies of other
chromosomes have shown that type 1 diabetes is associated with at least 15
additional loci on nine other chromosomes including one near the insulin gene on
chromosome 11 (Field et al 1997). It is estimated that the HLA region contributes
about 50% of the genetic susceptibility to type 1 diabetes, and the area on
chromosome 11 may contribute an additional 5-10% of total susceptibility.
1.1.6.2 The environmental basis of diabetes
The aetiological role of environmental factors is suggested by the major geographical
variations in diabetic prevalence, and the observation that immigrants take on the risk
of diabetes mellitus of their new country. Exposure to certain viruses i.e., the group
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B coxsackie virus and the rubella virus has been implicated (Pearson 1991). These
agents may provoke a cross reactive immunological response to the islet cells. There
is demonstrated short sequence similarity between certain islet (3 cell antigens and a
protein of the coxsackie B virus (Nepon 1995) in addition to a rubella virus protein
(Schatz et al 1995). Thus if the immune system targets these viral proteins the islet
cells may also be destroyed. A bovine serum albumin has also been found to have a
similar peptide sequence to that expressed by human islet cells. This has been
hypothesised to explain the association between lack of exclusive breast-feeding in
the first 3 months of life with the subsequent increased incidence of diabetes (Schatz
et al 1995). Environmental or dietary exposure to various toxins has also been
implicated in the destruction of genetically vulnerable B cells. Nitrosamines found in
smoked and cured meats and coffee have proposed diabetogenic effects (Pearson
1991).
1.1.7 Medical treatment of diabetes
1.1.7.1 Exogenous insulin therapy
The fundamental basis of treatment of diabetes mellitus is to replace the lack of
endogenous insulin secretion and action, by parenteral administration of an
exogenous supply. The first insulin preparations were purified from bovine and
porcine sources and administered in once or multiple daily doses. This allowed
control of severe hyperglycemia but was wholly inadequate at mimicking
endogenous release of insulin. In non-diabetic subjects a sharp rise in insulin occurs
after meals, which accounts for approximately 50% of insulin release from the
pancreas each day. These peaks in insulin secretion are superimposed on a more
constant background secretion. The onset of action of standard (soluble) insulin can
be delayed, and duration of action extended, by the addition of protamine or zinc to
form crystals in the preparation. Combinations of different insulin preparations have
allowed replacement regimes to be developed with the aim of mimicking
physiological insulin secretion more effectively.
In the 1980s human insulin became available with the advent of genetic engineering
and recombinant DNA technology. Human insulins are now the standard
preparations of use when initiating therapy as they have low risks of
immunogenicity, which can lead to allergy or drug resistance. They are also
manufactured more efficiently. Currently there are around 20 preparations of human
insulins almost all of which are produced by two manufacturers Eli Lilly and Co and
Novo/Nordisk Phar. Inc (Sengewald 1999). In a modern intensive regime of insulin
replacement a once daily long acting insulin is typically given to provide the
background insulin action, in combination with pre-meal injections of a short acting




Figure 1.1 A typical Insulin replacement regime
Short acting soluble insulin (SI) and long acting insulin (LI) are given in an intensive
(multiple injection) regime to mimic the lost physiological endogenous insulin
response to meals.
Insulin requirements are increased principally by increased carbohydrate intake but
also by weight gain of both lean body mass and fat mass. Increased insulin is also
required during infections and other medical or surgical stresses and during
pregnancy. In an individual the pharmacokinetics of replaced insulin can vary from
day to day. Absorption from the skin can vary with the injection site, depth and angle
of injection, ambient temperature and exercise of an injected limb. Injection into the
subcutaneous tissue of the abdomen produces the least variable results. Adequate
professional support to guide insulin replacement should therefore always be
available and is an important facilitator of glycaemic control.
1.1.7.2 Dietary therapy
Diet is another important factor in management. Post-prandial glucose concentration
is directly dependent on the carbohydrate content of the meal (Peterson et al 1990).
The aim of dietary advice is to regulate the carbohydrate intake throughout each day.
Ideally the carbohydrate should be unrefined and therefore slowly absorbed from
fibre rich foods to prevent rapid swings in circulating glucose. Carbohydrate should
provide approximately 50% of calorie intake. The total dietary prescription should
provide 24-30 kcal/kg current body weight, or in pregnancy 30-35 kcal/ kg pre¬
pregnancy ideal body weight (Mulford et al 1993, British Diabetic Association 1992)




1.8 Monitoring glycaemic control
Blood glucose levels provide the best assessment of daily glycaemic control. Regular
capillary samples throughout the day (4 to 7 point profiles) provide a detailed
assessment of pre- and post- meal glucose levels and aid tailoring of insulin
replacement. The aim is to achieve normoglycaemia (preprandial glucose values of <
6 mmol/L). Glucose concentrations can be determined by reagent sticks and
manually read against a scale, or determined and stored electronically via the
combined use of a glucometer. The use of the latter aids objective assessment of
treatment compliance.
Assessment of glycaemic control over a larger time period can be achieved by
quantifying the percentage of haemoglobin that has undergone the physiological
process of glycation (Hb Ale). This is a two-step reaction resulting in the formation
of a covalent bond between the glucose molecule and the terminal valine of the B-
chain of the haemoglobin molecule. The rate at which this reaction occurs is related
to the glucose concentration, and the percentage of glycated haemoglobin determined
by electrophoresis reflects this and the life span of the red blood cell (Goldstein et al
1986). HbAlc determination therefore reflects the average level of glycaemic control
over a period of several weeks. This objective assessment of glycaemic control has
proven valuable in clinical studies of diabetes, as its value is not readily manipulated.
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1.2 Diabetes and Pregnancy
1.2.1 Effect of pregnancy on glucose metabolism.
During normal pregnancy pancreatic (3-cell hyperplasia occurs with increasing
oestrogen and progesterone levels. Increased secretion of insulin and peripheral
utilisation of glucose results in a 10% reduction in maternal glucose levels in the first
trimester. There is reduced availability of gluconeogenic amino acids and a slate of
accelerated starvation occurs during fasting. This is marked by increased fat
breakdown and increased levels of triglycerides and ketones (Kuhl 1995).
Placental hormones, which include human placental lactogen, glucagon and Cortisol,
impair glucose uptake into insulin sensitive cells resulting in a state if insulin
resistance (Ryan and Erns 1988). In non-diabetic pregnancies there is a documented
44% decline in insulin sensitivity by the late third trimester. Overall glucose
homeostasis is maintained by an exaggerated rate and amount of insulin release from
the (3 cells (Yen 1973). However the altered metabolic state results in increased
prostprandial circulating concentrations of glucose which serves the fetus by
increasing glucose supply to the placenta.
In women with diabetes the altered glucose metabolism of pregnancy predisposes to
hypoglycaemia particularly in the first trimester. Hyperemesis and nausea result in an
exaggerated starvation state and increase the risk of ketoacidosis. Due to the insulin
resistance of pregnancy women can expect to almost double their pre-pregnancy
doses by 30 weeks gestation.
1.2.2 Diabetes and pregnancy - historical aspects
Prior to the discovery of insulin pregnancy was an extremely rare event for women
with type 1 insulin dependent diabetes. The majority of affected women were
ammenorrheic and infertile. Pregnancy when observed was associated with a greater
than 50% maternal and fetal mortality rate (Williams 1909) and therefore most
pregnancies were terminated by obstetricians. With the discovery of insulin fertility
was returned to diabetic women and maternal mortality approached that seen in the
non-diabetic population. However increasing numbers of women with more severe
disease became pregnant and the perinatal mortality rate remained high. Late
intrauterine death at 36-40 weeks gestation accounted for two thirds of all stillbirths.
The care of the pregnant diabetic women was pioneered by Priscilla While at the
Joslin clinic, (Boston, USA), and Jorgen Pedersen in Copenhagen. They, like the
physicians, recognised the importance of achieving good glycaemic control with
insulin in reducing the complications of this condition and were the first to advocate
the regular review of diabetic pregnant women by both an obstetrician and a
physician (White 1949, Pedersen 1954). Under their influence the perinatal mortalily
rate fell. Fetal monitoring when introduced in the 1960's and 1970's, initially as
biochemical screening of placental function and then as fetal heart rate and
ultrasound assessment, aided a lower perinatal mortality rate despite the lack of rigid
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glycaemic control in many patients. The leading causes of perinatal mortality became
congenital abnormalities, severe intrauterine growth restriction due to maternal
vascular disease and preterm birth. Unexplained intrauterine death remained more
prevalent in pregnancies to women with diabetes compared to pregnancies to non-
diabetic women.
With the improvement in perinatal mortality rate reducing the incidence of perinatal
morbidity (due to macrosomia, fetal distress in labour, birth trauma, neonatal
jaundice, hypoglycaemia and respiratory distress syndromes) and maternal morbidity
(due to progressive retinopathy, pre-eclampsia, infection, polyhydramnios and
caesarean section) have become the increasing aims of diabetic care (Coustan,
Berkowitz and Hobbins 1980).
White Description of diabetes/complications
class
A Diabetes treated with diet or drugs
B Age of onset s 20 years, and duration <10 years
C Age of onset 10 -19 years, or duration 10-19 years
D Age of onset < lOyears, or duration >20 years
E Calcification of pelvic vessels
F Nephropathy
R Proliferative retinopathy
FR Nephropathy and proliferative retinopathy
G Poor obstetric history
Table 1.2 The White classification of diabetic pregnancy.
Modified White classes based on the original classification (White 1949)
1.2.3 The St Vincent Declaration
In 1989 it was recognised by the European Office of the World Health Organisation
and the European Regional Committee of the International Diabetes Federation that
despite the previous efforts to improve diabetic pregnancy outcome, there remained
an unacceptable increased risk of perinatal death, neonatal morbidity and congenital
malformations in the infant of the diabetic mother. In response to this they issued the
St Vincent Declaration (WHO 1990), the aim of which was "to achieve pregnancy
outcome in the diabetic woman that approximates that of the non-diabetic woman"
and set a five year time objective to achieve this aim. In response to this document a
guideline of diabetic pregnancy management has been drawn up by the Scottish
Intercollegiate Guidelines Network (SIGN) to improve the care of diabetic women
when planning and during pregnancy (SIGN guideline No.9, 1996). Key areas
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recognised in this report include the use of pre-pregnancy care and access to a
specialised team including both an obstetrician and a diabetologist.
1.3 Maternal complications associated with insulin dependent
diabetes
Pregnancy occurring in an insulin dependent diabetic woman remains associated
with a range of maternal complications. Several classifications of diabetic
pregnancies have made use of these complications as predictive indicators of poor
pregnancy outcome (White 1949, Pedersen 1965). The incidence of these
complications with the exception of pre-eclampsia, can be reduced by tight metabolic
control.
1.3.1 Pre-eclampsia
Pre-eclampsia is a specific vascular disorder of pregnancy. It is characterised by
hypertension, proteinuria and oedema. The aetiology of this condition is yet to be
clearly determined but endothelial dysfunction is established as the pivotal
intermediate pathology. An abnormal maternal response to placentalion, which may
occur as a result of genetic or immunological factors, is believed to release an
undefined mediator into the maternal circulation. This factor is postulated to trigger
the vascular dysfunction.
The clinical disorder of pre-eclampsia may progress to eclampsia, where cerebral
manifestations of the disease, vasospasm and cerebral oedema cause convulsions.
Neurological sequelae of eclampsia include coma and cerebral haemorrhage.
Vascular dysfunction may provoke significant platelet consumption, a coagulation
disturbance and haemolytic anaemia. Vascular damage may also affect liver function
resulting in increased circulating concentrations of transaminases. The altered
placentation is associated with fetal complications such as intrauterine growth
restriction, hypoxia and in-utero demise.
Pre-eclampsia is more commonly observed in pregnancies complicated by maternal
diabetes. The incidence of this condition was described in the Joslin Clinic records as
approximating 50% before 1935 (White 1953). The incidence subsequently declined
due to improved maternal and fetal management and surveillance. However it has
recently been demonstrated that the incidence of pre-eclampsia remains raised in
diabetic (9.9%) compared to non-diabetic pregnancies (4.3%) (Garner el al 1990).
Diabetic pregnancies complicated with pre-eclampsia are associated with high
perinatal mortality and morbidity rates due to their association with premature
delivery (largely iatrogenic in maternal interests), and intrauterine growth
retardation. Differentiation of pre-eclamspsia from acute deterioration of
nephropathy with associated hypertension can be difficult. Thrombocytopenia,




Many clinical studies have assessed the short-term effect of pregnancy on diabetic
retinopathy. These studies have been relatively small and have varied greatly in (heir
methodology but have on the whole consistently demonstrated that pregnancy is
associated with increased incidence and progression of retinopathy in diabetic
women.
Moloney and Drury (1982) studied 53 pregnancies and found that background
retinopathy developed during pregnancy in 15% of women and that 29% of women
with background retinopathy prior to conception experienced progression. Both rates
were significantly increased above that in non-pregnant diabetic women over a
similar time course. Similar results were found by the Diabetes in Early Pregnancy
Study (Chew et al 1995). This was a prospective cohort study of 155 diabetic women
followed from pregnancy diagnosis to one-month post-partum. They demonstrated
that progression of retinopathy occurred in pregnancy and that this was more likely
to occur in those with more advanced initial disease; 6.8% of women with mild
background retinopathy (n = 32) progressed to develop proliferative retinopathy
compared to 30% of those with severe background retinopathy (n = 31). Progression
of retinopathy is additionally more likely to occur in patients with hypertensive
disorders, both hypertension preceding pregnancy and preeclampsia (Rosenn et al
1992, Lovestam-Adrian et al 1997). Regression of retinal changes has been
documented during the immediate post partum period (Maloney and Drury 1982,
Rosenn et al 1992).
Very few studies have addressed the long-term effect of pregnancy on retinopathy.
Kaaja et al (1996) studied 26 women 7 years after delivery and compared them to 16
matched controls and found no difference in degree of retinopathy, suggesting no
long-term effect of pregnancy on progression. A small prospective study (Miodovnik
et al 1998) supports this finding. Twenty-three pregnant women were compared to 23
non- pregnant women similarly treated for a nine-month "sham pregnancy" period.
The women were followed for 14 - 43 months post pregnancy. Progression of
retinopathy was found in four women who had been pregnant compared to
progression in three of the " sham pregnancy" group.
1.3.3 Diabetic nephropathy
Diabetic nephropathy is estimated to be present in up to 5% of type 1 diabetic-
pregnancies. In addition to hyperglycaemia, factors implicated in the development of
nephropathy; increased glomerular filtration rate; hypertension and increased protein
excretion are all increased or can occur more commonly in pregnancy. Pregnancy is
therefore likely to be associated with progression of nephropathy. In women with
advanced nephropathy (raised serum creatinine / reduced creatinine clearance) there
is evidence from a few small studies that this does occur. Biesenbach et al (1992)
followed 5 women through pregnancy and demonstrated a greater than expected fall
in creatinine clearance over the time course of pregnancy and the postpartum period.
All these women had developed end stage renal disease by 42 weeks postpartum. A
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similar study (Purdy et al 1996) suggested a more modest but still significant 40%
risk of accelerated nephropathy leading to end stage renal disease. In this study
pregnant women with moderate or advanced nephropathy were followed over as
similar length of time to non-pregnant diabetic women.
Cross sectional studies of parous and non-parous women have however not shown a
difference in prevalence or severity of nephropathy between these groups (Kaaja et al
1996, Hemachandra et al 1995). These studies included a large proportion of diabetic
women with no nephropathy or mild nephropathy at the time of conception. This
suggests that pregnancy itself may not be associated with development of
nephropathy or acceleration of mild disease. In the small prospective controlled
study by Modovnik et al (1998) none of the pregnant diabetic women or the "sham"
pregnant diabetic women had nephropathy prior to pregnancy and none developed
the complication when followed to 14-43 weeks post partum. This supports the
implications drawn from the cross sectional studies.
Advanced nephropathy therefore has a poor prognosis when combined with
pregnancy. Hypertension is a frequent associated factor occurring in 30% of those
affected at booking and in 75% by delivery (Lavoie et al 1988) and further drives
advancement of nephropathy. Women with milder forms of nephropathy may be
counselled more optimistically with regard to pregnancy outcome. Surveillance for
peeclampsia is required, as this additional vascular pathology may lower the
threshold for disease progression.
1.3.4 Macrovascular disease
Symptomatic macrovascular disease although commoner in diabetic women is rarely
seen during childbearing age because of its later clinical onset. Rosenn et al (2000)
detected 20 published case reports of myocardial infarction in diabetic women prior,
during or shortly after pregnancy between 1953 and 1998. Mortality was observed
only in the cases occurring during pregnancy or the puerperium (7/13), and only in
the cases documented prior to 1980 (7/10). The selection bias of these reported cases
is likely to be significant. Pregnancy may adversely affect coronary artery disease by
a number of mechanisms most notably increased cardiac output, oxygen
consumption and cardiac work. Particularly hazardous events in women with
underlying ischaemic heart disease include hypoglycaemia and the altered
haemodynamics occurring at delivery. Hypoglycaemia precipitates the release of
catecholamines with resultant tachycardia. In the immediate postpartum period there
is acute release of veno-caval obstruction, autotransfusion of uteroplacental blood
and rapid mobilisation of extracellular fluid. All increase venous return and may
demand an acute 60 - 80% increase in cardiac output.
1.3.5 Other maternal complications.
Approximately 80% of diabetic pregnancies are complicated by at least one episode
of maternal infection compared to 26% of non-diabetic pregnancies (Stamler et al
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1990). There is an increased incidence of urogenital, respiratory, wound and
endometrial infections. Pyelonephritis occurs in 4% if diabetic pregnancies compared
to 1% of non-diabetic pregnancies and is associated with increased incidence of
premature rupture of membranes, preterm labour, and perinatal morbidity (Cousins
1987).
Diabetes is associated with an increased maternal morbidity due to polyhydramnios.
The mechanism for the increased incidence of this condition is thought to arise from
an osmotic diuresis by a hyperglycaemic fetus (Naeye et al 1970). The condition may
also arise in association with a congenital malformation (Moya et al I960).
Polyhydramnios contributes to increased perinatal morbidity and mortality due to its
association with premature labour.
Maternal ketoacidosis remains a serious acute maternal complication, associated with
a 20% fetal loss rate (Hogay 1994). It occurs more frequently during pregnancy due
to the relative insulin resistance of pregnancy and the increased incidence of
predisposing factors; infections, hyperemesis gravidum and the use of tocolytic
therapy (B-sympathomimetic agents).
Hypoglycaemic episodes are also commoner during pregnancy reflecting altered
glucose metabolism. The incidence of this complication has risen due to the
improved aims of glycaemic control during pregnancy. If severe, hypoglycaemia
may precipitate seizures or loss of consciousness. Rosenn et al (1995) prospectively
followed 84 women from 9 weeks of pregnancy who had their intensive insulin
regimes adjusted weekly following glucometer readings. Clinical hypoglycaemia
requiring assistance from another person occurred in 71% of women. It is imperative
that the women and their partners are taught to recognise and treat this complication.
Animal studies have indicated that chronic maternal hypoglycaemia may have a
deleterious effect on the embryo during development (Buchanan et al 1986),
however there are no human clinical trials to support this.
1.4 Fetal complications of maternal diabetes
Improved maternal glycaemic control, fetal surveillance and neonatal intensive care
have reduced fetal/ neonatal loss in diabetic pregnancies (Reece 1994). However the
incidence of fetal complications remains significantly raised over that observed in
non-diabetic pregnancies largely from an increased spontaneous abortion rale,
increased incidence of congenital malformations and "unexplained" late fetal death.
1.4.1 Spontaneous miscarriage
Maternal diabetes mellitus has long been associated with an increased risk of
spontaneous miscarriage. Precise estimates of risk are difficult to obtain due
variations in definition of miscarriage and the poor quantification of the non-diabetic
background rate of pregnancy loss. A prospective uncontrolled trial by Miodovnik et
al in 1984 demonstrated an overall 30% spontaneous miscarriage rate in diabetic
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women (approximately 12 times the compared background rate). There was an
increased incidence in diabetic women with advanced diabetic diseases as defined by
White class and an association with poor glycaemic control in the first trimester. The
relationship between the increased risk of miscarriage and poor maternal glycaemic
control has recently been clearly demonstrated in the Diabetes in Early Pregnancy
study (1995) and the Diabetes Control and Complications trial (1996). The latter
demonstrated that diabetic women intensively treated to achieve good metabolic
control (HbAl = 7.4% at conception) were no more at risk of spontaneous
miscarriage (13.3%) than non-diabetic women.
1.4.2 Congenital malformations
Maternal diabetes is associated with a two to four fold increased incidence of
congenital malformation of their infant over the background incidence of 2%
(Lowey, Beard and Goldschmidt 1986, Mills et al 1988, Hawthorne et al 1997). One
recent population study of diabetic pregnancies (where there was no regional
guidelines for the management of diabetic pregnancy) has documented a much
higher (10-fold) prevalence (Casson et al 1997). As improved perinatal care has led
to a general reduction in the perinatal mortality of diabetes, this complication now
accounts for 40% of prenatal deaths. There is a high risk of neural tube abnormalities
(19.5/1000, compared with 2-5/1000 for non-diabetic pregnancies), (Milunsky et al
1982). Cardiac abnormalities are found in 4% of diabetic pregnancies (five-fold
increase) and include ventricular septal defects, transposition of the great vessels and
coarctation of the aorta (Rowland, Hubbell and Naclas 1973). Renal and
gastrointestinal anomalies are also more common. The caudal recession syndrome
although rare, occurs an estimated 200 times more frequently in diabetic compared to
non-diabetic pregnancies (Kucera 1971).
The association between poor maternal metabolic control and increased incidence of
congenital malformations has been recognised for many years. Recent studies have
stressed the particular importance of poor glycaemic control in the first trimester of
pregnancy (i.e. embryogenesis) in the pathogenesis of this complication (Reid et al
1984, Stubbs et al 1986). The causal effect of hyperglycaemia has been clearly
shown in animal studies (Eriksson et al 1982). In human studies support for this
aetiology arises from the lower incidence (4.7%) of congenital anomalies when tight
maternal metabolic control has been achieved (Mills et al 1988, The DCCT 1996).
1.4.3 Unexplained late intrauterine death
Unexplained stillbirth accounts for nearly 50% of the perinatal mortality rate of
diabetic pregnancies (Beard and Lowey 1982). Two recent population studies of
diabetic pregnancy outcome in Liverpool (Casson et al 1997) and the north of
England (Hawthorne et al 1997) document a stillbirth rate of 2% compared to a
background rate of approximately 0.5% in the non-diabetic pregnant population. The
stillbirth incidence is greater after 36 weeks gestation especially in diabetic
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pregnancies complicated by poor metabolic control, maternal vascular disease,
ketoacidosis, or pre-eclampsia. Predisposing factors are thought to include chronic
hypoxia, lactic acidaemia and hypertrophic cardiac myopathy. Chronic hypoxia may
arise from the organomegally induced by fetal hyperinsulinaemia and hence
increased fetal demand for oxygen (Carson 1980). Chronic hypoxia stimulates
extramedullary haematopoiesis. Fetal polycythaemia has been demonstrated in
diabetic pregnancies and may predispose to fetal intravascular thrombosis (Salvesen,
Brudenell and Nicolaides 1992). Lactic acidosis may occur, especially in association
with hypoxia, because the rate of maternal glucose transfer across the placenta is
independent of maternal perfusion whereas the rate of oxygen transfer is not.
1.4.4 Altered fetal growth
1.4.4.1 Macrosomia
Fetuses of diabetic pregnancies are often large for gestational age. Typical series
demonstrate that 25% of diabetic infants have a birth weight greater than the 90th
percentile for gestational age (Beard and Maresh 1989, Persson and Hanson 1996).
Infants weighing greater than 4.5kg at birth, irrespective of gestational age are
termed macrosomic. The increase in birth weight is secondary to increase in fat,
muscle and organ size. The growth promotion of the infant is believed to result from
poor maternal metabolic control. Pedersen first postulated this in 1954. He
hypothesised that maternal hyperglycaemia led to fetal hyperglycaemia, fetal
pancreatic (3-cell proliferation, and therefore fetal hyperinsulinaemia. Fetal insulin
then acts as a growth hormone.
The Diabetes in Early Pregnancy Study (Jovanovic-Peterson and Peterson 1990)
found that postprandial maternal blood glucose concentrations in the third trimester
were strongly predictive of birth weight and fetal macrosomia. Johnstone et al (2000)
demonstrated that the most predictive variable was glycated haemoglobin
concentrations at 27-33 weeks gestation. This however was documented to explain
only 6.3% of birth weight variance. This finding may help explain why despite
improved maternal control, the incidence of macrosomia remains raised. It indicates
possible aetiological roles for maternal weight; genetic factors and insulin like
growth factors. The antenatal diagnosis of this condition is limited which increases
further the risk of traumatic delivery of these infants. The macrosomic infant is also
at increased risk of unexplained fetal death and neonatal morbidity.
1.4.4.2 Intrauterine growth restriction
Intrauterine growth restriction is used to describe a range of disorders in which the
fetus fails to achieve its genetic growth potential. The condition may follow
intrauterine infection or accompany congenital abnormalities. In these pathologies
the fetus is usually symmetrically small. Asymmetrical growth restriction occurs in a
range of conditions (see sections 4.3.land 4.3.2) that are associated with inadequate
transfer of nutrients from the mother to the fetus, which limits growth. The fetus
preferentially channels glucose to the vital structures such as the brain at the expense
17
Gibson J.L.
of laying down glycogen in the liver. Fetal head growth is therefore preserved whist
liver and hence abdominal growth fall behind resulting in the asymmetrical picture.
Asymmetric intrauterine growth restriction of infants has been documented to occur
more commonly in diabetic pregnancies (Reece and Homko 1994). Its increased
incidence is limited to those mothers who have significant pre-pregnancy vascular
disease, possibly by limiting uterine perfusion, and to those that develop
preeclampsia during pregnancy.
1.4.5 Intra-partum fetal risks
The fetus of the diabetic mother is at increased risk of the two major complications
of labour, trauma and asphyxia. As previously described the fetus may be suffering
from a mild degree of asphyxia during the antenatal period and this will be worsened
in labour by hypoxia during uterine contractions. Trauma of the infant during
delivery almost exclusively occurs due to shoulder dystocia, as it is the body and not
the head of the macrosomic infant that is significantly enlarged. Maternal diabetes
increases the risk of shoulder dystocia 3-4 fold (Acker et al 1985).
1.4.6 Neonatal complications
The infant of the diabetic mother is at increased risk of a number of organ
dysfunctions and biochemical disturbances. An increased incidence of respiratory
dysfunction occur in part due to the increased incidence of preterm birth and
caesarean section in this group of infants and in part to a hyperinsulinaemic
inhibition of surfactant production (Bourbon and Farrell 1985). Hypertrophic cardiac
myopathy may cause ventricular outflow obstruction. Hypoglycaemia occurs
frequently and reflects poor maternal control during pregnancy and fetal
hyperinsulinaemia. Polycythaemia occurs more commonly in these infants for the
reasons previously described. Its associated hyperviscosity predisposes to necrotising
enterocolitis, renal vein thrombosis, and in association with the relative liver
immaturity described in these infants, neonatal hyperbilirubinaemia (Ylinen, Raivio
and Termo 1981). Hypocalcaemia and hypomagnesaemia are two other
complications described in diabetic neonates.
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1.5 Management of pregnancy in women with type 1 diabetes
1.5.1 Pre-pregnancy clinics
Many of the maternal and fetal complications of pregnancy can be reduced by good
maternal glycaemic control in pregnancy, however the fetal complications of
spontaneous miscarriage and congenital malformation require good maternal
glycaemic control at the time of conception. Significant maternal disease such as
nephropathy and ischaemic cardiovascular disease may advance during pregnancy.
For these reasons it is imperative that women optimise their diabetic management
before pregnancy and be adequately counselled to the expected effect of pregnancy
on their diabetes. Ideally all adolescent diabetic females should be given the relevant
advice through their General Practitioner and diabetic clinic, however this is
infrequently effective.
Steel and her colleagues in Edinburgh first demonstrated the need for specific pre¬
pregnancy clinics (Steel et al 1982). Pre-pregnancy clinics have been shown to be
cost effective in human and financial terms (Scheffler et al 1992). Pre-pregnancy
care allows evaluation of diabetic complications, communicates the advantages of
good glycaemic control during pregnancy and provides support to establish this prior
to conception by optimising diet, insulin therapy and glycaemic monitoring. Advice
about management of ketonuria and hypoglycaemia is given. It is an ideal forum for
smoking advice, Rubella immunisation and the commencement of folic acid
supplementation to reduce the risk of fetal neural tube defects.
A highly successful pre-pregnancy clinic in the United Kingdom is that founded by
Steel (1989). As the same physician runs the adolescent and pre-pregnancy service
over 75% of women have specific pre-pregnancy counselling. Unfortunately it is
recognised in other areas with less integrated access to pre-pregnancy care, only a
third of diabetic women appear to attend for advice. Such a service may self-select
the most motivated women who achieve good glycaemic control outwith pregnancy
(Gregory and Tattersall 1992). Promoting better utilisation of pre-pregnancy care is
fundamental if implementation of the St Vincent Declaration is to be achieved (Steel
and Johnstone 1992).
1.5.2 Antenatal care of the diabetic woman
An experienced multidisciplinary team led by a named obstetrician and physician
should provide comprehensive maternity care (SIGN publication no.9, 1996). This
can only be achieved if the care of all diabetic women is centralised to one
obstetrician within each hospital. Realistic individualised aims for each patient form
the basis of a successful patient - staff relationship (Johnstone 1997).
Dietary advice should be available at all diabetic antenatal clinics. Folic acid
supplementation should continue to 12 weeks gestation to reduce the risk of neural
tube defects (MRC Vitamin Study Research Group 1991). Diabetes specialist nurses
and midwifes have an important role in educating women on the need for home
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blood glucose monitoring (4-6 times a day, aiming for a blood glucose concentration
= 4-7 mmol/L) and intensive insulin regimes. They also counsel women how to cope
with various pregnancy related complications such as hypoglycaemia and
hyperemesis that may provoke ketoacidosis. Twenty-four hour access to emergency
services should be provided and the accessed instructions should be explicit.
The diabetic physician should review glycaemic control at each visit and aid the
specialist nurse/ midwife in altering intensive insulin regimes. Insulin regimes vary
with the physician's preference; most prescribe an intensive regime of multiple
preprandial doses of soluble insulin in combination to one dose of long acting insulin
commonly administered at night. Pregnancy induced insulin resistance requires
steady increases in insulin doses. Blood glucose profiles should be supplemented by
glycated haemoglobin measurements performed at least monthly. If glycaemic
control is being inadequately achieved intensive inpatient care may temporarily be
required.
Fundoscopy during each trimester is advised but may be required more frequently in
patients with poor glycaemic control, hypertension or advanced disease. Referral to
an ophthalmologist is indicated when there is potential to rapid development of
neovascularisation. The urine should be screened for protein at each visit. Twenty-
four hour protein and creatinine excretion rates should be studied by the physician on
a monthly basis if proteinuria develops. Treatment of established nephropathy might
require the use of antihypertensive agents.
The obstetrician should provide standard antenatal maternal care. Including
management of obstetric complications such as hyperemesis, ante-partum
haemorrhage, pre-eclampsia and threatened preterm labour. Initiation of any therapy
such as antihypertensives or steroid therapy for preterm delivery requires close
liaison with the physician. Obstetrical input is however more specialised toward the
fetus and the management and timing of delivery.
Visits to the antenatal clinic usually occur 2-4 weekly. More frequent review or
inpatient care may be needed if concerns arise. The specialist nurse midwife should
be able to provide telephone advice outwith clinic hours.
1.5.3 Fetal monitoring in diabetic pregnancy
Assessment of fetal wellbeing relies on an accurate estimation of gestational age. All
pregnancies should have gestational age as determined by last menstrual period
confirmed by first trimester ultrasound biometry. This booking scan also confirms
fetal viability. The increased risk of fetal loss in diabetic pregnancies does not
warrant repeated viability scans; however these should be performed if indicated
clinically.
The increased incidence of structural abnormalities in diabetic pregnancies justifies
the offer of routine fetal anomaly ultrasound screening to all women with diabetes
during pregnancy. This is usually performed at 18 weeks gestation. This may detect
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over 90% of major neurological abnormalities, but is effective in diagnosing only
around 50% of cardiac abnormalities. To improve detection detailed structural
assessment of the fetal heart may be repeated later in gestation.
The disorders of growth in diabetic pregnancies can be screened for by clinical
assessment of fundal height, performed as part of the standard antenatal check. This
is usually supplemented by serial ultrasound biometry in diabetic pregnancy due to
the increased incidence of growth disorders. It is routine in many units to perform
these fortnightly in uncomplicated pregnancies. Clinical examination and ultrasound
biometry are however both relatively poor predictors of eventual birth weight in
diabetic pregnancy. In a prospective study of 181 pregnancies clinical examination
performed at 34 weeks gestation had a sensitivity of 42% for detecting fetal
birthweight > 95lh centile, ultrasound had a 46% sensitivity (Johnstone et al 1996).
More complex derivations of fetal weight obtained by utilising an increased number
of ultrasound derived measurements add little to the detection rate of macrosomia
(McLaren et al 1995). It is estimated that only when fetal weight is 4700g can the
clinician be 90% suspicious that fetal weight is at least 4000g on the basis of
ultrasound assessment. The detection of increased fetal growth velocity may be
valuable in promoting improved maternal glycaemic control and allows assessment
of the safety of vaginal delivery.
Detection of reduced growth velocity is an indication to increase fetal monitoring.
This may be performed by more frequent ultrasound assessments of fetal wellbeing:
liquor volume, umbilical artery doppler assessments or biophysical scoring. Acute
assessment of fetal wellbeing can be performed be cardiotocography. All these
assessments have limited predictive value in non-diabetic pregnancy. In diabetic
pregnancy when fetal decompensation may occur quickly their limitations should be
recognised (Johnstone 1997).
Routine use of umbilical artery doppler measurements in diabetic pregnancies has
not been shown to be of value in screening for adverse fetal outcome in the absence
of intrauterine growth restriction (Johnstone et al 1992, Salvesen et al 1993).
1.5.4 Timing of delivery
Iatrogenic preterm delivery may be indicated by the development of fetal or maternal
compromise during pregnancy. In the uncomplicated pregnancy there is controversy
as to the optimal timing of delivery. (Drury 1986, Molsted-Pretersen and Kuhl 1986).
Concern about the risks of late unexplained fetal stillbirth and macrosomia favours
delivery before 38 weeks gestation, however this places the infant at risk from
disorders of prematurity to which the diabetic infant is more prone.
1.5.5 Method of delivery
Women with diabetes have a high rate of caesarean section even after controlling for
compounding factors (Remsberg et al 1999). Estimated fetal weight > 4.5kg may
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indicate delivery by elective caesarean section (Landon et al 1990). Conway and
Langer (1988) reported a 50% decrease in shoulder dystocia when they used
ultrasound to detect an estimated fetal weight greater then 4.25kg at term and
preformed elective caesarean section at this cut off. This increased their caesarean
section rate in diabetic pregnancies by 15%.
1.5.6 Management of delivery
Due to the higher risks of intrauterine asphyxia continuous fetal monitoring should
be performed during labour by cardiotocography. This should be supplemented with
fetal scalp pH measurements as indicated, and there should be a lower threshold to
resort to caesarean delivery if there is suspected fetal distress. An experienced
obstetrician should be available for delivery due to the increased risk of shoulder
dystocia. This is particularly indicated after slow progress in labour or for an assisted
delivery.
Maternal glycaemic control is achieved by an intravenous infusion of glucose and
insulin. This should be adjusted on the basis of at least hourly blood glucose
estimations (Beard and Maresh 1989).
1.5.7 Post-partum management
With delivery of the fetus and placenta maternal insulin sensitivity rapidly reverts to
the non-pregnant state. The insulin/glucose infusion can be discontinued after vaginal
delivery and the women re-established on her pre-pregnancy regime with her next
meal. The infusion is usually continued after caesarean delivery. Insulin may not be
required for many hours, its need and dose should be assessed by regular capillary
glucose measurements.
A paediatrician skilled in resuscitation should be present at the delivery particularly
if maternal glycaemic control has been poor. The risk of congenital abnormalities
should be recognised and respiratory rate monitored as an indicator of cardiac
diseases or respiratory compromise due to reduced surfactant production. The
neonate requires early feeding and should be closely observed for hypoglycaemia.




Vascular endothelial dysfunction in diabetes
2.1.1 Introduction: glycaemic control and diabetic vascular
complications
If there is one single systemic factor implicated in aetiology of the microvascular and
macrovascular pathologies of diabetes it is hyperglycaemia. The relationship
between the degree of glycaemic control achieved with insulin and the development
of diabetic vascular complications has been extensively studied. Initial clinical
studies in humans were Hawed by the inability to accurately and objectively quantify
the degree of glycaemic control and the severity of the vascular complications. These
studies were retrospective or non-controlled non-randomised studies. With time it
has become apparent that the degree of glycation of various plasma and cellular
proteins, haemoglobin in particular, reflects an integrated measurement of antecedent
blood glucose. This development coupled with the introduction of widespread
reliable techniques for self-monitoring of blood glucose have enhanced the ability to
assess glycaemic control reliably. New techniques of insulin delivery and more
complex regimes have enabled motivated diabetic populations to approach
euglycaemia. In addition quantitative assessments of diabetic microvascular
complications have been developed. These advancements have aided the study of
glycaemic control and diabetic complications.
The mechanism through which diabetes is causally related to vascular pathology is
yet to be fully elucidated. Vascular endothelial dysfunction is implicated and is likely
to play a central role. Endothelial dependent vasodilatation of blood vessels obtained
from diabetic subjects and of blood vessels from non-diabetic subjects exposed to
hyperglycaemia is abnormal. Intensive study of endothelial cell function both in-vitro
and indirectly in-vivo has suggested many biochemical mechanisms that could be
involved.
Utilising knowledge of these mechanisms studies of endothelial function are valuable
in assessing the response of diabetic subjects to differing treatments such as
intensified insulin regimes and different physiological conditions including
pregnancy.
2.1.2 Clinical studies of glycaemic control
Whole animal studies provided the first convincing evidence that the clinically
detectable vascular complications of diabetes are a direct consequence of metabolic
derangement in general and suggest the role of hyperglycaemia in particular. A
number of animal models of diabetes exist. The chosen species is made diabetic by
administration of specific islet toxins: Steptozotocin (STZ) in rats and dogs, or
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Alloxan in rabbits. In these whole animal studies microvascular pathology is more
amenable to clinical study than macrovascular disease. This reflects the short time
course of many studies and accessibility of the pathology to visualisation and
quantification. In addition animal models may not perform well as models of human
macrovascular disease. The rat model in particular appears to be relatively protected
against the development of atheroslerotic macrovascular disease.
The most notable whole animal studies were performed by Engerman and colleagues
using a canine model (Engerman and Kern 1986 & 1987), the retina of which are
highly comparable to that of the human. After the induction of diabetes, the dogs
were randomly assigned to 5 years of either poor control, a single daily injection of
insulin and an unrestricted diet, or good control, using twice daily insulin injection
prior to two prescribed meals. The retinae were studied in life by indirect
opthalmoscopy, fundal photography and fluorescein angiography and after sacrifice
by light and electron microscopy. At the end of the 5-year period there was
significant increase in the frequency of all studied retinal lesions in the poorly
controlled dogs compared to well-controlled dogs. The central role of
hyperglycaemia in particular, rather than other metabolic disturbances in general, in
the aetiology of these vascular lesions was supported by the similar retinal response
in dogs fed high galactose diets. In these dogs the level of glycated haemoglobin was
increased whilst lipids and branched chain amino acids were not.
For many years there was a paucity of high quality human data regarding glycaemic
control and the incidence or progression of vascular diseases despite numerous
studies. Retrospective and prospective uncontrolled studies noted a correlation
between blood glucose or HbAlc and the development and extent of microvascular
disease but by their nature could not address any causative role. More recently
several small prospective studies and one large prospective randomised controlled
clinical trial have examined the effect of glucose control on the progression of
diabetic microvascular complications.
The smaller studies, including those from the Oslo, Steno and Kroc groups, were
unable to convincingly demonstrate a beneficial effect of near normoglycaemia on
the vascular complications of diabetes. The Oslo study (Dahl-Jorgensen el al 1986)
followed 45 insulin dependent diabetic subjects randomised to either one of two
intensive insulin regimes (continuous insulin infusion or multiple (5-6)-insulin
injections/day) or to conventional twice-daily insulin injections. Mean blood glucose
after 2 years was 5.3 mmol/L, 6.4 mmol/L and 7.9 mmol/L and HBAlc levels were
8.7%, 9.1% and 10.2% in the respectively treated groups. After two years fewer
retinal microaneurysms and haemorrhages were seen in the two intensively treated
groups compared to the conventionally treated group, however this difference was
not maintained at 4 year follow up. Mean urinary albumin secretion did not change
or differ significantly between groups. The Steno study (Lauritzen et at 1985)
randomised 30 patients with advanced background retinopathy to continuous
subcutaneous insulin infusion [CS11] or conventional therapy. Mean blood glucose
and HBAlc values were lower in the intensively treated group. At two years 4
patients in the CSII group and 5 in the conventional treatment group developed
proliferative retinopathy. In a similar study of non-proliterative retinopathy the Kroc
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collaborative study group 1984) randomised 70 diabetic subjects to CSII or
conventional therapy was unable to demonstrate a significant benefit of intensive
therapy on diabetic microvascular complications at both 8 months and 2 years of
follow up.
The inability of these studies to demonstrate the role of poor glycaemic control in the
development of diabetic vascular dysfunction has subsequently been shown, with (he
publication of the Diabetes Control and Complications Trial (1993), to reflect their
small size, limited follow up periods and failure to address primary prevention.
The Diabetes Control and Complications Trial (The DCCT Research Group 1993) is
the most important study of diabetic control and vascular complications to date. This
was a large prospective randomised clinical trial. It studied 1,441 non-obese diabetic
subjects recruited from 29 clinical centres during 1983-89. The subjects aged
between 13-39 years were spit into two cohorts to address the questions: Will
intensive therapy prevent the development of diabetic microvascular disease?
(primary prevention); and will intensive therapy affect the progression of early
microvascular disease? (secondary prevention). Patients with diabetes of 1-5 year's
duration without retinopathy or microalbuminaemia participated in a primary
prevention trial. Patients with diabetes of 1-15 year's duration, who had already mild
to moderate non-proliferative retinopathy and mild/moderate nephropathy
(<200()mg/day albumin excretion), participated in a secondary prevention trial. In
both trials the patients were randomly assigned to receive conventional treatment (no
more than 2 insulin injections per day) or receive intensive insulin therapy (3-4
insulin injection/day or CSII; self-monitoring of blood glucose at least 4 times per
day). The subjects were followed an average of 6.5 years. The intensively treated
groups maintained a mean HbAlc of 7.2% over this time period compared to a
HBAlc of 8.9% in the conventionally treated group.
Over the follow up period intensive treatment produced substantial benefits. The
risks of de novo development (primary prevention trial) or of progression (secondary
prevention trial) of retinopathy were reduced by 76% and 54% respectively. In the
two trials combined the development of microalbuminuria was reduced by 35% and
of maeroalbuminuria by 56% in the intensively treated cohorts.
The follow up period of the DCCT, 6.5 years is inadequate to fully determine the
effects of glycaemic control on the development of macrovascular pathology. The
calculated risk reduction for all macrovascular events combined (myocardial
infarction, angina, and peripheral vascular disease) was 41%, but this change was not
statistically significant (The DCCT Research Group 1993).
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2.2.1 The role of the endothelium in vascular pathology
The endothelium is a key regulator of vascular function (Furchgott and Zawadzki
1980). Vascular pathologies in general frequently reflect specific endothelial
pathologies. The endothelium is not, even under resting physiological conditions,
simply the inert lining of blood vessels. It forms an active interface between the
blood and the underlying tissue.
In the 'resting' state the endothelium regulates vascular tone and maintains blood
fluidity by inhibiting coagulation and the adhesion of blood leukocytes and platelets.
It also maintains a selective permeability to proteins and fluid. In response to a vast
array of circulating stimuli such as infection or tissue injury the endothelial cell
becomes activated. Activation of the endothelium can alter vessel tone, promote
thrombus formation and the adhesion of blood cells such as neutrophils and platelets
to its surface, and increase the transmigration of fluid and cells into the underling
tissue. These functions are mediated through the production of numerous regulatory
substances (Wu and Thiagarajan 1996).
Molecules important in maintaining the inactivated thromboresistant 'resting' state of
the endothelium include prostacyclin (PGI2) and nitric oxide (NO). These molecules
are secreted from the endothelium and act in a paracrine fashion to inhibit platelet
and leukocyte adhesion and activation. They also exert a vasodilatory action on
smooth muscle cells, which determines resting vascular tone (Moncada and Vane
1979, Moncada et al 1991). The endothelium synthesises and expresses on its surface
other specific anticoagulant factors such as thrombomodulin (Esmon 1993) and
heparan sulphate (Rosenberg 1994). The complex of thrombomodulin and thrombin
acts as a catalytic surface for generation of activated protein C. It also binds and
inhibits thrombin and factor Xa. Heparan sulphate, a proteoglycan expressed on the
surface of the endothelium functions as a cofactor for antithrombin III enhancing
substantially its ability to bind thrombin. The endothelium can also promote
fibrinolysis by synthesis of tissue plasminogen activator (tPA).
In the activated state the endothelium may modify the secretion and expression of
these factors in addition to provoked expression or secretion of prothrombotic and
vasoactive molecules, von Willebrand factor produced by the endothelium is pivotal
in haemostasis and thrombosis (Handlin and Wagner 1989). It acts as the essential
ligand in platelet adhesion. It also binds and stabilises the activity of factor VIII. The
endothelium may choose to inhibit fibrinolysis via synthesis and release of
plasminogen activator inhibitor (PAI-1). Vasoactive factors produced by the
activated endothelium include endothelin, prostaglandin endoperoxide (PGH2) and
thromboxane (TXA2). Lipid based activators i.e. platelet activating factor (PAF) and
chemotaetic cytokines such as interleukin 6 and interleukin 8 may also be produced.
The endothelium has also been recently shown to express specific cell adhesion
molecules. These are intimately involved in the recruitment of leukocytes to the
endothelial surface (Figure 2.1), which can lead to further endothelial cell activation.
Endothelial cell activation is not an all or nothing response. The endothelium
orchestrates it metabolism in response to the nature, strength and duration of multiple
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stimuli. It perpetually modifies this response by interacting with other cells in its
environment such as neutrophils, which may or may not have been exposed to the
same or additional stimuli.
Excessive stimulation of the endothelium such as chronic exposure to a variety of
stimuli, including cytokines, microbial toxins and immunologic agents is likely to
occur in disease states and to underlie specific vascular pathologies. Such abnormal
stimulation of the endothelium is often termed endothelium dysfunction. In this state
the normal vasodilatory and thromboresistant actions of the endothelium appear to be
overwhelmed or lost.
2.2.2 The neutrophil and endothelial function
The neutrophil is a circulating leukocyte the main function of which is to mediate
acute inflammation by accumulating in tissues damaged physically, chemically or by
toxins. Neutrophils therefore intimately interact with the endothelium. Neutrophil
activation may be a consequence or cause of endothelial activation.
Once activated neutrophils can further endothelial activation or disease states, and
have been implicated in endothelial dysfunction and vascular damage (Harlan 1987).
Activation of neutrophils can trigger their degranulation and release of elastase and
other proteases. These enzymes can destroy the integrity of the endothelial cell layer,
vascular basement membrane and the subendothelial matrix. The neutrophil may also
release toxic oxygen radicals which can result in lipid peroxidation and endothelial
cell damage. Leukotrienes produced via arachadonic acid metabolism in the
neutrophils may exert a vasoactive function via the endothelium and may promote
activation of further neutrophils (Bray 1983). Endothelial damage promotes
endothelial expression of further molecules including specific cell adhesion
molecules which will further the inflammation response recruiting not only
neutrophils but also monocytes and lymphocytes to the area.
2.2.3 Cell adhesion Molecules: structure and function
Expression of cell adhesion molecules provides an important mechanism by which a
cell can interact with its environment. The environment of any cell is a complex mix
of potential signals. The endothelial cell for example is exposed to circulating soluble
molecules, circulating cells, neighbouring endothelial cells and insoluble molecules
that form the matrices of tissues. The cell can sample its environment via many
surface molecules that form part of its cell membrane. Of these molecules cell
adhesion molecules are principally responsible for interaction with other cells and
matrix molecules.
Adhesion molecules were so named because they were discovered to effect adhesion
of one cell to another or to its neighbouring matrix. The existence of these molecules
followed studies of leukocyte diapedesis from blood to tissue at sites of inflammation
and in the study of cell migration in embryology. Increasing study of these molecules
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has shown that they are involved in a diverse range of other biological events. It has
also demonstrated that they do not simply act to effect adhesion rather they effect
cell-cell or cell-matrix interaction in which cell-cell or cell-matrix attachment is often
only the first step.
A vast number of different cell adhesion molecules are now recognised.
Rationalisation of these molecules has enabled them to be classified into six families
on the basis of chemical, structural or functional studies: the immunoglobulin-like
superfamily, the cadherins, the integrins, the receptor protein phosphatases, the
selectins and the hyaluronate receptors. The basic structure of the integrin, selectin
and immunoglobulin cell adhesion molecules is shown in Figure 2.2.
The immunoglobulin superfamily are so classified because they all contain one or
more of a common Ig—like repeat within the extracellular domain, however they
exhibit a broad range of functional diversity. Members of this family play a critical
role in the development of the nervous system, in immune and inflammatory
responses and in embryonic development (Springer 1990, Tessier-Lavigne and
Goodman 1996).
The cadherins represent a family of adhesion molecules that play a critical role in
cell-cell interactions. They are involved in embryonic development, formation of the
epithelial layers of skin and intestine, and axonal formation in the nervous system
(Takeichi 1990).
The integrins regulate both cell-cell and cell-extracellular matrix protein interactions.
They play a key role in organogenesis, tissue remodelling, thrombosis and leukocyte
migration (Shattil and Ginsberg 1997, Springer 1994, Hynes 1992). Integrins are
composed of two subunits, a and (3, and are assigned to subfamilies according to the
type of these subunits. (32 integrins are restricted to leukocytes and are important in
their interaction with the endothelium.
Hyaluronate receptors are classified functionally rather than structurally. Members of
this group interact with hyaluronate, an abundant structural saccharide component of
extracellular matrices that is believed to play an important role in a variety of
physiological and pathological tissue processes including inflammation, cell growth,
cell migration and tumour progression.
Selectins are the most recently discovered group of adhesion molecules. They play a
key role in the recruitment of leukocytes from the circulation to sites of inflammation
and are important in fighting infection and in wound healing (Springer 1994, Carlos
1994). The selectins are divided into subgroups E, P and L denoting their association
with endothelial cells, platelets or leukocytes respectively.
Despite this diversity, all cell adhesion molecules share three important
characteristics (Freemont 1998). First, they are all glycoproteins and all act as a
molecular link between the outside and inside of the cell. As such they arc in general
membrane-spanning proteins with extracellular, intramembranous and cytoplasmic
domains. Second, all adhesion molecules 'work' by an external stimulus attaching to
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the extracellular domain and altering its structure. All but hyaluronate receptors are
involved in cell-cell interactions. Cells of the same or differing origins can interact
(homotypic or heterotypic adhesion). Integrins and hyaluronate receptors are
involved in cell-matrix interactions. The molecule that binds to the cell adhesion
molecule is very specific and is known as its receptor or ligand. The ligands for cell
adhesion molecules are other cell adhesion molecules either of the same or different
class, or specific matrix molecules. Third, cell adhesion molecules are attached to
other molecules within the cell through which they are able to influence the function
of the cell. The cytoplasmic domain effects either cell adhesion molecule linkage to
the cytoskeleton (cadherins and beta 1 and beta 3 integrins) or linkage to and
activation of second messenger systems involved in cytoplasmic or nuclear
metabolism. The second messenger systems activated are not specific but the same
messenger systems that are activated by many other receptor-ligand binding systems
such as cytokine-cytokine receptors (Schwartz et al 1994).
As well as allowing signal passage from the outside of the cell to the inside in
response to ligand binding, cell adhesion molecules are also involved in the passage
of information from the inside of the cell to the outside usually by modifying their
ligand binding affinities.
2.2.4 Cell Adhesion Molecules and endothelial function
Cell types differ in their function and therefore differ in their membrane repertoire of
cell adhesion molecules. Endothelial cells need to interact with circulating soluble
molecules and circulating blood cells principally leukocytes and platelets. Cell
adhesion molecules clearly play an important role in the interaction of the endothelial
cell with circulating leukocytes (Bevilacqua 1993).
Three of the main endothelial expressed cell adhesion molecules associated with
leukocyte activation are: E-Selectin, a member of the selectin family of cell adhesion
molecules, intercellular cell adhesion molecule-1 (ICAM-1) and vascular endothelial
cell adhesion molecule-1 (VCAM-1) from the immunoglobulin superfamily.
E-Selectin and ICAM-1 interact with a number of leukocytes including neutrophils.
E-Selectin is an endothelial glycoprotein that consists of a carbohydrate recognition
domain, an epidermal growth factor repeat and a number of complement regulatory
repeats. It is expressed in low levels on the endothelial cell surface but upon
activation of the cell its synthesis is increased along with its transportation to the cell
surface. It is synthesised and expressed in response to inflammatory stimuli including
the cytokines interleukin 1 (IL-1) and tumour necrosis factor (TNF) in addition to
bacterial endotoxin. Its expression reaches a maximal level after 4-6 hours of
endothelial stimulation. Endothelial expression of E-Selectin provokes the initial
loose attachment of the leukocyte to the endothelium via weak bonds with its ligand.
In the presence of fluid sheer stress, these weak bonds appear to allow the subsequent
rolling of the leukocyte along the endothelial surface (McEver 1991, Lasky 1992 and
Bevilacqua 1993). The ligands of the selectins are still subject to intense
investigation (Varki and Nelson 1997) and are believed to be cell surface glycans
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that possess a specific sialyl-LewisX-type structure that is also seen in blood group
antigens.
Intercellular cell adhesion molecule-I is a member of the immunoglobulin-like
superfamily. Its structure contains five immunoglobulin domains. It expression on
the endothelium is unregulated in response to 11-1 TNF and endotoxin. The half-life
of its expression at a few days is much longer than that of E-Selectin. Leukocyte
adhesion to ICAM-1 occurs after interaction of the leukocyte to E-Selectin. ICAM-1
mediates firm leukocyte adherence through interaction with its integrin ligands
expressed on the leukocyte surface. Leukocyte integrin activation appears to signal a
change in leukocyte shape so that it stretches out along the endothelial surface and
may aid transendothelial migration (Springer 1990).
Vascular endothelial cell adhesion molecule-1 is similar in structure to ICAM-1. It is
expressed in two forms containing six or seven Ig repeats. Its expression is up-
regulated by IL-1, IL-4, TNF and endotoxin over a similar time period as ICAM-1. It
binds to two integrin family members, alpha4betai and alpha^etay through which it
supports the adhesion and interaction with lymphocytes, monocytes and eosinophils
with the endothelium (Prober 1990, Petruzzelli 1999). It does not interact with
neutrophils, as they do not express its specific ligands.
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Studies of endothelial function can be performed in several ways. Macroscopic
vessels can be biopsied and studied in-vitro in tissue baths. These studies, on the
whole, assess the ability of the endothelium to regulate vascular tone. Altered
endothelium function is inferred from altered response to known vasodilators that
primarily exert their effect via the endothelium (acetylcholine and ADP), compared
to vasodilators acting directly on smooth muscle cells (sodium nitroprusside).
Release of mediators from endothelial cells in response to specific 'pure' stimuli
such as hyperglycaemia can only be assessed in vitro using these isolated vessel
preparations or by studying endothelial cell cultures. These studies are required to
unravel the complex biochemistry of endothelial function.
As the endothelium interacts continually with its complex environment, which
contains mixed stimuli, in-vivo studies of endothelial function would be ideal.
However in-vivo studies are limited primarily to the assay of circulating factors
released by the endothelium or to the study of circulating cells such as platelets and
neutrophils, whose functions are known to be closely related to that of the
endothelium. In-vivo studies of the vasoactive function of the endothelium have
recently been possible by techniques such as venous plethysmography or laser
doppler, however only perfusion changes in superficial tissue beds are accessible to
study.
2.3.2 Circulating concentration of cell adhesion molecules: a
novel marker of endothelial function?
ELlSAs capable of detecting soluble forms of cell adhesion molecules in peripheral
blood or in supernatants of cytokine activated endothelial cells have been developed
(Gearing et al 1992). These circulating cell adhesion molecules appear to be
structurally identical to those expressed on the cell surface suggesting that they arise
from proteolytic cleavage of these molecules. Circulating concentrations of
endothelial expressed cell adhesion molecules such as ICAM-1, VCAM-1 and E-
Selectin are detectable in healthy subjects and may reflect the cumulative effect of
multiple small stresses on the endothelium occurring during a normal day. The exact
mechanism of their production and the physiologic function of these shed molecules
remain unclear. They may reflect an excretory process of the endothelium by which
it down-regulates its adhesivness. In the circulation they may function to limit the
adhesion cascade by blocking leukocyte ligands. Alternatively they may upregulate
recruitment of leukocytes to the endothelium through ligand occupancy and cell
activation.
Elevated circulating concentrations of cell adhesion molecules have been found in a
number of inflammatory and vascular disease states including hypertension, chronic
renal failure and diabetes and appear to provide useful information about disease
activity (Gearing et al 1992). As a measure of endothelial activation and / or
dysfunction E-Selectin expressed exclusively by the endothelial cell has the potential
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to perform as a selective marker. Raised levels have been reported in variant angina,
ischaemic heart disease and diabetes (Gearing et al 1992, Miwa et al 1997, Blann et
al 1996). Increased levels may provide prognostic information and have been
demonstrated to predict progression of peripheral atherosclerosis (Belch et al 1997).
ICAM-1 and VCAM-1 are expressed by other cells in addition to the endothelium;
therefore some caution may be required in utilising the circulating concentrations of
these markers as an index of endothelial activation. Increased levels have been found
in specific cardiovascular pathologies (Blann and Lip 2000) suggesting that their
assay may nevertheless be of prognostic value.
2.3.3 Evidence of endothelial dysfunction in diabetes
2.3.3.1 Whole vessel studies of endothelial function in diabetes
Reduced endothelial dependent relaxation has been shown to occur in numerous in-
vitro studies of isolated arteries from diabetic animal models. Using isolated vessel
preparations most investigators have demonstrated a reduced vasodilatory response
of blood vessels from diabetic animals to acetylcholine (Oyama et al 1986, Kamata
et al 1989). In these vessels acetylcholine is known to exert its vasodilatory response
by stimulation of endothelial nitric oxide synthase and NO production. NO then acts
on the smooth muscle cells to stimulate guanylate cyclase, increase cyclic GMP and
effect vasodilatation. By demonstrating a normal vasodilatory response to
exogenously replaced NO donors, the above studies suggested that the abnormal
vasodilatory response lay at the level of the endothelium. Normalised vasodilatory
responses of aortic rings have been shown in diabetic rats models treated with insulin
confirming the role of diabetic metabolism in vascular dysfunction (Takiguchi 1988).
Few studies have assessed the effect of diabetes on smaller vessels in in-vitro. Using
the technique of small vessel "myography" resistance sized arteries (250pm in
diameter) have also been shown to demonstrate abnormal relaxation to acetylcholine
when prepared from a diabetic rat model (Taylor el al 1992, Poston and Taylor
1995). In a cohort of diabetic rats who had their glycaemic control restored by insulin
implants the endothelial dysfunction of these small vessels was reduced (Taylor
1994). Studies of small vessels from human diabetic subjects appear to support this
work. Blunted responses to acetylcholine have been shown to occur in corpus
cavernosum obtained from diabetic men compared to non-diabetic men (De Tejada et
al 1989) and in isolated small arteries from subcutaneous fat biopsies obtained from
diabetic compared with non-diabetic subjects (McNally et al 1994).
The use of forearm venous plethosmography in studies of diabetic subjects have
produced conflicting results. This is probably reflective of differing study designs.
They do although in general support abnormal vascular function in diabetes. Two
studies of the vascular response to nitric oxide synthase inhibitor have demonstrated
poorer vasoconstrictor effects in diabetic subjects, suggesting a reduced basal release
of NO in these subjects (Calver et al 1992, Elliot et al 1993).
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2.3.3.2 Plasma markers of endothelial dysfunction in diabetes
A vast range of agents synthesised by the endothelium have been measured as
circulating concentrations by assays performed on peripheral blood. Raised
concentrations of agents such as angiotensin converting enzyme (Schmitz 1G85),
Tissue plasminogen activator (Jensen 1989), endothelin (Takahshi 1990) and von
Willebrand factor (Stehouwer 1991) have been found in diabetic subjects and
provide indirect evidence of endothelial activation or dysfunction in diabetes.
Circulating levels of specific cell adhesion molecules have been demonstrated to be
increased in a number of studies on diabetic subjects. Gearing at al (1992) included
31 diabetic subjects on which to test their assay of circulating cell adhesion
molecules. Significantly raised mean concentrations of E-Selectin (23.4 units/ml)
and 1CAM-1 (94.5 units/ml) were found in these diabetic subjects compared to the
mean values detected in healthy non-diabetic subjects (E-Selectin = 10.8 u/ml,
ICAM-1 = 56.5 units/ml). They also demonstrated a smaller but still significantly
elevated circulating concentration of VCAM-1 in diabetic (69.6 u/ml) compared to
non-diabetic subjects (54.7 u/ml). Lampeter at al (1992) studied circulating
concentrations of ICAM-1 and L-Selectin (expressed by lympocytes). They
demonstrated increased concentrations of these molecules diabetic patients and
family members at risk of developing diabetes (HLA-DR-3 and DR4+).
Further indirect evidence of endothelial dysfunction in diabetic subjects is derived
from studies of circulating neutrophils and platelets. Circulating concentrations of
neutrophil elastase provide an indirect measure of neutrophil activation and
degranulation in vivo. The concentration of neutrophil elastase is normally very low.
Raised concentrations are a potential index of vascular pathology. In previous studies
our group has detected significantly raised circulating concentration of neutrophil
elastase in diabetic non-pregnant women compared to non-diabetic non-pregnant
women (Greer et al 1989) suggesting increased in-vivo activation of neutrophils as a
consequence of diabetes.
Platelets like neutrophils interact closely with the endothelium. Activation of
neutrophils and platelets therefore share a number of common pathways involving
endothelial activation. They can also directly interact with each other. Evidence of
increased platelet reactivity in diabetes has been suggested by studies on platelet rich
plasma preparations prepared from blood drawn from diabetic subjects (Halushka et
al 1983).
2.4.1 The aetiology of vascular dysfunction in diabetes:
hyperglycaemia
Numerous studies have aimed to determine the specific underlying aetiology of
vascular pathology in diabetes. Evidence that the vascular dysfunction may be
directly related to glucose concentration and not other metabolic derangement is
suggested by in-vitro studies of blood vessels.
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Rings of isolated normal rabbit aorta when exposed to elevated media concentrations
of glucose develop an abnormal relaxation to acetylcholine and ADP (Tesfamariam
et al 1990). This impaired vascular response characteristically mimics the abnormal
response rings aortic tissue from rabbits made diabetic by treatment with the alloxan.
(Tesfamariam and Cohen 1991). By altering the concentration of glucose to which
the vessel was exposed it was demonstrated that the resultant altered vascular
reactivity was concentration and time dependent. Exposure of pig coronary arteries
to elevated glucose concentrations has produced similar findings (Cohen and
Tesfamariam 1992).
2.4.2 Mechanisms of hyperglycaemia induced endothelial
dysfunction
Glucose and its metabolites are utilised in a number of intracellular pathways
therefore there are many mechanisms by which hyperglycaemia may result in
cellular dysfunction (Cohen 1993). These mechanisms have been investigated
primarily by utilising endothelial cell culture preparations. The most investigated of
these mechanisms include: (1) increased cellular sorbitol concentrations, (2)
increased cellular NADPH/NADP ratio, (3) altered protein kinase C activity and (4)
non-enzymatic glycation.
In most cells including the vascular endothelium glucose can be converted to sorbitol
via the enzyme aldose reductase. This is a rapid reaction, however the subsequent
metabolism of sorbitol to fructose occurs at a slower rate. Therefore hyperglycaemia
increases cellular sorbitol concentrations. As sorbitol does not readily diffuse across
cell membranes accumulation may cause dysfunction via an osmotic effect
(Gonzalez 1984). Sorbitol also competitively inhibits myoinositol uptake resulting in
abnormal inositol signalling. (Green 1987). Synthesis of sorbitol through the polyol
pathway utilises NADPH resulting in a reduced NADPH / NADP ratio. Depleted
cellular NADPH may cause oxidative stress, as it is required for the antioxidant
activity of glutathione reductase. Indeed a number of free radical scavengers have
been shown to prevent impaired endothelium dependent relaxation caused by
elevated glucose (Tesfamariam and Cohen 1992). NADPH is also required for the
action of nitric oxide synthase and therefore sorbitol formation may reduce
endothelial cell NO production.
Cell culture studies demonstrate an increased activity of protein kinase C (PKC)
when exposed to elevated glucose concentrations (Lee et al 1989). Phosphorylation
by PKC is a key mechanism of intracellular signalling known to regulate the
activities of many cellular processes including prostanoid production (Tesl'emariam
et al 1991) and possible inactivation of nitric oxide synthase.
Another mechanism by which hyperglycaemia may cause cellular dysfunction is by
the formation of advanced glycosylation end products (ACEs). Glucose can form
covalent bonds by non-enzymatic glycation, which may over time lead to the
formation of ACE products in an irreversible reaction. (Brownlee 1988). This may
occur in the extracellular pool affecting plasma proteins such as low density
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lipoprotein (LDL), albumin and haemoglobin. Accumulation of ACE products within
basement membranes renders them resistant to degradation and may therefore lead to
thickening of the basement membrane.
ACE formation may alter surface ligand conformation and therefore disrupt
signalling. They may cross-link DNA nucleotides and have a deleterious effect on
DNA breakage and repair. The binding of ACEs to macrophages triggers an increase
in the release of cytokines such as tumour necrosis factor (TNF) and interleukin-1
(1L-1) which increase vascular permeability and alter coagulation homeostasis
(Vlassara 1989). ACEs may bind to specific receptors. Receptor for advanced
glycation end products (RAGE) is a member of the immunoglobulin superfamily of
cell surface molecules can be expressed by the endothelium. Occupancy of this
receptor may activate cellular second messenger systems (Schmidt et al 1999). ACEs
also quench the effect of nitric oxide in its vasodilator action. Recently ACEs have
been shown to mediate prolonged activation of endothelial nuclear factor k(3
(Bierhaus et al 1997). Activation of nuclear factor k|3 is one of the final steps via
which the vast range of intracellular cytoplasmic second messenger systems exert
their effect on nuclear transcription. Acting in this way ACEs could chronically drive
endothelial activation. Inhibition of ACE formation in animal models is associated
with reduced diabetic vasculopathy (Bacala et al 1991).
In addition to the complex interacting mechanisms discussed above, all of which
would lead to an endothelial vasopressor response to hyperglycaemia, there is some
evidence that hyperglycaemia may exert a vasodilatory effect on the endothelium.
Acting to raise endothelial cell calcium, D-glucose may increase the synthesis of NO
and prostacyclin (Graier et al 1993). Increased vasodilatation has been documented
to occur in the early stages of diabetes. This vasodilatation will increase sheer stress,
which may initially promote further release of vasodilatory factors from the
endothelium but in the longer term increased shear is likely to result in vascular
damage. This has been postulated as an alternative primary cause of vascular damage
in diabetes. Prolonged exposure to elevated glucose acting in this manner would be
difficult to distinguish from the other mechanisms of hyperglycaemic vascular
dysfunction discussed above.
2.4.3 Alternative mechanisms of endothelial dysfunction in
diabetes.
Diabetes causes a disorder of other metabolic pathways other than that of glucose.
Disorders of lipid metabolism have been implicated in the aetiology of vascular
disease particularly macrovascular arteriosclerosis and is likely to contribute to the
vascular pathology of diabetes. Diabetic subjects have been shown to have elevated
hepatic synthesis of very-low-density lipoprotein (VLDL), leading to raised
triglyceride and decreased high-density lipoprotein (HDL) levels. Low density
lipoproteins are particularly sensitive to oxidation and oxidised LDLs are recognised
to be potent stimuli of leukocyte adhesion to endothelium through stimulation of
neutrophil adhesion receptors CD1 IB/CD18 (Lehr et al 1995). Oxidised LDLs may
also trigger endothelial dysfunction directly. There is evidence that this lipid
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derangement may be the result of raised systemic insulin levels (in treated type 1
diabetics and in type 2 diabetics). Insulin stimulates hepatic production of LDLs.
Experimental effects of hyperinsulinaemia include proliferation and migration of
vascular smooth muscle cells, cholesterol synthesis and cellular binding of LDL,
leading to arterial wall thickening and atheromatous lesions (Stout 1990). High
insulin levels are also associated with inhibition of fibrinolytic processes, mainly
though an effect on PAI-1 (Juhan-Vague et al 1989).
2.5.1 Pregnancy and endothelial function
Uncomplicated pregnancy occurring in healthy non-diabetic woman is associated
with altered endothelial function as suggested by documented changes in vascular
activity, and both the closely related coagulation and fibrinolytic systems (Greer
2000). In normal pregnancy the vasculature has to adapt to an increased circulating
volume and it accommodates this in association with a fall in blood pressure. This
must occur via vasodilation. Normal pregnancy is associated with enhanced NO
release and prostacyclin production (Lopez-Farre et al 1995).
There is evidence of a low grade of disseminated intravascular coagulation with
increased coagulation, fibrinolysis and platelet activation which involve, as a cause
or consequence, altered release of factors from the endothelium. The coagulation
factors VIII, X, XII and von Willebrand factor are increased in pregnancy. Von
Willebrand factor is synthesised by the endothelium (Stirling et al 1984).
Fibrinolytic activity is impaired during pregnancy (Halligan et al 1994). This is
largely the consequence of placental derived plasminogen activator inhibitor Type 2
(PAI-2) but there is also increased concentrations of the endothelial derived inhibitor
of plasminogen activator (PAI-1). Tissue plasminogen activator (t-PA) which is
derived from the endothelium also increases in normal pregnancy, as do plasminogen
concentrations.
Platelet activation is suggested by in-vitro studies of platelet rich plasma prepared
from pregnant subjects and is supported by evidence of increased platelet
degranulation (increased circulating thromboglobulin levels) in vivo (Douglas et al
1982). Studies of platelet aggregation in whole blood (more reflective of their normal
milieu than plasma preparations) have however in contrast not demonstrated
increased aggregation in healthy women as a consequence of pregnancy (Greer et al
1988).
Increased concentrations of plasma neutrophil elastase have been demonstrated in
uncomplicated pregnancies. Suggesting that normal pregnancy is associated with a
degree of increased neutrophil activation in pregnancy (Greer et al 1989).
The cause of this altered intravascular state and endothelial function in normal
pregnancy is unknown but the actions of the hormone oestrogen and altered lipid
profiles have been proposed as aetiological factors.
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2.5.2 Endothelial dysfunction and preeclampsia
Pre-eclampsia is the most common and most extensively studied vascular pathology
occurring in pregnancy. Endothelial dysfunction is considered to be a key
pathological process underlying this condition (Greer 2000). Reduced production of
prostacyclin has been documented, as has a related tendency to vasoconstriction with
increased vascular responsiveness to angiotensin II. Circulating endothelial-derived
factors such as von Willebrand factor, tPA and PAI are increased, as are circulating
concentrations of cell adhesion molecules, endothelin and fibronectin.
Associated with this endothelial dysfunction there is evidence of increased platelet
and neutrophil activation in preeclampsia. Neutrophil activation is suggested by
increased circulating concentrations of neutrophil elastase (Greer et al 1989).
Elastase levels correlated with that of uric acid, a marker of disease severity and with
von Willebrand factor concentrations, a marker of endothelial damage (Greer et al
1991). The circulating platelet count is often reduced in preeclampsia and platelet
derived ^-thrombomodulin is increased suggesting platelet activation and
consumption in preeclampsia. Our group has studied platelet aggregation in vitro
using whole blood samples. Increased platelet aggregation was observed in blood
drawn from women with preeclampsia (sampled between 28-39 weeks gestation)
compared to blood drawn at a similar mean gestation from matched uncomplicated
pregnant woman (Greer et al 1988).
Our group has also previously studied circulating concentrations of defined
endothelial cell adhesion molecules in preeclampsia (Lyall et al 1994). Raised levels
of VCAM-! (mean (SE): 842(50) ng/ml) were demonstrated in the plasma of women
whose pregnancies were complicated by preeclampsia when compared to matched
controls (mean (SE): 560(48) ng/ml). Circulating concentrations of E-Selectin and
ICAM-1 were not significantly different in pre-eclamptic subjects compared to non-
pre-eclamptic subjects.
2.5.3 Diabetic pregnancy and endothelial dysfunction
Studies of endothelial dysfunction in pregnancies complicated by maternal diabetes
are presently limited. Plasma endothelin-1 concentrations have been studied in
diabetic pregnancy and found to be increased compared to those measured in non-
diabetic pregnancies (Wolf et al 1997). By performing platelet aggregation studies in
whole blood our unit has assessed platelet function in diabetic pregnancy (Greer et al
1988). Blood from ten diabetic women during pregnancy was compared to that of 14
women with uncomplicated non-diabetic pregnancies and 12 non-diabetic
pregnancies complicated by hypertension (as described previously). There was
increased platelet aggregation to a known aggregatory stimulus, ADP. in the both the
hypertensive group and the diabetic group. No diabetic pregnancy was complicated
by hypertension in this study. The increased platelet aggregation was more marked in
the hypertensive compared to the diabetic group.
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Neutrophil activation in diabetic pregnancy has also been assessed by this group by
measuring plasma concentrations of neutrophil elastase by specific
radioimmunoassay (Greer et al 1989). Neutrophil elastase was increased in normal
pregnancy [median (range): 30(15-102) ng/ml]: compared to the normal non¬
pregnant state [17(8-27) ng/ml]. It was increased in plasma from non-pregnant
diabetic women [23(15-38) ng/ml] compared to non-pregnant controls and diabetic
pregnancies [46(16-38) ng/ml] compared to non-diabetic pregnancies.
These studies suggest that pregnancy in diabetic women may be associated with
increased endothelial activation or dysfunction. This may contribute to the vascular
complications previously documented to occur with a higher frequency in diabetic
women during pregnancy, or may at least make them more susceptible to these
complications. Further study of endothelial dysfunction was therefore warranted to






Figure 2.1 Endothelial-neutrophil interaction via the expression of
cell adhesion molecules.
The interaction of circulating neutrophils with the endothelium is complex.
Attachment activation, adhesion and migration though the endothelial layer
occur in specific steps each effected by cell adhesion molecules. Selectins play
a central role in initial attachment and activation by interaction with their ligand
(sLex). Immunoglobulin-like adhesion molecules (ICAMs) and integrins
interact with each other to mediate firm adhesion.
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Figure 2.2 The general structure of adhesion molecules
Schematic representation of three classes of adhesion molecules, the Integrins,
Selectins and Immunoglobulin (Ig) family members.
The Integrins are noncovalently linked heterodimers composed of alpha and beta
subunits. The Selectins comprise of a N-terminal lectin and EGF-type domain
( E ), followed by two-nine complement repeats (O)- The Ig superfamily are the
most structurally diverse and contain two-five Ig repeats «). Most cell adhesion
molecules have a transmembrane domain and a cytoplasmic domain. The
cytoplasmic domain activates second messenger systems which may lead to a




Circulating Cell Adhesion Molecule Concentrations in Diabetic
Women during Pregnancy
3.1 Introduction
Despite recent major advances in both obstetric care and medical management of
diabetes, these women remain at greater risk of morbidity during their pregnancy
than non-diabetic women. Two factors that contribute to this maternal morbidity are
an increased risk of pre-eclampsia (Gardner 1990) and progression of microvascular
disease, in particular retinopathy (Moloney 1982, Laatikainen 1987, Klein 1990).
The pregnancy-related mechanisms behind these conditions are unknown but are
associated with vascular damage and dysfunction.
It is recognised that the endothelium itself can play a key role in such vascular
pathology by a variety of mechanisms. One such mechanism is via the expression of
an array of leukocyte specific cell adhesion molecules, each of which is induced by a
variety of stimuli and will recognise specific ligands on various subsets of leukocytes
promoting their attachment and activation (Bevilacqua 1993). Surface expression of
these cell adhesion molecules is associated with their shedding into the peripheral
circulation.
Circulating concentrations of cell adhesion molecules are increased in diabetic
subjects and those at risk of developing diabetes (Gearing et al 1992, Lampeter el al
1992). Circulating concentrations of these molecules are also increased in a range of
vascular pathologies (Gearing et al 1992, Miwa el al 1997, Bann et al 1996, Belch el
al 1997). In pregnancy increased levels of one cell adhesion molecule VCAM-1 have
been documented in pre-eclampsia (Lyall et al 1994); a vascular pathology specific
to pregnancy. In these pregnant women the increased concentration of VCAM-I
occurred in addition to other potential mechanisms of vascular dysfunction;
increased platelet reactivity (Greer et al 1988) and increased neutrophil activation
and degranulation (Greer et al 1989). The latter two markers of vascular dysfunction
have also been documented to occur in diabetic pregnancy (Greer et al 1988 &
1989).
On the basis of this evidence we hypothesised that in diabetic women pregnancy is
associated with an increased endothelial expression and shedding of cell adhesion
molecules. If endothelial expression of cell adhesion molecules is increased this may
be associated with both the leukocyte activation and the increased incidence of
vascular pathology documented to occur.
The stimulus for vascular dysfunction in diabetic pregnancy could be directly related
to pregnancy per se or related to a pregnancy effect on another factor of which a key
candidate would be maternal glycaemic control. Maternal glucose levels may effect
changes in circulating cell adhesion molecule concentrations by a variety of
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mechanisms previously discussed, i.e. increased endothelial expression ol: cell
adhesion molecules may be provoked in response to II-1 release from leukocytes
driven by exposure to advanced glycated end products. The effect of pregnancy on
vascular function in diabetic women must thus be assessed in parallel to glycaemic
control in pregnancy.
In clinical studies plasma concentrations of von Willebrand factor act as a useful
confirmatory marker of vascular dysfunction, von Willebrand factor is a high
molecular weight glycoprotein that is synthesised by the vascular endothelium
(Bloom 1973), and megakaryocytes (Nachman 1977). It is constituatively released
from endothelial cells under normal conditions. In the presence of a number of
stimuli, principally vasoactive and pro-coagulant it is released from activated
platelets (Koutts 1978) and in increased concentrations from endothelial cells. It acts
to mediate the adhesion of platelets to collagen I and III exposed beneath the
vascular endothelial layer (Ruggeri 1987). Increased plasma von Willebrand factor
concentrations have been demonstrated in acute infections (Pottinger 1989), vascular
diseases (Belch 1987) and diabetes (Silveira 1992) and as such circulating
concentrations of this factor has been used as one of the principle measures of
vascular damage and dysfunction in vivo and in vitro. In diabetes increased
expression has been associated with both retinopathy and nephropathy (Porta 1987,
Coller 1978), and poor glycaemic control, von Willebrand factor concentrations are
increased and correlate with that neutrophil activation (elastase levels) in women
whose pregnancies were complicated by pre-eclampsia (Greer et al 1991).
The aim of this work was to determine the circulating concentrations of three
endothelial cell adhesion molecules — E-Selectin, ICAM-1 and VCAM-1 —
throughout diabetic pregnancy, to compare these to the concentrations found
throughout non-diabetic pregnancy and in non-pregnant diabetic women. E-Seleclin
and ICAM -1 were chosen for analysis as these molecules are intimately involved in
neutrophil activation and recruitment to the endothelium, and as we have evidence of
neutrophil activation in diabetic pregnancy. VCAM-1 was studied as the circulating
concentration of this molecule was found to be selectively elevated in pregnancies
complicated by pre-eclampsia, a vascular pathology specific to pregnancy. We aimed
to correlate circulating cell adhesion molecule concentrations with maternal
glycaemic control, plasma von Willebrand concentrations and clinical outcome.
3.2 Materials and Methods
3.2.1 Subjects
Pregnant women (n = 26) with type 1 insulin-dependent diabetes attending the
combined antenatal-diabetic clinic at Glasgow Royal Maternity Hospital were
recruited into the study during an 18 month period. Approximately one third of these
women had previously attended the general diabetic clinic at Glasgow Royal
Infirmary, and therefore had received formal pre-pregnancy advice. Blood samples
were drawn when attendance coincided with the following gestational ages, 8-12 (n
= 15), 18 (n = 15), 28 (n = 16), 32 (/; = 16) and 36 (n = 15) weeks' gestation. Ten
42
Gibson J.L.
women were sampled longitudinally throughout all five designated gestations of
pregnancy. At each time point studied, additional blood was drawn to assess
glyeaemic control by glycated haemoglobin measurement (HbAlc).
Healthy non-diabetic women (n = 58) attending a low-risk antenatal clinic were
studied as controls. The initial aim of the study was to sample control women
longitudinally throughout their pregnancy in a similar manner to the diabetic women,
however this proved problematic for a number of reasons. First, low risk women, in
contrast to diabetic women, are now seen infrequently at their base maternity unit for
review. Most of their care is provided in the community. Following their booking (12
week) visit the majority will next be reviewed at the hospital around 36 or 41 weeks
gestation on the discretion of their consultant. A few may be seen at 28 weeks
gestation depending on the provision of their community care. Second, scheduled
return appointments were not infrequently altered at patient request to accommodate
social circumstances. This, and the fact that cohorts of women booking at the same
clinic would frequently not have even original planned review appointments at the
same clinic, made an attempt to longitudinally sample the same control woman
throughout pregnancy time consuming and often unsuccessful. Third, women who
have access to convenient community based care are understandably unwilling to
attend hospital specifically for study blood letting. Finally, blood sampling in the
community was not possible due to the lack of centrifuge facilities. For these
reasons, and the lime constraints of the author, control women were eventually all
recruited and sampled cross-sectionally at 12 (n = 20), 28 (n = 19) and 36 (/; = 19)
weeks' gestation. Non-diabetic women incurring complications during pregnancy
were excluded from the study.
Non-pregnant diabetic and non-pregnant non-diabetic women were also studied (n =
22 and n = 28 respectively). Glycated haemoglobin was measured at the time of
sampling in the diabetic group. All subjects gave informed consent. The study was
approved by the local ethics committee.
All samples drawn were analysed for cell adhesion molecule concentrations. The
sample size for CAM analysis was calculated on the basis of 90% power with
significance set at the 5% level. This indicated a minimal sample size of 12 women
to compare pregnant and non-pregnant groups, based on data from a previous report
of cell adhesion molecule concentrations in pregnant and non-pregnant women
(Lyall 1994).
Samples drawn at 36 weeks gestation in the diabetic and non-diabetic pregnant
groups, the non-pregnant diabetic samples and the non-pregnant non-diabetic
samples were additionally analysed for von Willebrand concentrations.
3.2.2 Preparation of samples
Peripheral venous blood was drawn from the subjects using a 20-ml syringe and 21-
gauge needle. Blood was drawn without the use of a tourniquet, as it is known that
von Willebrand factor, and therefore probably many other markers of endothelial
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function, is increased by venous stasis (Porta et al 1982). This may result from both
haemoconcentration and damage to the vascular endothelium (Stehouwer et al 1991).
The blood was transferred into pre-chilled tubes containing lithium heparin as
anticoagulant. Plasma rather than serum (in which coagulant factors have been
removed) is necessary for the determination of circulating von Willebrand
concentrations. Heparin was chosen as the anticoagulant as cell adhesion molecule
concentrations have been found to be higher in heparin-plasma samples than citrate-
plasma samples. Plasma was prepared by centrifugation at 2000 times g at 4°C within
5 minutes of blood sample collection. Aliquots of plasma were stored at -70°C until
analysis.
The cell adhesion molecules were measured by a commercially available enzyme-
linked immunosorbent assay (R&D Systems Europe Ltd., Abingdon, Oxon, UK).
Von Willebrand factor concentrations was measured by an established in-house
enzyme-linked immunosorbent assay. Rabbit anti-human polyclonal anti-vWF
antibody was used as the capture antibody. Peroxidase-conjugated rabbit anti-human
polyclonal anti-vWF antibody was used as the signal antibody (Ingerslev 1987).
3.3 Statistical analysis
3.3.1 Clinical data
Maternal age of studied groups was compared by Student's / test. Parity, smoking
habit and While class (for diabetic groups) (While 1949) were compared by X2
analysis.
3.3.2 Maternal glycaemic control (diabetic groups)
Haemoglobin Ale values were normally distributed. The effect of gestation on
HbAlc values was assessed by multiple measures analysis of variance. Subsequent
comparison of gestational to non-pregnant HbAlc values was assessed by Student's I
test.
3.3.3 Cell adhesion molecule concentrations
Cell adhesion molecule concentrations approximated normal distribution in pregnant
but not non-pregnant groups. Data from non-pregnant diabetic and non-diabetic
subjects were analysed by the Mann-Whitney U test. During pregnancy, change
relative to gestation within the diabetic subgroup (n = 10) was assessed by multiple
measures analysis of variance, and within the control group by simple analysis of
variance. Descriptive summary statistics for the comparison of pregnant groups is
presented as mean [SDJ. Comparison of non-pregnant data and non-pregnant to




If CAM concentrations were found to change significantly with gestation then
individual gestational time points could be compared between diabetic and control
groups at 12, 28 and 36 weeks gestation (Student's l test), and to non-pregnant values
(Mann-Whitney U test).
If there was no change in CAM concentrations with gestation, pregnancy was then
statistically assessed as a single time point in subsequent analysis of this data, and
data available from women not sampled longitudinally throughout pregnancy could
be included for analysis. For any diabetic women sampled more than once during her
pregnancy one of the available values was selected randomly to represent pregnancy.
(Available values were separately printed, folded to conceal the printed value, then
placed and mixed in a vessel, from which one was drawn by a non-author). In this
situation subsequent comparison between the pregnant diabetic and non-diabetic
groups was assessed by Student t test and used data available from all diabetic
subjects sampled (n = 28). The Mann-Whitney U test was used to compare pregnant
and non-pregnant women. In a similar manner, comparison of the pregnant diabetic
group and the control pregnant group allowed all control pregnancies sampled (n =
58) to be presented for analysis.
3.3.4 Von Willebrand factor concentrations
Von Willebrand factor concentrations approximated normal distribution in pregnant
and non-pregnant groups. Statistical analysis between pairs of groups was performed







There was no significant difference between the groups in terms of number of
previous pregnancies, smoking habit or White class (Table 3.1). Diabetic women
were younger than non-diabetic controls. One diabetic woman suffered progressive
retinopathy during pregnancy and required laser photocoagulation for proliferative
disease and early delivery (at 36 weeks' gestation). No diabetic woman developed
pre-eclampsia or gestational hypertension.
3.4.2 Maternal glycaemic control
Glyeaemic control in diabetic groups, as assessed by HbAlc determination,
improved significantly with gestation. By 18 weeks' gestation HbAlc measurements
were reduced significantly compared to those seen in non-pregnant diabetic women
and remained so for the remainder of pregnancy (Table 3.1).
3.4.3 Cell adhesion molecule data
All cell adhesion molecule concentrations were above the detection limit of the
applied assay (ICAM-1: 7ng/ml in plasma prior to dilution, VCAM-1: l()Ong/ml, E-
selectin: 2ng/ml). Comparison of the non-pregnant groups (Figure 3.1) demonstrated
significantly increased median [range] concentrations of the cell adhesion molecules
E-selectin (63.0 [20.2-107.0] ng/ml) and ICAM-1 (281.5 [171.6-778.4] ng/nrl) but
not VCAM-l (459.7 [301.0-909.7] ng/ml) in diabetic women compared to those
found in non-diabetic women (43.5 [18.1-93.2], 243.6 [ 174.4—329.2] and 476.0
[253.8-929.4] ng/ml respectively).
In pregnancy there was no significant change in the measured concentrations of the
cell adhesion molecules: E-selectin and ICAM-1 with respect to gestation in either
the diabetic (n=10) or control group (mean values throughout gestation for these
groups are shown in Table 3.2 and Table 3.3 respectively). No significant difference
in E-selectin and ICAM-1 concentrations was found on comparison of diabetic
pregnant (n=28) and non-diabetic pregnant data (n = 58), (E-selectin, mean [standard
deviation]: 50.2 [16.0] ng/ml vrs 46.5 [17.6] ng/ml and ICAM-1: 274.5 [ 107.5] ng/ml
vrs 287.2 [99.0] ng/ml respectively). Comparison of values in pregnant and non¬
pregnant women revealed that the median [range] circulating concentration of E-
selectin was significantly lower (P < .05) in pregnant diabetic women (49.9 [21.2-
75.3] ng/ml) compared to that found in non-pregnant diabetic women. There was no
significant difference in the concentration of ICAM-1 between diabetic groups, or of
either measured cell adhesion molecule between non-diabetic pregnant and non¬
pregnant groups (Table 3.4).
The circulating concentration of VCAM-1 changed significantly with respect to
gestation in the diabetic pregnant subgroup but not the non-diabetic pregnant group.
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Mean values at each gestation for both groups are given in Table 3.2. However there
was no significant difference in VCAM-1 concentrations between diabetic and non-
diabetic women at any corresponding gestation. (All available diabetic data was used
in this and the following analyses). Comparison of values in pregnant and non¬
pregnant diabetic women revealed a significant difference (P < .02) between diabetic
women sampled at 36 weeks gestation (n = 15) (median [range]: 582.8 [387.0-848.6]
ng/ml) and non-pregnant diabetic women (n = 22) (459.7 [301.0—909.7] ng/ml), but
not between any other gestational and non-pregnant data. There was no significant
difference between control pregnant and non-pregnant control VCAM-1 data.
3.4.4 von Willebrand factor data
The mean [SD] concentrations of von Willebrand factor in the non-pregnant diabetic
women (95.6 [27.5] ) and non-pregnant non-diabetic women (84.6 [35.5] u/ml) were
not statistically different. The mean [SD] von Willebrand factor levels were
significantly higher in pregnant diabetic women (200.1 [78.5] u/ml, P < 0.001)
compared to non-pregnant diabetic women. The mean [SD] von Willebrand
concentration was also significantly raised in the pregnant non-diabetic women
(189.5 [48.5] u/ml, P < 0.001) when compared to non-pregnant non-diabetic women.
There was no significant difference in von Willebrand factor concentrations between




Our finding that circulating concentrations of E-selectin and ICAM-1 arc selectively
elevated in non-pregnant diabetic women compared with those measured in non¬
pregnant non-diabetic women corresponds with previous studies in the general
diabetic population (Gearing 1992, Lampeter 1992). Increased endothelial expression
of these cell adhesion molecules, reflected by increased circulating concentrations,
provides a mechanism for the neutrophil activation and the vascular damage
demonstrated to occur in diabetes.
Clinical studies have demonstrated an increased incidence of vascular pathology in
diabetic women as a consequence of pregnancy. Based on these studies we
hypothesised that pregnancy in diabetic women would be associated with further
increased circulating concentrations of cell adhesion molecules. However, we found
no such increase in the circulating concentration of E-Selectin and ICAM-1 in the
pregnant diabetic group compared to the non-pregnant diabetic group or with
increasing gestation. Indeed, the concentration of E-Selectin, actually decreased from
that seen in the non-pregnant diabetic women as a consequence of pregnancy.
Altered shedding, dilution or excretion of cell adhesion molecules may occur as a
result of pregnancy so that the circulating concentrations of these molecules may no
longer represent their endothelial expression. However, the constant circulating
concentration of these cell adhesion molecules found throughout non diabetic
pregnancy and between non-diabetic pregnant and non-diabetic non-pregnant groups
suggests that this is not the case, as we would not expect any change in the
endothelial expression of cell adhesion molecules during uncomplicated pregnancy
in this group of women. Therefore, although the possibility of altered renal clearance
in pregnant diabetic women can not be excluded, the circulating concentrations of E-
selectin and ICAM-1 measured in the present population of diabetic women suggests
that pregnancy per se is not associated with increased endothelial expression of these
cell adhesion molecules.
The specific population of diabetic women participating in the present study may
account for apparent discrepancy between these findings and the outcome of the
referred clinical studies. Studies specifically determining the effect of pregnancy on
retinopathy such as that by Klein et al (1990) and the large Diabetes in Early
Pregnancy Study (Chew 1995) have stressed the importance of poor glycaemic
control at the onset of pregnancy, rapid improvement of glycaemic control during
pregnancy and advanced retinopathy before pregnancy as the major risk factors for
progression of retinopathy. Such factors have clearly been proven to be pivotal to
progression of retinopathy in the short-term upon the sudden introduction of tight
glycaemic control in the non-pregnant state (Kroc Collaborative study Group 1984,
Lauritzen 1985, Dahl-Jorgensen 1986). The women in the present study
demonstrated reasonable glycaemic control at the onset of pregnancy, and although
their control improved significantly during pregnancy this may not have been so
abrupt as to provoke increased endothelial expression of cell adhesion molecules,
vascular damage and retinal pathology.
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Clinical study (Garner 1990) demonstrating an increased incidence in pre-eclampsia
in pregnancies to diabetic women has shown that, as for progressive microvascular
disease, the incidence of this complication is increased in women with advanced
diabetic disease as classified by White class. The limited number of diabetic women
participating in our study and the lack of women with advanced diabetic disease may
explain why no woman in the present study developed this complication. We cannot
assess from this study whether women with more advanced diabetes would
demonstrate increased endothelial expression of cell adhesion molecules during
pregnancy which could in turn be associated with vascular complications, and this
requires further investigation. Only one woman with proliferative retinopathy during
pregnancy was sampled during this study. The concentrations of cell adhesion
molecules found within the plasma from this woman (E-selectin 48.1 ng/ml and
ICAM-1 263.6 ng/ml at 36 weeks' gestation), were not outside the range of
concentrations measured in diabetic women without complication.
It is tempting to speculate that the decreased circulating concentration of E-selectin
found in our population of diabetic women during pregnancy reflected their
improved glycaemic control as a consequence of this event. Hyperglycaemia has
been proven to cause vascular damage in animal models (Engerman and Klein 1986)
and improved glycaemic control is associated universally with delayed onset and
progression of microvascular disease in both animal and clinical studies when
maintained over the long term (Godine 1988). The introduction of improved
glycaemic control over a short period of time, such as during pregnancy, obviously
has a more complex relationship with vascular pathology. It is possible that the small
but significant improvement in glycaemic control in our population of women, who
demonstrated good glycaemic control before the onset of pregnancy, was of a
magnitude to provoke only a positive effect on the endothelial environment. We did
not directly correlate this short term improvement in glycaemic control, as assessed
by HbAlc measurements, with E-selectin concentrations due to this complex
relationship and because part of the reduction in HbAlc values may be explained by
a physiologic increased flux of red blood cells into the circulation during pregnancy
(Lind 1979)
No difference in the circulating concentration of VCAM-1 was found between non¬
pregnant diabetic and non-diabetic women. The ligand recognised by VCAM-1, very
late antigen-4, is not expressed on neutrophils but on other leukocytes important in
the later stages of inflammation. A selective increased endothelial expression of E-
selectin and ICAM-1 in diabetic subjects may emphasise that the vascular endothelial
damage occurring in this disease is an ongoing acute process reflecting short-term
fluctuations in glycaemic control, emphasising the need for improved control, such
as that demonstrated on a daily basis during pregnancy, in the general diabetic
population.
The significance of the change in VCAM-1 concentration during diabetic pregnancy
is unclear. A similar pattern of circulating VCAM-1 concentration was seen
throughout non-diabetic pregnancy but did not attain statistical significance. This
pattern, an initial decrease and then progressive increase, resembles the physiologic
change in blood pressure during pregnancy and hence could be a response to, or an
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altered shedding due to, this characteristic. Due to this pattern of VCAM-1 levels in
diabetic pregnancy VCAM-1 concentrations were significantly increased above those
measured in non-pregnant diabetic subjects at 36 weeks gestation but not at any other
measured gestational time-point. Of note the circulating concentration of VCAM-1
has been demonstrated to be increased in pre-eclampsia (mean: 841.9 [SD 49.7
ng/ml] compared to control pregnant women (mean: 560.2 [SD 47.9 ng/ml]) when
sampled in the third trimester of pregnancy (Lyall 1994). The mean VCAM-1
concentration can be seen to be much greater in the pre-eclamptic subjects than seen
in our diabetic cohort at 36 weeks gestation, suggesting that this finding at this
gestation in diabetic women is of little significance. This is further suggested by the
finding that the VCAM-1 concentrations at 36 weeks gestation in diabetic pregnancy
actually approximated the VCAM-1 concentrations found in the control pregnant
subjects both in the study of CAM concentrations in pre-eclampsia and the present
study. Furthermore if increased endothelial expression of VCAM-1 provides a
mechanism for vascular dysfunction this obviously is not primarily neutrophil
mediated.
We have demonstrated that pregnancy is associated with increased circulating
concentrations of von Willebrand factor in both diabetic and non-diabetic women.
This finding has previously been described in studies of uncomplicated pregnancies
in healthy subjects (Bergmann 1991, Deng 1994) and is thought to reflect a hormonal
/ oestrogen (Norris et al 1997) or lipidaemic (Sattar et al 1997) effect to promote
coagulation and fibrinolysis. Studies of pregnant women have however demonstrated
further increased circulating concentrations of von Willebrand factor in pregnancies
complicated by conditions associated with vascular damage i.e. pre-eclampsia
(Bergmann 1991). The degree of elevation of circulating values correlated with the
severity of pre-eclampsia (Deng 1994). Furthermore abnormally increased
circulating concentrations of von Willebrand factor have been found pregnancies
which later progress to become complicated by pre-eclampsia, suggesting that von
Willebrand factor concentration is a sensitive indicator of vascular damage and
dysfunction.
In the present study the circulating concentration of von Willebrand factor was not
significantly different in diabetic women compared to non-diabetic women during
pregnancy. This finding correlates with our demonstration that the circulating
concentrations of the specific cell adhesion molecules: E-seleclin, ICAM-1 and
VCAM-1 were not increased in diabetic women during pregnancy, and supports our
suggestion that the vascular damage and/or dysfunction are not increased in this
population of diabetic women during pregnancy.
In contrast to previous studies we did not demonstrate that von Willebrand factor
concentrations were significantly elevated in non-pregnant subjects as a consequence
of diabetes. This is contrary to what we would have expected given our finding of
increased circulating concentrations of the cell adhesion molecules E-Selectin and
ICAM-l in these women. However although not significant, the measured mean
concentration of von Willebrand factor in the diabetic non-pregnant women did tend
to be raised above that of non-pregnant non-diabetic women. We must therefore
consider that the power of the present study may not have been sufficient to
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statistically demonstrate such a difference between these non-pregnant groups,
reflecting the small number of women studied and the variance of von Willebrand
factor concentrations within these groups.
Alternatively it may be a true finding that significantly elevated CAM concentrations
occurs in isolation of von Willebrand concentrations in our population of non¬
pregnant diabetic subjects. These women demonstrated reasonable glycaenric control
and did not, on the whole, suffer any diabetic vascular complication other than mild
background retinopathy. The systemic indices of their perhaps mild vascular
dysfunction may not be uniform. The possibility of locally raised von Willebrand
factor concentrations in specific vascular beds i.e. the retina and the kidney cannot be
excluded.
Recently our laboratory has assessed endothelial function in diabetic pregnancy
utilising small artery wire myography preparations (Ang et al 2002). The vessels
(mean diameter 295 microns) were dissected from subcutaneous fat biopsies from
woman with pre-existing type 1 diabetes during pregnancy and non-pregnant diabetic
subjects. There was no difference in the response of these vessels to nitric oxide on
comparison of these groups, supporting our suggestion that pregnancy does not
increase vascular dysfunction in diabetic women.
One limitation of this study was the inability to sample some diabetic women and all
the control women longitudinally throughout pregnancy. This created a number of
statistical difficulties. Any change in the concentration of CAM throughout
pregnancy had to be analysed by different methods in diabetic and control groups. In
longitudinal data, each data point has a relationship/direct influence with the next.
Multiple measures analysis of variance is the most appropriate and most sensitive
analysis of such data. This was therefore applied to the diabetic data but could only
include for analysis the 10 women with complete longitudinal data sets. The cross-
sectional sampling of control pregnant women allowed assessment only by simple
analysis of variance, which is less sensitive. Subsequently, once it was demonstrated
that the concentrations of certain CAMs (E-Selectin and ICAM-1) did not change
during pregnancy, comparison of diabetic to control pregnancy values utilised
random gestational timed samples rather that simply choosing to compare samples
taken at a single gestation time point i.e. 36 weeks. This appears more "noisy" but is
in fact more statistically correct, as it avoids the introduction of any unintentional
bias to the analysis. Previously published studies have avoided these statistical
challenges by sampling women only once during pregnancy, typically at 34-36
weeks gestation. However, although our statistical analysis is more complex than in
these studies it is equally valid, and has greater ability to establish the effect of the
dynamics of pregnancy on circulating markers of endothelial dysfunction.
In conclusion, our findings do not support the hypothesis that increased endothelial
expression and shedding of cell adhesion molecules occurs in diabetic women as a
consequence of pregnancy. Rather, our findings suggest that the endothelial stimulus
to neutrophil activation and, hence, vascular damage, may actually decline in these








3.6 Recent advances in the study of cell adhesion molecules
Since the completion of our experimental work in the study of CAMs in diabetic
pregnancy, the study of CAMs out-with pregnancy has continued to advance at a
rapid rate. The study of CAMs remains an exciting area of research for a number of
reasons; circulating concentrations of CAMs act as useful tools to investigate the
pathophysiology of cardiovascular disease, they appear stratify disease severity and
prognosis (Blann and Lip 2000). In addition, the ability to 'blockade' CAM ligand
binding sites has opened a number of therapeutic possibilities in the management of
specific forms of cardiovascular disease (Harlan and Winn 2002).
The complex pathophysiology of diabetic vascular complications remains at the
forefront of study. Recent studies in the non-pregnant type 2 diabetic populations
have demonstrated that elevated circulating levels of E-Selectin and vWF are
correlated more closely to LDL cholesterol rather than HbAlc levels (Steiner et al
1994). Thus, promoting greater study of the primary aetiological role of 'insulin
resistance' in macrovascular disease (Chen et al 1999). Advances in this area will aid
our understanding of the aetiology and complications of gestational diabetes and type
2 diabetes affecting pregnancy, and may have implications for the optimum insulin
replacement profiles in type 1 diabetic subjects.
The therapeutic possibilities of CAM ligand blockade advanced from the
demonstration that knockout mice deficient in E-Selectin, P-Selectin or ICAM-1
develop less atherosclerosis than other mice (Mayadas et al 1993, Nageh et al 1997).
Blockade of leukocyte adhesion to the endothelium by monoclonal antibodies or
other antagonists to CAMs has been demonstrated to reduce vascular injury in
animal models. The disruption of selectin-carbohydrate ligands and integrin-
immunoglobulin superfamily appear to be the most efficacious (Cornejo et al 1997).
Trials of such therapy to reduce inflammatory based tissue injury in human diseases
(multiple sclerosis, inflammatory bowel disease and psoriasis) have shown some
success (Biogen: Press release 2004, Gencntech: Press Release 2001). The results of
similar studies in vascular ischaemia-reperfusion disorders (stroke, myocardial
infarction, and haemorrhagic shock) have however been disappointing to date (Dove
2000). Other strategies to disrupt the leukocyte-CAM interaction include the
disruption of second messenger systems with anti-sense oligonucleotides (Schreiber
et al 2001), and the inhibition of nuclear factor-Kb (Barnes et al 1997), both of which
have the potential to reduce the 'inside-out' signalling of CAM activation.
Although the use of such therapeutic moieties are not yet established, the use of
circulating CAM levels to stratify the risk of cardiovascular disease progression is
supported by a number of studies. Raised ICAM-1 predicted future acute coronary
events in a population with previously documented coronary vascular disease (Haim
et al 2001), whilst raised VCAM-1 was the strongest predictor of future
cardiovascular deaths in a similar population (Blankenberg et al 2001). Raised CAM
levels, specifically ICAM-1 (Ridker et al 1998, Hwang et al 1997) and P-Selectin
(Ridker et al 2001), have also been shown to predict future cardiovascular disease in
apparently healthy individuals. Acting as such a marker of severe disease or active
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disease raised circulating CAM concentrations could be used successfully to target
the use of established therapeutic agents and reduce morbidity and mortality.
The value of such advances in these areas of CAM research has at present little
implications for the management of diabetes in pregnancy. The therapeutic use of
CAM blockade in the treatment of vascular condition arising in or affecting
pregnancy is unlikely ever to be justified due to the importance of CAMs in fetal
structural development, even if placental transmission of putative therapeutic agents
could be made negligible. However, as the value of soluble CAM concentrations in
cardiovascular risk assignment becomes established, certain diabetic women,
especially those with an apparent absence of clinically evident vascular
complications, may be advantaged by selection for more intensive care/insulin
regimes on the basis of circulating CAM levels in early pregnancy. Future research
































































































Table3.1ClinicalharacteristicsofDi b tindCo t olGr ups(f rthstu ycirc l tingl adhesionmoleculeconcentrations). Datarepresentedsmean(standarddevi tio ).a>b>cComp risoofm t r lgbe w ns u ygro psc r n ing gestationsw sas essedbyStud nte t(P<.05).*HbAlcv luechang dsi nificantlywi hge tat onintdiasubgr up
(P<.002,datanotshown).Comparisonofgestationalwi hnon-pregnantHbAlcv luesa ses edbyStud nte .l normalreferencerange=3.4-5.2%.'P<.02,^ 0 ,§0 05
Gibson J.L.
Study Weeks No. E-Selectin ICAM-1 VCAM-l


























Table 3.2 Plasma cell adhesion molecule concenlrations
throughout pregnancy in women with diabetes.
Data are presented as mean (standard deviation). The values are calculated
from the assay results of the subgroup of 10 diabetic subjects sampled
longitudinally throughout pregnancy. Change in concentration with respect to
gestation in this diabetic group was assessed by multiple measures analysis of
variance. VCAM-l concentration changed significantly with gestation in the
diabetic population.
*P < .05.




Study Weeks No. E-Selectin ICAM-1 VCAM-1
group gestation ng/ml ng/ml ng/ml
Control 12 20 44.7 (9.8) 268.6 (102.7) 446.8 (1 17.1)
Control 28 19 48.8 (20.9) 293.9 (89.2) 420.1 (134.9)
Control 36 19 45.8 (19.7) 293.6(101.6) 502.6 (139.2)
Table 3.3 Plasma Cell Adhesion Molecule Concentrations during
pregnancy in control subjects.
The subjects were sampled cross-sectionally at each gestational time point.
Data are presented as mean (standard deviation). There was no change in the
concentration of any cell adhesion molecule with respect to gestation in the
control group as assessed by analysis of variance.




Study group No. E-selectin ICAM-1
ng/ml ng/ml
Diabetic non-pregnant 22 63.0 (20.2 -107.0)* 281.5 (171.6-778.4)
Diabetic pregnant 28 49.9 (21.2 -75.3)* 252.0(180.9-777.3)
Control non-pregnant 28 43.5 (18.1 -93.2) 243.6 (174.4-329.2)
Control pregnant 58 45.3 (22.0-98.9) 260.8 (170.3-574.2)
Table 3.4 Plasma Cell Adhesion Molecule Concentrations:
Comparison of pregnant and non-pregnant groups
(E-Selectin and ICAM-1)
Data are presented as median (range). There was no significant difference in
E-Selectin or ICAM-1 concentrations on the comparison of women with and
women without diabetes during pregnancy. This contrasts the findings on
comparing non-pregnant data (figure 3.1). E-Selectin concentrations were
significantly lower in diabetic women during pregnancy than in non-pregnant
diabetic women. * P < 0.05.




















































Figure 3.1 Plasma cell adhesion molecule concentrations: Comparison
of non-pregnant groups.
Box plots (Median, 25th and 75th percentile, 10th and 90th percentile) of plasma cell
adhesion molecule concentrations in non-pregnant diabetic and control women. The
Mann -Whitney U test was used to compare diabetic and control data.





Maternal diabetes mellitus and placental terminal villus
structure
4.1.1 Pathophysiology of the placenta in relation to fetal
complications.
The placenta forms the interface of the maternal and fetal environments. The fetus
has an integral relationship with the placenta and is reliant on its multiple functions.
The placenta effects the transfer of maternal nutrients and oxygen to the fetus and the
reverse transfer of metabolic waste products such as carbon dioxide, urea and
bilirubin to the maternal circulation. It is involved in the synthesis of various
hormones. It also provides an immunological barrier, protecting the fetus from the
maternal immune system in addition to certain bacteriological and viral pathogens.
Placental structure and function frequently reflect and may contribute to the
aetiology of a number of fetal and maternal complications. Pathological examination
of the human placenta has demonstrated characteristic placental lesions in the
presence of many maternal complications, such as pre-eclampsia, anti-phospholipid
syndrome (APS) and anaemia, and fetal conditions such as intrauterine growth
restriction and hydrops. Characterisation of placental abnormalities has helped
decipher the pathophysiology of certain fetal complications: placental infarction in
maternal APS and terminal villous deficiency in IUGR (Macara et al 1996). The
placenta from pregnancies complicated by maternal diabetes mellitus has been
subject to numerous studies but a lack of consensus of characteristic findings
remains.
4.1.2 The development of the human placenta
Fertilisation of the oocyte initiates development of two specialised structures: the
fetus and the placenta. The fertilised oocyte or zygote undergoes a series of rapid
mitotic divisions. When successive cleavages have resulted in a 12 to 16 cell
structure, 3 days post fertilisation, the period of the morula begins. Fluid filled spaces
appears inside this compact mass of cells. This blastocyst cavity separates the cells
into two parts: the inner cell mass, from which forms the embryo and the outer cell
layer termed the trophoblast which gives rise to the placenta.
At implantation (day 5-6) the trophoblast attaches to the endometrial epithelium
(Schlafke 1975). Rapid proliferation of the trophoblast occurs within the innermost
layer of the trophoblast, the cytotrophoblast. Cells from this layer migrate
peripherally and lose their cell borders forming an outer multinucleated mass, the
syncytial trophoblast. Finger like processes of the syncytial trophoblasl invade the
endometrial stroma and form lacunae. When the trophoblast invades the maternal
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vasculature blood enters the lacunae and a primitive placental circulation is
established (Moore 1982)
4.1.3 The development of placental villi
Proliferation of the cytotrophoblast to form finger like extensions covered with
syncytial trophoblast herald the formation of the first villi (Castellucci 1982). From
day 15 secondary villi are formed when mesenchyme extending from the embryo
grows into the villi and differentiates into connective tissue (Luckett 1978). When
the blood vessels form in this connective tissue the tertiary villi are formed (Demir
1989) and a primitive blood supply from the fetal circulation to the placenta is
established. From the 6lh week post fertilisation these mesenchymal villi branch,
giving rise to others by trophoblastic sprouting and vascularisation. At this stage in
placental development there is no formal intervillous circulation and the developing
placenta and fetal tissues are hypoxic relative to the mother (Rodesche et al 1992).
This may serve to protect the developing embryonic tissues from exposure toxic free
radical formation. It is not until the 10-12 week post fertilisation that the intervillous
space is perfused with maternal blood. This follows trophoblast invasion of the
maternal uterine spiral arteries (Hustin et al 1988) and establishes the haemochorial
relationship between fetal and maternal blood in the human placenta.
The mesenchymal villi develop a reticular stroma and at this stage of development
are termed immature intermediate villi (Kohnen 1994). The connective tissue in the
stroma of these villi becomes denser as they develop into fibrosed stem villi. The
development of additional immature intermediate villi ceases at the end of the second
trimester. Transformation of immature intermediate villi into stem villi continues and
therefore the number of stem villi becomes finite.
At the beginning of the third trimester the mesenchymal villi switch from developing
into immature intermediate villi to differentiation into mature intermediate villi
(Castellucci 1990). These villi do not further differentiate but instead give rise to
terminal villi.
4.1.4 The terminal placental villus
Terminal villi form when the longitudinal growth of the capillaries within the mature
intermediate villi exceeds the long longitudinal growth of these villi. The capillaries
become coiled and form loops that bulge through the trophoblast surface layer
(Kaufmann et al 1985 & 1988). The bud-like terminal villi are therefore formed
passively, rather than by active differentiation. Due to the mechanism of their
formation the trophoblast layer of the terminal villi is stretched and thinned. These
thinned areas are where the distance dividing the maternal and fetal blood is at its
minimal. Especially thinned areas overlying capillary loops are termed epithelial
plates or vasculosyncytial membranes. Terminal villi thus effect the vast majority of
feto-maternal and maternal-fetal transfer of substances.
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4.1.5 The basic structure of the human placenta at term.
The basic structure of the placenta at term (Figure 4.1) consists of several main stem
villi (rami chorii) each of which branches dichotomously to form a further 3-30
generations of stem villi (ramuli chorii). These in turn have given rise to mature
intermediate villi and thereafter to terminal villi (Castellucci 1990, Leiser 1991).
Stem villi are identified histologically by their dense fibrous stoma that reaches to the
trophoblast surface. The trophoblast surface of stem villi may be damaged and
replaced by fibrinoid in term placentae. Stem villi contain large blood vessels that
have an identifiable media and adventitia on light microscopy. At term they account
for 20% of villous volume.
The mature intermediate villi account for 30 - 40 % of villous volume. They in
general have a smaller diameter (60 - 150 pm) than stem villi, and demonstrate an
absence of stromal fibrosis and vessels with an identifiable media. They instead have
a loose connective tissue rich in cells and poor in fibres and contain slender
capillaries. At term a small proportion of villous volume is composed of immature
intermediate villi (<10 %) that are identifiable by net like connective tissue forming
stromal channels and proportionally to their size relatively few fetal vessels.
Terminal villi account for 40% or more of villous volume at term. They average 40 -
80 pm in diameter, contain scant amounts of connective tissue fibres and cells.
Capillary lumens account for approximately half of their stromal volume, and bulge
against 30 - 40% of the surface trophoblast forming the 'vasculosyncytial
membranes' (Kaufmann 1985).
4.1.6 Placental Transport Functions
The trans-placental passage of substances is either passive, determined by
concentration gradients, or by unidirectional facilitated or active, carrier-mediated
transport. Oxygen and carbon dioxide are small molecules and cross the placenta by
simple diffusion down a concentration gradient. Passage across the placental barrier
is usually rapid and therefore their rate of exchange is largely determined by their
delivery to the area i.e. is blood flow limited. Maternal blood flow in the intervillous
space and fetal flow through the villous capillaries determine the delivery to and
removal of substances at the area of exchange and set the concentration gradients.
Transport of glucose as an energy supply to the fetus also occurs down a
concentration gradient but is effected by placental facilitated diffusion. The glucose
transporter GLUT1 has been identified in both the microvillous and basal plasma
membranes of the syncytium. This transport system for D-glucose becomes saturated
only at high, supra-physiological maternal concentrations of glucose (>20 mmol/1)
(Hauguel et al 1986). Fetal arterial or plasma D-glucose is therefore a function of the




Other nutrients may be transported to the fetus against a concentration gradient.
Amino acids concentrations are higher in fetal than maternal plasma and. An optimal
fetal supply is determined by active transport systems. Transfer of these substances
to the fetus is therefore potentially less sensitive to maternal concentrations and to
placental structural than that of oxygen and glucose.
The active functions of the placenta require an energy source. The placenta utilises
glucose as its main energy supply. Although it is estimated that the placenta can
utilise one-third of transported glucose for its own metabolic process, it only appears
to be capable of limited metabolism of this glucose to lactate via anaerobic
glycolysis. The lactate is passed to the fetus where it is further metabolised/ oxidised
through the Krebs cycle and therefore provides the fetus with energy equivalent to
glucose. The placenta therefore utilises little of energy substrate passing from the
mother to the fetus (Desoye and Shafrir 1996).
4.1.7 Regulation of placental blood flow
Utero-placental and feto-placental blood flows are major determinants of maternal-
fetal exchange. Utero-placental blood flow is compromised in maternal pre¬
eclampsia as a consequence of inadequate trophoblast invasion of the uterine spiral
arteries. Blood circulating around the intervillous space may be impeded by the
architecture and density of the villous tree. A reduction in utero-placental blood flow
by 35-45% has been documented in maternal diabetes (Nylund et al 1982)
presumably reflecting an increased villous mass. Recent stereolological studies have
however calculated that the intervillous volume is conserved in diabetic pregnancies
when the mother achieves good glycaemic control (Mayhew et al 1994).
Feto-placenta blood flow may be influenced by the architecture of the villous
vascular tree and the vascular tone of vessels with a smooth muscle component, such
as the arteries and arterioles of the stem villi. The placental is not innervated (Reilly
& Russell 1977); thus vascular tone of the feto-placental circulation may only be
regulated by local concentration changes in vasoconstrictor or vasodilator
substances.
Nitric oxide is likely to be a key vasodilatory agent. Nitric oxide synthase has been
located by immunocytochemistry in both the feto-placental vascular endothelium and
in the villous syncytiotrophoblast (Myatt et al 1993). Placental vascular sensitivity to
NO has been demonstrated in perfused cotyledons (Myatt et al 1991). Other
vasodilatory agents such as atrial natiuretic peptide (ANP) and prostacyclin may play
additional roles. ANP receptors have been characterised in smooth muscle cells from
stem vessels (McQueen et al 1991). However ANP has not been documented to be
synthesised by the normal term placenta (Inglis et al 1993) and may therefore act in
an endocrine fashion after production by the fetal heart (Wharton et al 1988). The
role of prostacyclin is unclear, as inhibition of its synthesis has been documented to




Thromboxane, endothelin and angiotensin II have all been demonstrated to have a
vasoconstrictive effect on the feto-placental circulation (Mak et al 1984, Myatt et al
1991, McQueen et al 1991). Thromboxane may be produced by the trophoblast,
arterial smooth muscle cells (Templeton et al 1991) or by circulating platelets.
Endothelial cells are known to synthesise ET-1, and synthesis of ET-1 has been
demonstrated in the human placenta (Benigni et al 1991). Angiotensin II may act in
an endocrine manner following production by the fetal kidney. There is also some
evidence to support local production of angiotensin within the placenta (Ihara et al
1987).
The production of the vasoactive substances is likely to play a role in local regulation
of blood flow in the placenta at term and possibly during development. The precise
mechanisms of such a vaso-regulatory system are not yet deciphered. Studies of
pregnancies complicated by IUGR have however suggested that it is the structure of
the distal villous tree that has a more important influence on feto-placental blood
flow. The vessels of the distal villous tree do not contain smooth muscle therefore
their vascular resistance will not be influenced by vasoactive substances. It is the
architecture of these small diameter vessels, particularly their length and branching
patterns that appear to play a key role in feto-placental blood flow impedance (Krebs
et al l 996).
4.2.1 The study of placental structure
Gross examination of placenta should include placental weight and macroscopic
appearance. Placental weight correlates poorly with fetal weight and may be altered
in specific pathological conditions: increased in diabetes and fetal hydrops and
reduced in 1UGR and preeclampsia. Macroscopic lesions such as areas of infarction
and haemorrhage visible to the naked eye and are valuable findings.
Light microscopy is used to study the placenta in more detail. It allows individual
villous types to be visualised, allowing assessment of numbers and basic structure.
To aid assessment of structural components specific stains of the tissue sections can
be used, such as the Masson trichrome technique, which accentuates stromal
staining. More specific structural proteins can be targeted for staining by
immunohistochemical techniques and can to advance the study of tissue morphology
at this magnification.
Histomorphometric techniques have been devised to calculate an estimated
quantification of villous or specific tissue volumes. These stereological studies lay a
grid system of points and intersections over the viewed light microscopy image.
Tissue volumes and surface areas are estimated by counting tissue overlying grid
points and intersections and entering these values into established formulae (Aherne
& Dunhill 1966, Boyd et al 1986, Teasdale 1981,1983,1985). Profile counting of
structures such as villi can be used to derive length densities (Mayhew et al 1992).
The densities are corrected for tissue shrinkage during processing. Component
densities can be converted into absolute quantities using estimates of placental
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volume calculated from organ weight and density (Assumed to be 1.05g/ml).
(Mayhew et al 1994).
Electron microscopy allows the tissue to be studied at higher magnification. It thus
allows structures indiscernible to light microscopic analysis to be visualised i.e.
collagen fibres or intracellular organelles, and measured i.e. the thickness of the
trophoblast basal lamina.
4.2.2 Placental vascular casts: an alternative method of
ultrastructure determination.
Many studies may be limited by their two dimensional analysis of villous sections.
Three-dimensional studies of placental villi may improve our understanding of
pathological findings. This may be of particular importance in determining the
precise structure of the intravillous vascular tree. The vascular infrastructure of
placental villi has been studied in animal and human placenta by microvascular
casting techniques (Thiriot and Panigel 1978, Habashi et al 1983, Lee and Yen 1983
and Leiser et al 1985) and have allowed detailed analysis of the villous vascular tree.
The technique employs a low viscosity plastic to perfuse one or several adjacent
cotyledons via cannulation of an extra cotyledonar artery. The low viscosity of the
polymer liquid is essential, and has been perfected by Leiser (1985) for this
technique to allow uniform filling of placental microvessels at low pressure.
Following polymerisation and hardening of the vascular cast the overlying tissue is
corroded from the cast by immersion in a strong alkaline solution. The three
dimensional vascular network may then be analysed by scanning electron
microscopy. Using this technique our department has successfully studied and
detailed placental terminal villous vasculature abnormalities in pregnancies
complicated by intrauterine growth restriction (Krebs et al 1996).
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4.3.1 Placental angiogenesis and villous structure in pregnancies
complicated by intrauterine growth restriction.
In certain pregnancies complicated by IUGR Doppler studies have observed that the
diastolic component of the arterial flow rate in the fetal umbilical artery was reduced,
absent or even reversed (Jouppila et al 1984, Laurin et al 1987, Fairley et al 1991),
indicating increased vascular impedance (Adamson et al 1980). Recent studies of
terminal villous structure and terminal villous vascular development in such
pregnancies have recently been performed in our department (Macara et al 1996,
Krebs et al 1996). These studies have greatly advanced the understanding of the
pathophysiology of this condition.
Macara et al (1996) studied the anatomical composition of placenta from pregnancies
complicated by severe intrinsic intrauterine growth restriction associated with absent
arterial flow in the fetal umbilical artery. They demonstrated that there was
significantly less villous tissue in these placentae than in matched controls, as could
be expected reduced placental weight. However importantly they demonstrated that
this was a selective reduction in the volume of peripheral villi in these IUGR
placentae. Placental vascular casts were also prepared from these IUGR pregnancies.
Analysis of these casts by scanning electron microscopy demonstrated the peripheral
vascular network to be abnormal, being composed of fewer vessels which were
elongated, and lacked branches, coiling and sinusoidal dilatations (Krebs et al 1996).
As vessel coiling and branching underlies terminal villous formation these findings
are consistent with reduced terminal villous formation and therefore numbers.
The cross-sectional ultrastructure of the terminal villi was studied in detail by
transmission electron microscopy of perfusion fixed placental tissue obtained from
the same pregnancies (Macara et al 1996). The terminal villi were smaller in
diameter than those seen in control placentae. They demonstrated increased numbers
of syncytial trophoblast nuclei, reduced cytotrophoblast nuclei, thickened trophoblast
basal lamina and increased stroma. They noted that these findings were not
consistent with villous hypoxia in vivo rather they suggested increased oxygenation
of the villi. Further immunohistochemical studies performed on paraffin embedded
tissue demonstrated increased stromal deposition of collagen and laminin and a
reduced numbers of proliferating cytotrophobast in these villi, further evidence that
these villi appear to have been exposed to increased oxygen tensions.
These studies demonstrated that the pattern of vessel growth and terminal villous
structure in these IUGR pregnancies was not characteristic of placental ischaemia or
hypoxia. Indeed the morphology of the terminal villi suggest that that these villi were
exposed to greater than normal partial pressures of oxygen delivered by the maternal
blood. A primary disorder of placental angiogenesis was therefore implicated in the
aetiology of this 'intrinsic' type of IUGR. This is an important observation and has
implications in the management of such IUGR pregnancies. Attempts to supplement
maternal oxygen or to dilate the maternal circulation are unlikely to be of therapeutic
benefit and may be inappropriate (Kingdom et al 1997).
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4.3.2 Fetal hypoxia: Placental angiogenesis and villous structure.
By defining the pathological basis of fetal hypoxia in severe 'intrinsic' intrauterine
growth restriction Kingdom and Kaufmann (1997) were able to move away from the
belief that fetal hypoxia is always secondary to placental hypoxia. They proposed
varying mechanisms of fetal hypoxia: (1) pre-placental hypoxia, in conditions such
as maternal anaemia, heart disease or pregnancy at high altitude, (2) utero-placental
hypoxia in pre-eclampsia and (3) post-placental hypoxia in 'intrinsic' IUGR.
In pre-placental hypoxia there is a reduction of the oxygen content of blood flowing
from the mother though the normally dilated spiral arteries and bathing the placental
villi. All these conditions are associated with the same characteristic placental villous
structure. Capillary volume capacity is increased (Jackson et al 1987). There is
increased capillary branching (Ali et al 1996) and the volume of the cytotrophoblast
is increased in pregnancy at high altitude. Hypoxic hypoxia induced in the guinea pig
model is associated with increased elaboration of villous vasculature in addition to
decreased density of the stromal matrix (Scheffen et al 1990). Maternal anaemia is
also associated with evidence of increased angiogenesis, with increased capillary
volume (Burton et al 1996) and branching (Kadirov et al 1996). Proliferation and
volume of cytotrophoblast is increased in an inverse relationship to the severity of
anaemia (Kadirov et al 1996).
Pre-eclampsia is associated with utero-placental hypoxia. Aberrant invasion of the
spiral arterioles by proliferating trophoblast in the second trimester results in these
vessels maintaining their high resistance to maternal blood flow. A limited flow of
normally oxygenated blood is available to bathe the placenta. Capillary volume
fraction is increased (Salvatore 1968, Burton et al 1996) and there is an increased
amount of villous cytotrophoblast (Fox 1964).
In pre-placental hypoxia and utero-placental hypoxia the placental villi are hypoxic
in series with the fetus. Placental histological findings are therefore similar in both
conditions with evidence of increased angiogenesis and cytotrophoblast proliferation.
This is in contrast to the histological findings in placenta from 'intrinsic' 1UGR
pregnancies. The lack of angiogenesis and reduced cytotrophoblast volume in these
placental villi demonstrates that they are well oxygenated but fetal hypoxia still
occurs. The deficient placental angiogenesis is suggested to restrict the ability of the
fetus to extract oxygen from the placenta, therefore giving rise to the term post-
placental hypoxia.
4.3.3 The control of placental angiogenesis
Capillary growth and branching are important in the formation of the placenta and its
development as low impedance circuit. Angiogenesis is stimulated by the release of
growth factors from oxygen deprived villous tissues. Studies have demonstrated that
placental tissue expresses a number of angiogenic growth factors such as basic
Fibroblast Growth Factor (bFGF) (Ogawa 1991, Shreeniwas et al 1991), Vascular
Endothelial derived Growth Factor (VEGF) (Sunderkotter et al 1994, Sharkey et al
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1993, Ahmed et al 1995) and Placenta Growth Factor (P1GF) (Ahmed et al 1997) and
their receptors including VEGFR-1 (Flt-1) and VEGFR-2 (fllk-l/KDR) (Ahmed et al
2000). The villous macrophage appears to be the dominant site of production of
bFGF and VEGF and is implicated to play a key role in villous oxygen-sensitive
angiogenesis.
Vascularisation of the placental villi starts at day 21 post conception (Demir et al
1989) and is the result of local de novo formation of capillaries from the
mesenchyme of the secondary villi. The appearance of macrophages in these villi
predates capillary formation consistent with a role in angiogenesis. Their expression
of angiogenic growth factors suggests they perform this function via a paracrine
mechanism (Desmir et al 1989, Ahmed et al 1995).
Villous vasculature increases by branching until the end of the first trimester. The
vessels in the largest villi become surrounded by adventitia and the villi differentiate
into stem villi. From 26 weeks of gestation until term the villus vasculature
undergoes a change from branching to non-branching angiogenesis. This is the stage
of formation of the mature intermediate villi and from then on angiogenesis
determines the capacity of the villi for gas exchange.
VEGF appears to perform as a key angiogenic factor. VEGF expression in the human
placenta has been localised by in-situ hybridisation and immunohistochemical
techniques to the villous trophoblast and macrophages of both fetal and maternal
origin. If exerts its effects by binding to two tyrosine kinase receptors VEGFR-1/ Flt-
1 and VEGR/KDR present on endothelial cells (de Vries et al 1992).
P1GF belongs to the VEGF family and shares 53% homology with VEGF (Magilone
et al 1991). Its expression in the human placenta has been localised to the villous
synctiototrophoblast and the media of larger stem vessels (Shore et al 1997, Khaliq et
al 1996). In in-vivo and in-vitro studies VEGF binds to both FLt-1 and KDR
receptors and performs as a potent stimulus for endothelial proliferation, migration
and production of the plasminogen activators required for proteolytic degradation of
the extracellular matrix. P1GF appears to act as a less potent stimulus for endothelial
cell chemotaxis and proliferation. P1GF binds to FLt-1 but not the KDR receptor.
In the human placenta it is proposed that the type of angiogenesis; branching or non-
branching is dependent upon the relative expression of VEGF, P1GF and the VEGF
receptors (Kaufmann et al 1985, Leiser et al 1985). VEGF and KDR are most intense
during early gestation and decline as pregnancy advances (Jackson et al 1994). P1GF
and Flt-1 expression increases towards term. VEGF appears to promote the initial
capillary formation and branching angiogenesis. P1GF appears to be more involved
in non-branching angiogenesis, the formation of intermediate villi and with
increasing vessel length the subsequent formation of terminal villi when villous
length overtaken.
Oxygen saturation may be a major regulator of the balance between VEGF and
PLGF function. In placental tissues VEGF is up-regulated by hypoxia and down-
regulated by hyperoxia (Shore et al 1997, Wheeler et al 1995). Hypoxia has been
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demonstrated to down regulate P1GF mRNA and protein in human placenta (Khaliq
et al 1999). The importance of the interaction of growth factors in establishing
placental angioarchitecture is emerging in studies of IUGR pregnancies. P1GF
expression is significantly increased in these pregnancies (Ahmed et al 2000),
supporting the suggestion that the villi are "hyperoxic" (Kingdom and Kautmann
1997) and provides a mechanism, a premature P1GF to VEGF dominance that may
account abnormal villous vascualture in this condition.
4.4 The placenta from pregnancies complicated by maternal
diabetes.
The placenta from diabetic pregnancies has been subject to many studies however
there remains a lack of consensus as to the presence and nature of any characteristic
findings. The earliest studies of diabetic pregnancies commented on the increased
weight and blood content of the placentae and correlated this to the increased size of
the fetus (Klebe 1974). Recent studies of placentae from diabetic pregnancies have
suggested that placental (and fetal) weight is normalised if good maternal glycaemic
control is achieved throughout pregnancy and there is an absence of any additional
complications such as pre-eclampsia and intrauterine growth restriction (Mayhew
1994).
Structural studies of placenta from diabetic pregnancies have largely been based at
the light microscopy level. Observed abnormalities are varied and have included
increased villous oedema (Aladjem 1967, Fox 1969, Jones and Fox 1976a),
immaturity (Laurin et al 1987) increased cytotrophoblast numbers, syncytial
trophoblast knot formation and increased macrophage numbers (Fox 1969, Jones and
Fox 1976b) in addition to increased stromal fibrosis (Jones and Fox 1976a).
Increased oedema and increased cytotrophoblast numbers are often described as
villous immaturity in these studies. Most studies have reported abnormalities of the
villous vasculature. The majority of studies reported an increased total surface area
of capillaries, however, this has been in association either with (Teasdalel981,
1983,1985, Boyd 1986, Bjork & Persson 1984, or without (Clavero et al 1963) a
reported increased surface area of the villi.
The varied pathological findings between studies reflect to some extent the differing
methodologies of the studies, but most importantly the differing populations of
diabetic women sampled. The majority of studies fail to define their populations of
diabetic women (with regard to their duration and severity of diabetes) and could
include placenta obtained from women with recent onset diabetes and those with
advanced diabetic vascular complications. Some studies also contain placentae from
diabetic pregnancies complicated by other pathological conditions. The difficulty of
interpreting the published literature of diabetic placenta may be illustrated by
considering in more detail the revered studies by Boyd (1986) and Teasdale (1981-
85).
Boyd et al (1986) used morphometric techniques to compare villous surface area and
the volume of parenchymal tissue to that of non-parenchymal tissue in fourteen
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diabetic pregnancies and twenty-two control pregnancies. Parenchymal tissue was
termed to compose of villi (including fetal vessels) and the maternal intervillous
space i.e. the volume of placenta potentially effecting nutrient exchange. Non-
parenchyma comprised chorionic and decidual plates, fetal vessels with a diameter
greater than 1mm. They demonstrated that the total volume of placenta was larger in
diabetes (+12%), however the volume of parenchymal tissue was disproportionately
increased (+20%), as was villous surface area (+52%). The difference was
maintained despite correcting for an increased birthweight in these diabetic
pregnancies. This data suggested that despite just being larger, placentae from
diabetic pregnancies had altered differentiation with apparent increased nutrient
exchange capacity per volume. The diabetic subjects were described as having
diabetes of 3-23 years gestation and who achieved 'moderate' or 'good' diabetic
control during pregnancy. None developed preeclampsia or hypertension during
pregnancy.
The exhaustive studies performed by Teasdale (1981-85) also used morphometric
techniques to assess relative quantities of parenchyma and non-parenchymal tissue in
diabetic pregnancies. Again parenchyma was defined as the part of the placenta that
contained the structures or compartments that are strictly concerned in metabolic
exchange between the mother and fetus. In these studies parenchyma composed the
intervillous space, the trophoblast volume and the fetal capillaries of both peripheral
and stem villi. Non-parenchyma included the connective tissue of the villi. Teasdale
separately studied placenta from pregnancies from women classified as white class A
(1981), B (1983) and C (1985). His results suggested a tendency to an increased
surface area of exchange in these placenta compared to controls but confusingly the
volume of parenchyma to non-parenchyma tissue was relatively increased in class A
diabetic pregnancies reduced in class B diabetic pregnancies but conserved in
placenta from White class C pregnancies.
The definition of parenchyma differs between studies. Teasdale attempted clarify the
previous confusing pathological findings of diabetic placenta by stratifying maternal
diabetic disease. Both studies did not assess maternal glycaemic control, which may
be a more important variable in placental differentiation.
In reviewing the published studies of diabetic placental pathology it is important to
note that the current management of diabetes now outdates the majority. The
management of diabetes in general, and diabetes in pregnancy has improved
substantially over the past 20 years. The findings of the quoted studies, even if
consistent, may not be representative of placental structure in current populations of
diabetic women who have the potential to achieve far superior glycaemic control
than their predecessors.
There are few recent studies of diabetic placentae. The most notable are from
Mayhew et al (1994) and use stereographical techniques to compare the structure of
placentae from pregnancies to women with diabetes who demonstrated good
glycaemic control with that from non-diabetic control pregnancies. Placentae were
obtained from two groups of diabetic women, 39 women classified as White's group
A-C and 16 women with a longer history of diabetes or diabetes complicated by
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vascular pathology (White groups D-F/R), in addition placentae from non-diabetic
control pregnancies (n = 34). Good glycaemic control was advocated (aiming for a
mean blood glucose < 6 mmol/L, HbAlc values were < 7% in all groups at term). All
pregnancies were delivered after 37 weeks gestation with no evidence of fetal
malformation. Their study demonstrated that despite a tendency to increased
placental weights in pregnancies to diabetic women classed in A, B and C White
Classes, there was no significant difference in fetal and placental weights between
control pregnancies and any class of diabetic pregnancy suggesting that improved
maternal glycaemic control normalises findings.
At an ultrastructural level they calculated that the volume of peripheral villi, the
intervillous space, non-parenchyma and fibrin deposits were similar in diabetic and
control placentae. On assessment of villous composition they found that these
volume of fetal capillaries was significantly increased in diabetic placentae. They
found comparable volumes of cytotrophoblast, syncytiotrophoblast and stromal
connective tissue in diabetic and control placental villi. They additionally calculated
that diabetic placental villi had both an increased length and surface area of
capillaries. The villi themselves were of increased length but not surface area in
diabetic placentae. These findings suggest that in diabetic pregnancies the placental
villi are hypervascularised. They concluded that the villi in placentae from diabetic
pregnancies appear potentially better adapted to effect nutrient exchange raising the
possibility that the fetuses of diabetic mothers may be trying to adapt to a state of
chronic hypoxia.
In parallel studies (Mayhew et al 1993) they aimed to assess the oxygen diffusive the
diabetic placentae. The oxygen conductance of a placenta was calculated by
estimating and summating the conductance of six tissue compartments; maternal
erythrocytes, maternal plasma, trophoblast, stroma (including capillary endothelium),
fetal plasma and fetal erythrocytes. This complex analysis aims to assess the ease
with which oxygen can dissociate from maternal haemoglobin, pass through tissue in
soluble form and associate with fetal haemoglobin. The physiochenrical variables of
conductance (chemical reaction rates of oxygen and maternal and fetal blood,
solubility of oxygen in plasma and villous tissue) are fixed and were taken from
previously published data therefore placental conductance was calculated to be
altered by stereologically derived physical quantities such as erythrocyte surface and
volume of stroma. The total oxygen diffusive conductance was calculated to be
increased in diabetic placentae particularly those in diabetic white groups A-C (36
ml.min'.kPa1) compared to control placenta (29. ml.min'.kPa1). The main changes
were documented to occur on the fetal side with increased stromal conductance,
increased fetal plasma conductance and increased erythrocyte conductance. The
villous stoma and trophoblast were calculated to be the major contributors (80%) to
total resistance to total oxygen diffusion. Notably there was no difference in
trophoblast conductance between groups.
Further analysis of a subgroup (n=16) of these diabetic placenta and control
placentae (n=6) was performed at a later data and aimed to compare derived star
volumes of villous 'domains' and intervillous pores. The derived star volumes are a
measure of three dimensional spaces (and how this relates in four random directions
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to an arbitrary test point) and aims to measure the ease by which maternal blood can
bathe the villous tree and the efficiency of the villous tree in interacting with this
bathing blood. The star volumes of peripheral villi and intervillous spaces did not
alter significantly between groups confirming a lack of aberration of the maternal
side of the placenta in pregnancies complicated by diabetes.
There have been few studies placentae from diabetic pregnancies based at the
electron microscope level. Thickening of the trophoblast basement membrane is the
most consistently noted abnormality (Okudara 1966, Fox 1969, Jones and Fox 1976).
The most recently dated study (Honda 1992) also demonstrated this abnormality in
addition to suggesting that the terminal villi were of smaller diameter in diabetic
pregnancies, that there are abnormalities of villous branching (hyper of hypo-
ramification), increased syncytial knot formations and decreased number of vascular
syncytial membranes
In summary studies of diabetic placentae have produced varying results. They have
often failed to define the severity of diabetic disease in the studied women making
comparisons of study populations and results impossible. Additionally not until
recently have studies recognised the importance of co-assessing maternal glycaemic
control. Despite these limitations aberrations of villous vascular development
appears to be a consistent finding in diabetic placenta and has persisted despite
improvements in diabetic management and maternal glycaemic control over time.
The importance of aberrant placental angiogenesis has recently been highlighted in
studies of intrauterine growth restriction and hypoxia. To explain the increased risk
of intrauterine stillbirth and hypoxia documented to occur in diabetic pregnancies
further study of villous development in this condition is required.
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Figure 4.1(A-B) The basic structure of the human placenta at term.
(adapted from Bernirschke and Kaufmann 1995)
(A-B) A diagrammatic representation of the branching pattern of the villous tree.
Ch P = Chorionic plate; T = truncus chorrii; I-IV = generations of rami.
The vessels are shown within the distal villous tree in figure 4.1(C).
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Figure 4.1(C) The basic structure of the human placenta at term.
(adapted from Bernischke and Kauftnann 1995)
(C) Fetal vessel architecture of an ending stem villous of the last ramulus (line hatched)
and a terminal convolute composed of one mature intermediate villus (point shaded)
together with its terminal villi (unshaded). Arterioles are point shaded, capillaries are
black and venules are unshaded. Note the serial arrangement of capillary loops




The three dimensional vascular structure of the placental
terminal villus in diabetic pregnancy.
5.1 Introduction
Maternal diabetes mellitus is associated with a range of fetal complications. Perinatal
mortality rate has fallen from greater than 50% to 2-3% between 192f, when insulin
was discovered, and the present day. This reflects improved maternal blood glucose
control, improved methods of fetal surveillance, avoidance of unnecessary premature
delivery and the introduction of neonatal intensive care. The loss rate however
remains 2-3 times higher than that seen in the non-diabetic population. Sudden
intrauterine death contributes significantly to this raised perinatal mortality rate
(Beard and Lowey 1982). The fetus of the diabetic mother also remains at risk of
fetal distress and asphyxia in labour. The pathophysiology of these complications is
poorly understood. It is hypothesised that the diabetic fetus is prone to hypoxia in
utero (Casson et al 1980).
Development of the peripheral placental villous 'tree' and its vascular network serves
to increase the placental surface area available for materno-fetal exchange and
therefore fetal oxygen delivery. Analysis of placental structure often demonstrates
specific abnormalities in association with fetal hypoxia, specifically that the
peripheral villous vascular ultrastructure is altered. This may reflect or contribute to
the fetal hypoxia. (Kingdom and Kaufmann 1997).
In a recent stereological study of placenta from diabetic pregnancies Mayhew et al
(1994) demonstrated that the peripheral villi appeared hypercapillarised in the
placenta obtained from diabetic pregnancies compared to those examined in matched
non-pregnant control cases. The volume of the peripheral villi was not statistically
different in placenta from diabetic and the control pregnancies, therefore individual
placental villi appeared better developed to effect materno-fetal exchange in the
placenta obtained from the diabetic subjects.
The terminal villus is where the majority of materno-fetal exchange occurs. Recently
our department (Krebs et al 1996) has published studies of this specific specialised
villus. Using a microvascular casting technique this group was able to demonstrate
the three-dimensional vascular ultrastructure of the terminal villi in pregnancies
complicated by intrauterine growth restriction and matched control cases. Using this
technique they were able to clearly demonstrate aberrant (hypovascular)
development of the terminal villi in placenta from growth restricted pregnancies
suggesting a role in the aetiology of this condition.
The aim of the present study was to employ microvascular casting techniques to
study in detail the three dimensional vascular structure of the terminal villi in
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placentae of well controlled diabetic pregnancies. To correlate our findings to fetal
outcome and to the recent light microscopy studies.
Placentae were studied from ten well-controlled insulin dependent diabetic women
and ten gestationally matched healthy non-diabetic women. The women were
matched for parity and smoking habit. Diabetic women were younger (mean: 24.1
years [SD 4.4] than non-diabetic women (mean: 30.6 years [SD 4.74]); p<0.01. The
average duration of diabetes was 12.3 years [SD 4.1] in this cohort of diabetic
women. The diabetic women were seen at least fortnightly in a specialised diabetic-
antenatal clinic. Insulin requirements were adjusted on the basis of twice weekly 4
and 7 point blood glucose measurements. Diabetic control was also assessed by
HbAlc determination at each clinic visit. The diabetic pregnancies were electively
delivered at 38 to 39 weeks gestation if they were undelivered at this time.
The non-diabetic women were recruited from the low risk antenatal clinic and all had
an uncomplicated antenatal course. In all pregnancies, both diabetic and non-diabetic
gestation was confirmed by ultrasound within the first 16 weeks and all resulted in
the delivery of a singleton neonate, which was structurally normal in development.
Clinical characteristics of individual cases are given in Tables 5.1 and 5.2.
5.2.2 Preparation of the vascular casts
The placentae were obtained immediately post delivery, briefly examined for any
gross pathology. Preparation of the vascular casts followed the preparation of tissue
for transmission electron microscopy studies (chapter 6) but occurred within 30
minutes of delivery.
A chorionic branch of the umbilical artery with its corresponding vein was identified
on the fetal surface of the area of the placenta to be assessed. The artery was
cannulated with a 16-gauge cannula (Venflon), and secured with a single suture (2/0
chromic catgut) to prevent backflow of the perfusate. The venous outflow was
punctured to complete the open vascular circuit. The cotyledon vascular circuit was
then flushed with a minimum of 100 mis 0.9% sodium chloride until the venous
effluent was clear of fetal blood. A low viscosity plastic polymer was then prepared
as follows: 0.5g of catalyst was dissolved in 5 ml of methyl methacrylate. This was
then added to a disposable glass beaker containing 20 ml of Mercox CL-2B resin
base. The contents of the beaker were then stirred with a glass rod for 30 seconds.
The resultant plastic polymer was then drawn into a 50ml syringe and infused into
the chorionic artery until the venous effluent was pure polymer. The vein was then
ligated and infusion continued until resistance was felt. The arterial site was then
clamped. The perfused and immediately adjacent placental cotyledons were grossly
dissected from the remaining placental mass. They were then allowed to sit







of the placenta was then grossly dissected from the remaining placental mass, and
left overnight at room temperature to ensure complete polymerisation of the cast.
The placental tissue was subsequently corroded from the cast by alternate (6 hour)
immersions in 20% potassium hydroxide (at 40 °C) and distilled water. At least six
cycles of the immersion process were performed per cast to ensure that the cast was
free of any tissue debris and the final immersion solutions were clear. A resultant
placental vascular cast is depicted in Figure 5.1. The casts were then immersed in
fresh distilled water and fractured along lines of natural cleavage into samples
approximately 0.5 to 1 cm square. Random fractured sections of the cast were
sputtered with gold for 3 minutes. They were then coded and examined, blinded to
clinical data, in a digital scanning electron microscope. All casts were stored in a
desiccator until analysis (Leiser et al 1985).
5.2.3 Analysis of the vascular casts
Each cast was initially viewed at low power (xlOO) to determine areas were the
intermediate and terminal villous vasculature could be easily delineated. A terminal
capillary loop was defined as the total capillary structure branching from the
intermediate villous vasculature, which formed one spatial discrete capillary system.
Analysis of the terminal capillary loops was performed at high magnification (x500).
Four areas of each vascular cast were examined allowing an average of 35
consecutive terminal capillary loops to be measured (range 27-42)
Each capillary loop was assessed in the horizontal plane by rotating the cast
appropriately. The following capillary parameters were assessed by the author: (1)
the length of the terminal capillary loop, defined as the distance from the base of the
capillary loop to its tip, (2) branching, the number of visible branching points (3) the
degree of capillary coiling, (defined subjectively as 0 = no coiling, 1 = mild coiling,
2 = moderate coiling and 3 = high degree of coiling), and (4) the degree of any
capillary dilatations, (again defined subjectively from 0 to 3 with increasing degree
of dilatation). A typical analysis is demonstrated in Figures 5.2 and 5.3.
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5.3 Statistical analysis of the vascular casts
Length data were log (x) transformed and branching data were square root
transformed prior to analysis to resemble normal distribution. The data for capillary
length and number of capillary branches were expressed as geographic mean
(standard deviation). Diabetic and non-diabetic data were compared by Student's t
test. Inter-group comparisons of coiling and dilatation data were performed by Chi-
Square analysis. P values < 0.05 were considered to be significant.
5.4 Results
5.4.1 Comparison of clinical data
The mean birth weight was significantly greater in diabetic compared to control
pregnancies (4.27kg [SD 0.91] vs. 3.42kg [0.46]; p<0.02). The mean placental
weight was also significantly greater in diabetic compared to control pregnancies
(937.5g [174.4] vs. 716.0g [151.1]; p<0.05). The placental to fetal weight ratio was
not significantly different in diabetic and control cases.
5.4.2 Comparison of vascular casts
There was no gross abnormality of the placenta collected from diabetic pregnancies
compared to control pregnancies. Low powered views and initial high-powered
views of the plastic casts demonstrated that all casts appeared highly comparable.
Typical capillary loops from a control placenta are shown at a 100-fold
magnification in Figure 5.4, and at a 500-fold magnification in Figure 5.5.
Corresponding images of capillary loops from a diabetic case are shown in Figures
5.6 and 5.7.
The capillary loops in the diabetic casts when compared en mass were significantly
longer than those in the control cases (mean 8.55 xl()-5 m [SD 2.86] vs. 8.11 [SD
2.68]; p<0.05. The mean capillary lengths of the capillary loops in each cast are
illustrated in Figure 5.8.
The terminal capillary loops also demonstrated increased visible branching points in
the diabetic placental casts compared to control casts (2.52 [SD1.86] vs. 2.25 [1.72];
p<0.05). The mean numbers of capillary branching points in each cast are illustrated
in Figure 5.9. There was no significant difference in either the degree of capillary




Placental studies can be compromised by inadequate sampling techniques. The
human placenta varies in its anatomy in different regions. Globally the areas
immediately beneath the cord and at the periphery will clearly differ in volume of
large stem villi they contain. The areas immediately beneath the chorionic plate are
less readily bathed by maternal blood. Areas of infarction are sometimes evident.
However even with the main bulk of the placenta considerable heterogeneity exists.
The placental villi are arranged in placentomes (Shuhmann 1981). This represents a
functional unit: a villus tree and its maternal blood supply. The maternal blood enters
at the centre of the villus tree, where stem and immature intermediate villi are
concentrated, and exits the intervillous space near clefts between neighbouring
villous trees, where mature intermediate and their terminal villi are concentrated.
Providing a central parabasal placentome is adequately studied the findings can
representative of the whole placenta (Bacon et al 1986). This is the methodology
employed in this study: casting a number of central placentomes and then analysing
random fractured sections. However, it should be noted that this is not a true
stereologic morphometric study, which requires initial random sampling and then
systematic sampling around this site (Mayhew and Burton 1988). An attempt to
improve the validity of our data, analyses on the first 4 casts were repeated using
measurement data from 10, 15, 20 25, 30 and 35 terminal capillaries (Maraca 1995).
This demonstrated that there were no difference in the means and standard deviations
obtained for 20 or more capillary loops. Measurements of > 20 capillary loops were
therefore obtained for each cast. As scanning electron microscopy can only
adequately assess the capillary loops exposed on the surface of the fractured cast
specimen, all capillary visualised in random areas were analysed, generating
numbers for analysis between 27 and 42, in an attempt to avoid introducing selection
bias i.e. of particularly evident capillary loops. These limitations of our study should
be acknowledged when assessing our findings.
We have demonstrated that the terminal villous capillaries are of increased length
and have an increased number of visible branching points in placentae examined
from diabetic pregnancies compared to control pregnancies. Although to date studies
of placentae obtained from diabetic pregnancies have produced conflicting results,
these findings support a recent study of gycaemically controlled diabetic
pregnancies, in which increased villous vasculature has been demonstrated (Mayhew
et all994). In this previous study the placental villi were described as being better
developed in diabetic pregnancies, with an increased volume, surface area, length
and mean diameter of the terminal villous vasculature.
Terminal villi begin to form early in the second trimester of pregnancy. They occur
where the stimulus for vascular growth in the intermediate villi is greater than the
growth of these villi themselves. They therefore form as grape like outpouchings of
these capillaries, carrying before them a surface layer of trophoblast (Kaufmann and
Burton 1994, Benirschke and Kaufmann 1985). Further stimulation of vascular
growth results in increased length and number of these terminal villous capillary
loops and villi. The increased terminal capillary length demonstrated in this study
79
Gibson J.L.
might suggest that the vascular stimulus to capillary growth is increased in diabetic
pregnancies. One of the most potent stimuli to angiogenesis is hypoxia.
Oxygen deprived tissues release a range of angiogenic growth factors such as bFGF
(Ogawa 1991), VEGF (Sunderkotter 1994, Wheeler, Elcock and Anthony 1995)
PIGF (Ahmed, Whittle and Khaliq 1997). Increased placental angiogenesis has been
demonstrated to occur in situations in which there is decreased oxygen delivery to
the placenta. This may arise either by reduced oxygenation of the maternal blood;
pregnancies at high altitude (Jackson, Mayhew and Hass, 1987) or maternal anaemia
(Fox 1978, Burton 1996), or where there is reduced flow of normally oxygenated
blood to the placenta e.g. in pre-eclampsia (Salvatore 1968, Burton et al 1996). No
diabetic women studied developed pre-eclampsia during the studied pregnancy, and
none of the diabetic women studied were anaemic therefore the angiogenic stimulus
to terminal villous capillary growth was not as a result of such pre-placental or utero¬
placental mechanisms.
Maternal diabetes may however cause a unique form extra villous hypoxia. It has
been suggested that the fetal metabolism is greater in diabetic pregnancies than non-
diabetic pregnancies. This occurs due to the increased circulating concentrations of
insulin and resultant organomegally of these fetuses (the Pedersen hypothesis). The
increased fetal metabolic rate results in increased fetal consumption and demand for
oxygen. This in turn requires that more oxygen be delivered to the fetus from the
placenta and therefore that the placenta must extract more oxygen from the maternal
blood in the intervillous space. The resultant relative hypoxia in the intervillous
space may be the trigger for increased terminal villous angiogenesis.
The metabolism of placenta itself is also likely to be increased in diabetic
pregnancies contributing to a local 'hypoxic' environment. Alternatively the
increased fetal growth and metabolism may not play an aetiological role in increased
placental angiogenesis rather both may occur as a direct result of a maternal signal
i.e. insulin like growth factors.
The finding that capillary branching is increased in diabetic placentae is notable.
Firstly such detailed analysis of terminal villous capillary structure can only be
inferred but not visualised by any other histological techniques (i.e. stereological
studies). Secondly as increased branching occurs in association with increased
capillary length important information can be gained regarding the function of these
terminal capillary loop systems. The feto-placental vascular tree in order to function
efficiently needs to act as a high flow low impedance circulation. The terminal villi
by nature of their formation arise in series. In order to maintain low resistance in
such an increasing circuit capillary branching and reanastamosis occur so blood may
flow through part of the capillary system in parallel. These adaptations may maintain
a low total resistance of a more volumous capillary vascular system (Kaufmann
1988). Therefore the increased capillary growth demonstrated in diabetic placentae
may not be pathological but a continuation of the normal physiological development
of the placenta resulting, as suggested by Mayhew (1994), a better developed villus




The mean terminal capillary lengths in the present study were stikingly shorter than
those measured in pregnancies complicated by intrauterine growth restriction
(217.8pm (SD71.9) and the gestationally matched control placentae (136.9pm (SD
29.8). The average gestation of the studied pregnancies was 31 weeks in both the
IUGR and control groups. The increased length of these peripheral capillary systems
reflects a lack of terminal villous formation. In the control group this reflects the
normal limited development of the peripheral villous tree at this gestation. As
terminal capillary loops form from the intermediate villus capillary network the
average length of the most peripheral capillary system will reduce. In essence the
ratio of terminal villi to intermediate villous capillary systems measured will
increase. The disproportionately increased length of the terminal capillary loop
systems measured in the IUGR group indicates a failure of the normal development
of the peripheral vascular villous tree. This is supported by findings that the volume
of the peripheral vascular tree (intermediate and terminal) villi is reduced in IUGR
pregnancies (Jackson et al 1995).
The mean gestation of the diabetic pregnancies studied in this study [37.2 weeks (SD
1.1)] was less than the mean gestation of the control pregnancies [38.6 weeks (SD
0.70]; p<0.005. This difference could have a confounding effect on the capillary
indices assessed for the reasons discussed above. However at these later gestations it
is unlikely that de novo terminal villus formation is significant, rather it is the
'differentiation" of the numerous formed terminal villi that is important in placental
adaptation to fetal demands. Studies of placentae from accurately dated pregnancies
progressing to 42 and 43 weeks' gestation have found the terminal villi to be
elongated, branched and notched (Kaufmann and Bernische), supporting this
hypothesis. Gestational effects, outwith the first trimester, are after all a response to
fetal growth and demands and not a reflection of time per se. Placental oxygen
diffusive conductance (Mayhew et al 1993), and fetal oxygen uptake (Hofman 1983,
Bell et al 1985) are more closely correlated to fetal weight gain than to gestation. The
increased length and branching of the terminal capillary loops in diabetic cases is
more likely to reflect the increased fetal demands of these pregnancies than a
gestational artefact.
The significant difference between diabetic and control indices measured reflects the
large number of terminal villous capillary loops assessed in each group. Given the
small differences in the mean capillary length and visible branching points between
the studied groups analysis of fewer capillary loops would not have had sufficient
power to demonstrate these differences. It could therefore be argued that these small
differences are unlikely to be functionally significant given the presumed functional
reserve of the human placenta. Certainly the differences demonstrated in the present
study are not of the same magnitude as the pathological differences seen on
comparison of villi from IUGR and matched control pregnancies. We would argue
however that the total number terminal capillary loops in an entire placenta is vastly
greater than that studied here suggesting that when extrapolated to the entire organ
our findings may have a valid significance.
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Previous studies of diabetic pregnancies have produced conflicting results, several
indicating severe pathology of the placental tree. The women in the present study
were intensively reviewed throughout their pregnancies; as a result demonstrated
good and continually improving glycaemic control throughout pregnancy. Such
improved control is likely to have influenced placental development and resulted in
the lack of any major demonstrable abnormality of the placental tree. Such
'normalisation' of placental structure in diabetic pregnancies is reassuring to the
obstetrician, however our findings suggest that despite good maternal well-being and
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Figure 5.1 A placental vascular cast (macroscopic image)
A vascular cast of one whole placental cotyledon can be seen (left) with its
associated chorionic plate vessels (CPV). The upper vessel is the artery
through which the plastic polymer is infused into the cotyledon vascular
circuit. The lower vessel is the vein. Once the venous effluent consists of
pure plastic this vessel is ligated to allow optimal filling of the cast. The




Figure 5.2 Assessment of terminal capillary loop length and
branching.
The upper micrograph demonstrates the measurement of the terminal capillary loop
length. The capillary loop was rotated to lie in the horizontal plane. The length was
measured from the base of the capillary loop, where it arose from the intermediate
villus vasculature, to its tip.
The lower micrograph shows a terminal capillaiy loop system demonstrating 4
visible branching points (*)
The terminal villus capillary loops were slightly longer and more branched in the
diabetic cases compared to control cases; p<0.05.
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Figure 5.3 Assessment of terminal capillary loop coiling
and dilatation.
In the upper micrograph two terminal villi capillary loop systems demonstrate a
moderate (++) degree of coiling (arrowed). In the lower micrograph two
capillary systems demonstrate no degree of coiling (arrowed).
There is evidence of capillary dilatations in the lowermicrograph (*).
There was no difference between diabetic cases and control cases on
comparison of these parameters.
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Diabetic villi Control villi
Figure 5.8 Mean terminal villous capillary length: diabetic vrs. control
cases.
The mean length (+ one standard deviation) of the capillaries in each of the 10 diabetic
and the 10 gestationally matched control placental vascular casts.
The capillaries in the diabetic cases were slightly but significantly longer than those









Cases from diabetic subjects Cases from control subjects
Figure 5.9 Mean number of visible capillary branches: diabetic vrs.
control cases.
The mean number (+ one standard deviation) of visible capillary branching points of
each of the 10 diabetic and thelO control placental vascular casts.
The number of terminal villus capillary branches was slightly but significantly greater




The cross-sectional ultrastructure of the terminal villus in
diabetic pregnancy
6.1 Introduction
Maternal insulin dependent diabetes is associated with a range of fetal complications.
The incidence of many of these complications has reduced with improved maternal
glycaemic control. However the risk of fetal compromise remains increased in
diabetic pregnancies compared to non-diabetic pregnancies. Of particular importance
the fetus of the diabetic mother appears to be of increased risk of intrauterine
hypoxia manifest by an increased risk of unexplained stillbirth and fetal distress in
labour.
By analysis of vascular casts prepared from placentae from pregnancies complicated
by maternal diabetes we have demonstrated that the terminal villous capillary
ultrastructure, although grossly comparable to control cases, demonstrates increased
length and branching in these diabetic cases, despite apparent good maternal
glycaemic control. This finding supports a previous study that suggested that the
peripheral villous vascular tree is of greater volume in pregnancies complicated by
maternal diabetes, possibly as an adaptation to fetal hypoxia (Mayhew et al 1994).
Fetal hypoxia occurring in association with placental hypoxia can be associated with
other villous ultrastructural characteristics in addition to increased capillary volume
(Kingdom & Kaufmann 1997, Bernishcke and Kaufmann 1985). To further
investigate the possibility of placental hypoxia in diabetic pregnancies the cross-
sectional ultrastructure of terminal placenta villi from such pregnancies was assessed








Placentae were obtained from ten insulin dependent diabetic women and ten
gestationally matched healthy non-diabetic women. The women were matched for
parity and smoking habit. Diabetic women were younger (mean age = 25.9 [SD 3.5]
years) than non-diabetic women (30.2 [SD 4.6] years; p < 0.05)
Clinical characteristics of individual cases are given in Figures 5.1 and 5.2.
Diabetic control as assessed by HbAlc determination was found to improve
significantly with gestation in the diabetic pregnant group, (mean [SD] HbAlc =
7.13 [0.84]% at 12 weeks gestation, 6.01 [0.48]% at 36 weeks gestation, P < 0.01,
non-diabetic reference range = 3.4 - 5.2%)
6.2.2 Preparation of tissue for transmission electron
Within 5 minutes of delivery a random placental cotyledon was perfusion fixed to
secure tissue of sufficient quality for transmission electron microscopic assessment.
A chorionic plate artery and its corresponding artery were identified. The artery and
vein were prepared as described in section 5.2.2. Venous puncture of the vein
ensured optimal fixation of the entire specimen and was necessary to limit any
artefact that might arise from feto-maternal fluid shift. (Burton et al 1988). The artery
was initially flushed with 10 mis of normal (0.9%) saline to irrigate the vascular bed.
Immediately thereafter the artery was perfused at a constant pressure with 20 mis of
2.5% neutral (pH 7.2): buffered gluteraldehyde over a 5 minute until the perfused
tissue became pale and firm. Thereafter approximately 10- 15 2 mm blocks of fixed
tissue were randomly excised from a central area above the basal plate. The excised
blocks were stored in 15-20 mis of the of 2.5% gluteraldehyde until they were
processed for examination by transmission electron microscopy.
6.2.3 Tissue processing for transmission electron microscopy.
Five random tissue blocks were rinsed in phosphate buffer, then post-fixed for 45
minutes in 1% osmium tetroxide. The blocks were then rinsed again in phosphate
buffer and then dehydrated by immersion in ascending concentrations of ethyl





6.2.4 Analysis of tissue by transmission electron
microscopy.
Three blocks of tissue were examined per case. The tissue blocks were coded to
allow analysis blinded to clinical details. From each tissue block semithin (0.5 -
4.0pm) sections were prepared with an LKB ultramicrotome. These were stained
with toludine blue to allow visualisation of the cut section by light microscopy.
When the section visualised contained terminal villus cross-sections the area
corresponding to this was isolated from the tissue block using a standard paring
technique. Ultrafine sections of this area were then cut with the LKB ultramicrotome
using a fresh class knife. The cut sections collected into a water filled trough
mounted on the knife surface. The floating sections were than captured onto a copper
plated grid. Each copper grid retrieved an average of 2 sections. The sections were
then stained by immersion in uranyl acetate for 10 minutes and then lead citrate for a
subsequent 2 minutes. The sections were then stored in a grid box until analysis.
The grids were viewed in a Philips CM 10 transmission electron microscope. By
viewing the three prepared sections per case analysis of a minimum of seven (usually
10-14) terminal villous cross-sections was possible per case. Villous sections that
appeared longitudinal, oblique or branched were excluded from analysis. Each
terminal villus was viewed and photographed at three standard final magnifications.
The total villous composition and stromal content was assessed at x 575 and x 2700
magnification. Areas comprising vasculosyncytial membranes were viewed at x
14850.
6.2.5 TEM assessment of villus parameters
Terminal villi were identified for analysis using the morphometric characteristics
described by Kaufmann et al (1985) (see section 4.1.5). The following parameters
were assessed in detail: villous diameter, capillary diameter, number of capillary
cross-sections per villus, cytotrophoblast (nuclear) number, syncytiotrophoblast
(nuclear) number, stromal composition, trophoblast basal lamina (densa) thickness,
and the thickness (diffusion distance) of the vasculosyncytial membranes.
Villus diameter derived by measuring the villus in a random set of two perpendicular
planes and then calculating the average. Capillary diameter was defined as the
smallest measurable diameter of the capillary section (Figure 6.1). This was to avoid
skewing the data by the inclusion of oblique capillary sections. All capillary sections
per villous were assessed. The thickness of the lamina densa was measured in the
areas were this layer was clearly defined and was within the region of a defined
vasculosyncytial membrane (Figure 6.2). The minimal thickness ol this layer was
measured for each photographed 'membrane'. The minimal thickness of the entire
vasculosyncytial membrane (outer trophoblast to inner capillary margins) was
measured in each instance. The density of the villus stroma was assessed
qualitatively in each case, assessing in particular the presence of collagen fibers and
of background fibrillar material (Figure 6.1).
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6.2.6 Preparation of tissue for light microscopic studies.
Following delivery, and subsequent to obtainment of tissue for TEM studies and
initial cast preparation for SEM studies, full thickness blocks of placentae were cut
from the remaining specimens. Several blocks from the diabetic and control
pregnancies were taken in a random fashion, avoiding the area immediately beneath
the umbilical cord insertion and at the extreme periphery of the placentae. The
placental blocks were immersed in neutral buffered 4% formalin solution for 24
hours to effect fixation. The tissue blocks were then processed in the standard
manner for paraffin embedding.
6.2.7 Tissue processing for immunohistochemisty.
Serial sections of tissue (3-5um) of tissue were cut from one random parraffin block
obtained from 10 diabetic and 10 control cases. Individual sections were mounted
onto glass slides. The glass slides had been pre-treated to aid adhesion of the tissue
sections to the slides; the slides had been immersed in ethyl alcohol, incubated with
2% APES for 20 seconds, then washed in acetone and aqua dest (1 minute each). The
cut sections mounted on the glass slides were incubated at 37°C overnight. Then
stored in 'air-tight' slide boxes until analysis.
From each case one cut section was prepared for each primary antibody. Prior to
exposure to the antibody the sections were deparaffinised in xylene (2 x 10 minutes)
and graded ethanol (100%, 96% and 90% ethyl alcohol for 5 minutes each).
Endogenous peroxidase activity within the specimen was then blocked by incubation
with 1% hydrogen peroxidase in methanol. The sections were then washed in PBS
[sol]. The sections to be stained for Ki-67 antibody binding were immersed in 10
mM citric acid and pre-treated by microwave (4x5 minutes at 600 Watts) to expose
the antigen.
Immunohistochemistry
The following primary antibodies were employed: Collagen 1 (1 in 50 dilution),
Collagen IV (1 in 90 dilution) both from Europath UK, Collagen III (1 in 50 dilution,
Biogenesis, UK), Laminin (1 in 2000 dilution) and Fibronectin (1 in 500 dilution)
both from Dako UK, Ki-67 (1 in 20 dilution, Dianova Germany). The sections for
each antibody were all processed simultaneously in a single run. A commercial
steptavidin-biotin technique was utilised (Histostain SP, Zymed ,CA).
Ki-67:
The slides were incubated with 10% non-immune goat serum to eliminate
background staining. The sections were then incubated with the primary antibody,
Ki-67 (diluted 1:20 in PBS [sol] with 1.5% BSA; Key et al 1993) for 60 minutes.
The slides were washed three times in PBS [sol] then incubated with the secondary
biotinylated goat anti-rabbit antibody for 30 minutes. The slides were then washed
again in PBS[sol] and the sections were then incubated for 5 minutes with the
steptavidin-peroxidase conjugate, followed by a further wash in PBS[sol]. The bound
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antibody was visualised by incubating the sections with an AEC chromagen /
hydrogen peroxide mixture for 15 minutes. The slides were then washed in distilled
water (2x5 minutes) and then counter-stained with haematoxylin (3 minutes).
A negative control was generated by replacing the primary antibody with PBS [sol]
/1.5%BSA. The control remained negative. A positive control slide was generated by
including a section of a tonsil gland. The rapidly dividing lymphocyte population
within in this structure stained positive with Ki-67.
Stromal staining:
The polyclonal antibodies; Fibronectin, Collagen I, Collagen III, Collagen IV.
The sections were covered with a serum blocker [(20%) normal swine serum in PBS]
for 20 minutes to reduce non-specific background staining. After tipping the blocker
from the slides. The primary antibody was added to the sections. After an incubation
period of 18 hours (at 4°C) the sections were washed in PBS [sol] (3 x 10 minutes).
A secondary antibody (swine anti-rabbit 1:100 in 4% NSS/PBS) was then applied to
the sections. After a 45-minute period the sections were then washed three times in
PBS. Peroxidase conjugated steptavidin (1:800 in 4% NSS/PBS) was then applied to
the sections. After a further 45-minute incubation period the sections were washed
again PBS (x3). AEC was then applied to the sections for 15 minutes. The sections
were then washed twice in distilled water and then counterstained with haematoxylin
for 3 minutes before mounting with coverslips.
The monoclonal antibody: Laminin.
A similar protocol to above was followed with the following modifications: 2% BSA
in PBS was used as the initial blocking solution, the secondary antibody applied was
peroxidase conjugated rabbit anti-mouse (1:50 in 2% BSA/PBS), peroxidase
conjugated avidin (1:100 in 4% NSS/PBS) was used as the third layer.
Negative controls for each stromal antibody were generated by omitting the primary
antiserum. The specificity of the procedure was verified using pre-absorbed specific
antiserum. Positive controls were generated by applying each antibody to sections of
hepatic and vascular tissue. The staining patterns of which were known from
previous laboratory work.
6.2.7 Analysis of tissue by light microscopy.
Stained slides were blinded and coded prior to analysis. Ki-67 antibody positively
stained trophoblast nuclei were counted in 50 terminal villi per case. In addition
stained nuclei in the stromal compartment were also counted.
Analysis of specimens stained for collagens I, III and IV, laminin and libronectin
was performed in a visually qualitative method by the author. Staining was scored (0,
+, ++, +++, ++++) in the following locations: the area immediately underlying the
trophoblast and the capillaries, representing their basement membranes, and in the
stromal core of the terminal villus.
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6.3.1 Statistical analysis of TEM assessed villous parameters
All parameters approximated normal distribution. Mean values were compared by
student's t test. A P value of < 0.05 was taken to indicate a significant finding.
6.3.2 Statistical analysis of immunohistochemical studies
The number of cell nuclei positively stained with Ki-67 in each compartment in
diabetic and control placentae were compared by student's t test. The numbers (of
stained cells per compartment in 50 villi) were log (x) transformed prior to analysis.
The density of stromal staining for Fibronectin, Laminin, and Collagens 1, 111 and IV
in the diabetic and control groups were compared by Chi- square analysis.
6.4 Results
6.4.1 Clinical data
The mean birth weight was significantly greater in diabetic compared to control
pregnancies (4.20kg [0.86] vs. 3.52kg [0.49]; p<0.05). The mean placental weight
was not significantly different in diabetic compared to control pregnancies (848.5g
[181.1] vs. 734.Og [112.0]). The placental to fetal weight ratio was also not
significantly different in diabetic and control cases.
6.4.2 Transmission electron microscopy data
The terminal villi of diabetic placentae were visually grossly comparable to those of
control placentae. Specifically, we demonstrated no significant difference in villous
diameter, villous capillary diameter, cytotrophoblast or syncytiotrophoblast nuclei
number between study groups. However, the measured thickness of the trophoblast
basal lamina (Figure 6.3) and the diffusion distance across the vasculosyncytial
membranes (Figure 6.4) were increased in the terminal villi from diabetic compared
to control placentae. There were also an increased number of capillary cross-sections
per villus in diabetic pregnancies (Figure 6.5). Absolute values are given in Table
6.1. Typical images of trophoblast basal lamina thickness and vasculosyncytial
membrane thickness in diabetic and control cases are shown in Figures 6.6 and 6.7.
Terminal villus cross-sections from a control case are shown in Figure 6.8 and from a




There was no significant difference in the numbers of Ki-67 stained cytotrophoblast
cells in diabetic (mean 28 per 50 villi, SE 0.52) and control pregnancies (mean 23 per
50 villi, SE 1.63). There was also no significant difference on comparison of Ki-67
stained stromal cells in diabetic (mean 10.5 per 50 villi, SE 2.4) and control
placentae (6.5 per 50 villi, SE 0.5). Typical staining patterns of nuclei are shown in
Figure 6.10. Positive and negative control slides are shown in Figure 6.11.
Typical staining patterns of collagens, laminin and fibronectin were not significant
different on comparison of diabetic and cases. A typical assessment (of villi studied
from either of the two groups) of the areas comprising the trophoblast basement
membrane, the capillary basement membrane and the stromal compartment is given




In the previous chapter we have demonstrated that there is evidence of increased
vascularity of the terminal placental villi in diabetic compared to control
pregnancies. We have confirmed this finding in the present cross-sectional studies of
villous ultrastructure; transmission electron microscopic studies have demonstrated
an increased mean number of capillary cross-sections per villus diabetic cases
compared to control cases whilst the mean capillary diameter was conserved. These
complimentary findings support published morphometric data that the volume of the
peripheral villus vasculature is increased in diabetic pregnancies (Mayhew et al
1994). One of the most potent stimulators of angiogenesis is hypoxia. We have
therefore assessed in more detail the overall ultrastructure of terminal villi in diabetic
pregnancies, in particular looking for other ultrastructural adaptations that could be
associated with villous hypoxia in these pregnancies.
The external surface of the terminal villi is composed of trophoblast and as such the
trophoblast is directly exposed to the maternal environment. Abnormalities of
trophoblast structure and function have been shown to occur in response to a number
of maternal disease states and conditions. The trophoblast is a metabolically active
structure. Damaged or aged trophoblast nuclei are shed from the villous surface after
they have been sequestered or pushed into knots. The syncytiotrophoblast is a
specialised structure that has lost the capacity to replicate. It is the mitotic function of
the underlying cytotrophoblast to ensue an adequate syncytiotrophoblast
compartment. The mitotic index of the cytotrophoblast may therefore provide a
measure of the metabolic strain of the syncytial trophoblast. An increase in the
mitosis of cytotrophoblast, and an increased thickness of the cytotrophoblast layer
(Fox 1964, Piotrowicz et al 1969, Bernishke and Kaufmann 1985) is seen in hypoxic
conditions. Indeed the proliferation rate of the cytotrophoblast has been shown to be
inversely related to villous oxygen content (Arnholdt et al 1991).
In our study similar numbers of cytotrophoblast and syncytiotrophoblast nuclei were
seen in diabetic and control terminal villi. This finding is consistent with recent
studies of diabetic placenta specifically that the volume and nuclear content of the
trophoblast is similar in diabetic and control pregnancies (Mayhew 1994). These
findings could be consistent with either similar rates of production and loss of
trophoblast or an increased production and increased loss rate with no overall change
in total mass of trophoblast.
By utilising immunohistochemistry to demonstrate actively dividing cells (Ki-67
staining nuclei) we have provided evidence that the mitotic index of the
cytotrophoblast is comparable in diabetic and control placentae. Our finding that the
cytotrophoblast layer is not increased nor demonstrates increased turnover argues
against significant whole villous hypoxic in diabetic pregnancies.
Increased thickness of the trophoblast basement membrane has been demonstrated to
occur in a number of previous electron microscopy studies of placental ultrastructure
in pregnancies complicated by maternal diabetes mellitus (Okudaira et al 1966, Fox
1969, Jones and Fox 1976). Increased thickness of basement membranes is also a
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common pathological feature demonstrated to occur in a range diabetic-
complications outwith pregnancy, such as retinopathy and in nephropathy (in
association with both glomerular and tubular cells) and neuropathy (Williamson and
Kilo 1973, Sternberg et al 1985, Ziyadeh et al 1989, Ziyadeh 1993).
Increased thickness of the trophoblast basement lamina may reflect an increased
production or a reduced breakdown and remodelling of this layer. Increased
trophoblast turnover stimulates synthesis of basement membrane contents. This has
been proposed as the probable mechanism as to the increased thickness of this layer
previously demonstrated to occur in ischaemic villi (Fox 1978). Assessment of
trophoblast turnover in our study does not support such a mechanism and indeed
other studies have suggested that increased thickness of the trophoblast basement
membrane is not a characteristic feature of villous hypoxia per se. Studies of rhesus
monkey placenta (a similar hemochorial placenta to human) in which villous oxygen
content is increased not decreased, either by ligation of the umbilical cord or removal
of the fetus, is associated with increased thickness of the trophoblast basal lamina.
(Panigel and Myers 1972). This occurs in addition to increased villous stoma density.
Assessment of stromal density in our study of villi from diabetic pregnancies, both
by transmission electron microscopy and by immunohistochemistry has
demonstrated that the stromal content is not altered in diabetic compared to control
pregnancies, suggesting that these villi are not significantly hypoxic or 'hyperoxic'.
Increased trophoblast basal lamina thickness in diabetic placentae must therefore be
secondary to a different mechanism than that occurring in the rhesus monkey
placenta or in IUGR.
Hyperglycaemia may exert a direct effect on basement membrane production.
Glucose has been demonstrated to increase the production of collagen IV, the
predominant constituent of the basement membrane, in in-vitro studies of murine
proximal tubule cells (Ziyadeh et al 1990). Reduced breakdown of the basement
membrane may also result from hyperglycaemia. Non-enzymatic glycation of the
structural composition of the basement membrane and subsequent formation of
advanced glycosylation end products (ACEs) may make the basement membrane
aberrantly resistant to degradation (Lubec et al 1980). Multiple factors thus can
mediate the regulation of basal lamina production and therefore the thickness of this
layer is not a sensitive indicator of villous oxygen content.
The average thickness of the vasculosyncytial membrane was found to be increased
in diabetic pregnancies. As this structure represents a key diffusional barrier to
oxygen transfer it may be expected that this layer would thin when the fetal placental
unit had a tendency to hypoxia. This has been documented to occur by both active
remodelling of plasma distribution by the trophoblast and by the passive
peripheralisation and indentation of capillaries as their increasing length outstrips
that of the villus. In theory hypoxia could adversely affect active remodelling of the
vasculosyncytial membrane regions by causing increased turnover of the syncytial
trophoblast. Our data of trophoblast turnover do not support such a mechanism
underlying this finding in diabetic pregnancies. It is possible that increased metabolic
activity of the trophoblast in the areas of nutrient exchange, secondary to increased
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maternal plasma glucose concentrations could be responsible for the increased
thickness observed in this layer in this area.
Reduction in the diffusional barrier of vasculosyncytial membranes to comparable
distances seen in control villi may not be required in diabetic pregnancy. Transfer of
oxygen from the mother to the fetus is dependent on a range of other factors such as
the uterine artery and umbilical partial pressures of oxygen, flow rates, maternal and
fetal oxyhaemoglobin saturation curve characteristics. The oxygen gradient between
the maternal and fetal blood may be sufficiently high as to diminish the importance
of this dividing 'membrane' at least within the small range of thickness differences
demonstrated in our study. The increased capillarisation of the terminal villi in
diabetic pregnancies may also, by providing increased a total surface area for
exchange, reduce the necessity of very short individual VSM widths.
In the discussion section of chapter 5 we highlighted the limitations of placental
studies with regard to sampling techniques. A sampling error can be magnified
during analysis; selected placental blocks, giving rise to selective sections given rise
to selected fields of view and then to selected measurements (Mayhew and Burton
1988). This is particularly of concern in TEM studies due to the small fields of view.
We attempted to validate our light microscopy data by taking large full thickness
placental blocks and sections. We attempted to validate our TEM data by sampling
from central region of the parabasal plate (Bacon et al 1986) and to sample a number
a number of blocks, from a number of placentae in each experimental group
(Gundersen and 0sterby 1981).
In combination our placental studies have demonstrated there are some, but not
consistent, changes in the terminal villus ultrastructure that could represent a
tendency to villus hypoxia in diabetic pregnancies. Of the changes demonstrated
increased vascularity is the only factor that could reflect villous hypoxia. Increased
thickness of the vasculosyncytial membranes and trophoblast basal lamina are not
indicative of trophoblast hypoxia. They could however if occurring in response to an
alternative stimuli predispose to intravillous hypoxia by increasing the diffusional
barrier to oxygen, however the composition of intravillous stroma is not altered in
diabetic cases arguing against such a putative chain of events.
Angiogenesis itself may occur in response to an alternative stimulus other than
hypoxia. Vascular growth can occur in response to increased vascular sheer stress.
Increased growth of the fetus or metabolic requirements of the fetus could result in a
hyperdynamic circulation. Long-term sheer stress initiates remodelling and
proliferation of the vascular endothelial cells (Hudlicka et al 1992, Karimu and
Burton 1994, Resnick and Grimbrone 1995).
In conclusion we have demonstrated small but significant differences in components
intimately involved in nutrient exchange between groups. Although some of these
features may be associated with villus hypoxia, the overall morphology of the




Parameter Units Diabetic Control
Villous diameter (x 10-5 m) 5.76 [1.20] 5.65 [1.16]
Capillary diameter (x 10"5 m) 1.35 [0.47] 1.37 [.049]
Capillary cross-sections (no.) 3.80 [0.53] 3.21 [0.36]f
VSM thickness (x 10-6 m) 2.98 [1.02] 2.61 [0.98]*
Basal lamina thickness (x 10-8 m) 6.83 [2.00] 6.26 [1.42]t
Syncytiotrophoblast nuclei (no.) 8.6 [5.4] 7.5 [4.1]
Cytotrophoblast nuclei (no.) 0.98 [1.1] 0.84 [1.0]
Table 6.1. Terminal villus ultrastructural characteristics: diabetic vs.
control cases.
Data are presented as mean [SD]. Comparable parameters were analysed by Student's
t-test. * P < 0.005, f P < 0.05.
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Trophoblast BM Capillary BM Stroma
Collagen IV +++ +++ ++
Laminin ++++ +++ +
Fibronectin + ++/+++ +
Collagen 1 0 ++ ++
Collagen III 0 + ++/+++
Table 6.2. Qualitative assessment of stroma composition in diabetic
and control cases.
There was no difference on comparison of stromal characteristics between diabetic





Figure 6.1 Cross-sectional ultrastructure of a terminal villus
This terminal villus contains 3 capillaries. Measurement of the shortest
diameter of the capillary sections is shown (double arrows). This was
necessary to avoid skewing the data by the inclusion of tangential sections of
capillaries. Cytotrophoblast nuclei (C) surrounded by a pale cytoplasm and a
defined cell border can be counted. Syncytiotrophoblast nuclei (S) surrounded
by a darker cytoplasmic mass can also be counted. The density of the stroma








Figure 6.2 The structure of the vasculosyncytial membrane
The vasculosyncytial membrane comprises the thinnest area between the
maternal and fetal surfaces of the placenta. Measurement of this distance is
shown by the white double arrow. The thickness of the trophoblast basal
lamina was measured in this area of the villus. The measured thickness of the




Diabetic cases Control cases
Figure 6.3 Mean trophoblast basal lamina densa thickness: diabetic vs.
control cases.
The mean thickness (± one standard deviation) of the trophoblast basal lamina densa in
the 10 diabetic and the 10 control cases.
The trophoblast basal lamina densa measured slightly but significantly thicker in the
villous cross-sections viewed in diabetic compared to control cases; p<0.05.
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Diabetic cases Control cases
Figure 6.4 Median (range) vasculosyncytial membrane thickness:
diabetic vs. control cases.
Box plots (Median, 25th and 75th percentiles, 10th and 90th percentiles) of
vasculosyncytial membrane thickness in diabetic and control cases.
This plot demonstrates that outlying measurements occur in both diabetic and control
cases. The vasculosyncytial membranes measured slightly but significantly thicker in


















Diabetic cases Control cases
Figure 6.5 Capillary cross-sections per villus: diabetic vs. control cases.
The mean number (± one standard deviation) of capillary cross-sections viewed in villi
from the 10 diabetic and the 10 control cases.
Statistical analysis revealed significantly more capillaries per villus in diabetic
compared to control cases; p<0.05.
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Figure 6.6 Trophoblast basal lamina densa thickness: comparison
of a diabetic and a control case.
The thickness of the trophoblast basal lamina (densa) was measured where
discrete cross sections could be easily identified (arrowheads). The trophoblast
basal lamina cross-sections, in the regions defined as vascular syncytial




Figure 6.7 Vasculosyncytial membrane thickness: comparison of
a diabetic and a control case.
A typical vasculosyncytial membrane from a control case (upper) and a







Figure 6.8 The cross-sectional structure of terminal
villi from a control case.
The upper villi contain 2-3 capillary cross-sections and the lower villus contains 2.
The syncytial trophoblast cytoplasm stains denser that the cytotrophoblast. The
central villous core of stroma can be easily visualised. VSM = vasculosyncytial
membrane. Magnification x 700.
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Figure 6.9 The cross-sectional structure of terminal
villi from a diabetic case.
The upper villus contains four capillary cross-sections and the lower villus
contains three. The cytoplasm of the syncytial trophoblast stains darker than that
the cytotrophoblast, reflecting its higher rate ofmetabolic activity.
The central villous core of stroma can be easily visualised.
VSM= vasculosyncytial membrane, magnification x 700.
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Figure 6.10 Cytotrophoblast mitotic activity: Ki-67 staining.
Actively dividing cells are stained positive by the Ki-67 antibody (arrows).
There was no significant difference in the number of positively stained
cytotrophoblast cells per villus on comparative analysis of control cases (top)
and diabetic cases (bottom). Magnification x 320.
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Figure 6.11 Positive and negative control slides for Ki-67
immunohistochemistry.
The positive control slide was a section of tonsil gland. The rapidly dividing
lymphocyte population is correctly stained with the Ki-67 antibody. The
dividing cells stain brown. The negative control was generated by replacing the
primary antibodywith PBS[sol.]/1.5%BSA. Magnification x 320.
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Figure 6.12 Distribution of collagen type IV in the terminal villi of
control and diabetic cases.
Similar staining patterns for collagen IV were seen in villi from control cases (top)




Figure 6.13 Distribution of laminin in the terminal villi from
control and diabetic cases.
Similar staining patterns were seen for laminin in control cases (top) and
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Figure 6.14 Distribution of fibronectin in the terminal villi from
control and diabetic cases.
Similar staining patterns for fibronectin were seen in the viilli from control cases
(top) and diabetic cases (bottom). Magnification x 320.
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Figure 6.15 Distribution of collagen type I in the terminal villi
from control and diabetic cases.
Similar staining patterns for collagen type I were seen in villi from control
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Figure 6.16 Distribution of collagen type III in the terminal villi
from control and diabetic cases.
Similar staining patterns for collagen type III were seen in villi from control





Women with insulin dependent diabetes comprise a large proportion of women with
a prior medical condition considering pregnancy. Prior to the 1960s these women
were actively discouraged against pregnancy due to the high incidence of maternal,
fetal and perinatal complications. In the present day diabetic women now expect a
successful pregnancy outcome with little or no risk to themselves. This change of
expected outcome has been possible primarily due to improvements in replacement
insulin regimes, and to a much lesser extent improved fetal monitoring.
Despite more optimistic outcomes for the mother and fetus population studies still
indicate a significantly raised incidence of complications; especially fetal loss rates,
fetal abnormalities, and raised mean birth weight in pregnancies to diabetic mothers
(Casson et al 1997, Hawthorn et al 1997). The effect of pregnancy on maternal
vascular pathology has not been subjected to such comparable study. The favourable
findings with regard to (a lack of) progression of vascular complications reported in
clinical trials of intensive maternal insulin regimes may not be mirrored in local
populations. The 5-year aim of the St Vincent declaration (World Heath Organisation
1989), that women with diabetes should have a pregnancy outcome similar to that of
non-diabetic women has not been achieved.
The majority of pregnant women enter pregnancy without major recognised vascular
complications. In these women the risk of complications arising in pregnancy
appears to be associated with glycaemic control. Of the fetal complications,
spontaneous miscarriage and congenital abnormalities are the most clearly linked to
maternal glucose levels, and it appears that a relatively modest degree of glycaemic
control is required to reduce the incidence of these complications (Greene et al 1989,
Mills et al 1988, Kitzmiller et al 1991). This degree of glycaemic control must, to be
effective in this respect, be achieved prior to the first 7 weeks of pregnancy, when
fetal organogenesis is occurring. To this aim pre-pregnancy clinics have been
established and have proved beneficial when uptake of this service has been good
(Steel 1996).
In our population of diabetic women only one-third had been seen prior to pregnancy
within the regional tertiary referral diabetic centre, and therefore had access to formal
pre-pregnancy management. The lack of fetal structural abnormalities in our
population of diabetic pregnancies must therefore reflect the improved diabetic care
and glycaemic aims of the whole (non-pregnant) diabetic population. As such this is
an important acknowledgement. Unlike fetal structural abnormalities, which are
usually diagnosed after 18 weeks gestation, we cannot assess the incidence of
spontaneous miscarriage in our studied population of diabetic women. This
complication often predates the 12-week booking appointment and therefore affected
pregnancies would not present for recruitment to the study. However given the
similar range of glycaemic control required to reduce the incidence of both structural
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abnormalities and spontaneous miscarriage the pre-pregnancy target of glycaemic
control in our population of diabetic women is likely to have also been beneficial in
the later effect.
To reduce the incidence of fetal complications occurring in later pregnancy, fetal
macrosomia and intrauterine death, there appears to be a stricter threshold for
maternal glycaemic control. The Diabetes in Early Pregnancy Study (Jovanovic-
Peterson et al 1991) has demonstrated that the risk of fetal macrosomia, due to sub-
optimal maternal glycaemic control is a continuum. The risk of macrosomia is more
closely related to the one-hour post-prandial maternal blood glucose concentrations
than any other index of glycaemic control i.e. HbAlc values. This demonstrates that
small fluctuations in maternal glycaemic control have an important influence on fetal
growth.
Higher post-prandial glucose concentrations are seen in diabetic women compared to
non-diabetic women even in the face of stringent glycaemic control. This occurs
because currently utilised insulin preparations cannot mimic the sharp post-prandial
action of endogenous insulin. Soluble insulin has a peak action around 2-4 hours
after administration, which is not physiological. To reduce the risk of macrosomia
improved insulin preparations are required (Johnstone 1997). New insulin
preparations have been developed with quicker durations of action. Insulin Lispro is
an analogue of human insulin. Its rapid absorption from the subcutaneous injection
site allows for the faster peak of action, less than one hour after injection. This
mimics more closely the physiological insulin release seen in non-diabetic subjects in
response to a carbohydrate load. Studies demonstrate that it significantly reduces
post-prandial glucose concentrations in non-pregnant diabetic subjects (Anderson et
al 1997). Studies of these preparations in pregnancy are at present very limited, but
currently support this finding. Jovanovic et al (1999) demonstrated a beneficial effect
of this insulin in women with gestational diabetes; compared to women treated with
conventional soluble insulin. The group treated with Lispro achieved lower post
prandial glucose concentrations without an increased risk of hypoglycaemic events.
On going clinical trials of new insulin preparations are keenly awaited.
The acknowledgement that currently achievable maternal glycaemic control is
suboptimal with regard to fetal wellbeing is supported by our placental studies. The
placenta and fetuses of diabetic mothers tended to be of increased weight when
compared with those from control pregnancies despite apparent good glycaemic
control during pregnancy. In addition subtle abnormalities of the fetal terminal villus
architecture were determined in the placentae collected from the diabetic group.
These findings although not, as a whole, consistent with significant feto-placental
hypoxia, do represent some form of altered maternal-fetal dynamics in these key
exchange units. As such these alterations may provide a marker for the increased risk
of fetal compromise in late gestation.
In an attempt to reduce the fetal risks of compromise and stillbirth in diabetic
pregnancies a number of studies have assessed the benefit of Doppler ultrasound of
the umbilical arterial blood flow. One suggestion to explain the increased incidence
of acidaemia in fetuses of diabetic mothers is that of impaired fetal placental
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perfusion. If blood flow to the placenta is restricted this should be made evident by
increased impedance within the umbilical artery. One isolated study (Bracero et al
1986) has demonstrated such an association between increased umbilical artery
impedance and poor maternal glycaemic control. This was correlated with an
increased risk of fetal complications such as stillbirth and neonatal morbidity. Other
reported studies of Doppler have not supported this finding (Landon et al 1989,
Dickler et al 1990, Zimmermann et al 1992 and Kofinas et al 1991). Landon et al
(1989) demonstrated no significant association between impedance to flow in the
umbilical arteries and maternal blood glucose or HBAlc levels. Johnstone et al
(1992) studied 128 pregnancies in a Scottish population and confirmed that there
appeared to be no association between impedance to flow in the umbilical arteries
with either short or long term glycaemic control. In this study an antenatal diagnosis
of fetal compromise (non-reassuring CTG or poor biophysical profile) was made in 7
pregnancies which were promptly delivered by caesarean section. Of these 7
pregnancies only three had abnormal Doppler characteristics. The baby in the poorest
condition at birth, requiring ventilation for asphyxia had normal Doppler indices
measured earlier the same day as fetal delivery. The majority of evidence therefore
suggests that in maternal diabetes (without significant complicating vascular
pathology), impedance to flow in the umbilical arteries is not related to either short
or long term maternal glycaemic control, or fetal compromise.
The reason why Doppler assessment of umbilical artery blood flow is not an
effective screening tool for fetal compromise/hypoxia may be explained by our study
findings. We have demonstrated in support of work by Mayhew et al (1984), that the
placenta has a more voluminous vascular capillary network in diabetic pregnancies.
The terminal capillaries comprise the largest volume of placental vessels and are of
the smallest diameter. Blood flow through these capillaries therefore exerts the most
significant effect on the impedance of umbilical artery flow. This has clearly been
demonstrated in studies of pregnancies complicated by intrauterine growth restriction
(Macara et al 1994, Krebs et al 1996). In this condition the reduced numbers of
terminal villi capillary loops appears to be the likely underlying mechanism by which
umbilical artery blood flow is hampered by down stream resistance. In intrauterine
growth restriction the paucity of terminal capillary vasculature is likely to be a
causative mechanism of the fetal condition. In diabetes it is more likely that the
capillary volume of the placenta reflects a primarily fetal drive. Thus in diabetes
even if an increased capillary volume was reflective of fetal acidaemia or relative
fetal hypoxia, the increased capillary volume by its very nature would have a
protective effect on umbilical artery blood flow resistance, negating the value of
assessing this resistance as an index of hypoxia.
Severe maternal hyperglycaemia may have a time dependent effect on feto-placental
blood flow resistance. Ishimatsu et al (1991) demonstrated increased umbilical artery
impedance is association with high maternal blood glucose levels. The umbilical
artery impedance subsequently returned to normal once the maternal glucose
concentration fell to within the euglycaemic range. To act in this away glucose must
be having an effect on the muscularised vessels of the placenta such as those in the
intermediate or stem villi. Any mechanism by which hyperglycaemia reduces
prostacyclin production, or nitric oxide production could underlie this mechanism.
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Doppler assessment of umbilical artery flow in this acute condition, although
attractive as a test in theory, would not be useful. Hyperglycaemia itself is more
readily and less expensively determined. The known adverse fetal effects of such
severe maternal hyperglycaemia are established and should not require additional
indicators.
Evidence of altered placental structure in diabetic pregnancies despite apparent good
maternal glycaemic control coupled with the realisation that these placental
adaptations are not readily assessed by current fetal monitoring techniques leaves us
with difficulties in the management of these pregnancies especially near to term.
Faced with the remaining increased risk of stillbirth in these pregnancies most
clinicians will remain justified in elective delivery of these pregnancies once they
reach expected fetal maturity i.e. around 38 weeks gestation, especially if the fetus is
macrosomic.
Our study of maternal vascular dysfunction has more encouraging findings. The lack
of raised levels of specific cell adhesion molecules in diabetic women during
pregnancy suggests that pregnancy per se, at least in women without major pre¬
pregnancy vascular pathology, does not have a detrimental effect on diabetic
vascular complications. It is therefore no longer justified to dissuade the majority of
diabetic women on the basis of their health. They should be encouraged that
improved glycaemic control is associated with a reduced measure of vascular
dysfunction. Sharing such information can only improve the patient-clinician
relationships, may promote attendance at pre-pregnancy clinics and improve long
term diabetic care and outcomes.
The aim to correlate our maternal vascular findings with our placental findings is
problematic due to the apparent vascular wellbeing in our cohort of diabetic mothers
during pregnancy. However it is likely that this maternal vascular health contributed
to the lack of significant placental villous structural anomalies. The benefits of
glycaemic control summating at the maternal-fetal interface.
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Where do we go from here?
Maternal vascular endothelial function
In our small study of endothelial function in diabetic pregnancy we have
demonstrated a general "normality" of circulating cell adhesion molecules in women
achieving good glycaemic control. Repeating this study in a future cohort of diabetic
women, advantaged by improved insulin preparations, regimes and glycaemic
control is therefore unlikely to demonstrate any additional benefit. A much larger
study however would allow diabetic women to be subdivided on the basis of
circulating CAM concentration centiles. This would facilitate the clinical and
scientific comparison of those with the highest and lowest values, helping to decipher
and weight the significance of improved glycaemic control, and other compounding
factors; such as blood pressure, pre-existing clinical cardiovascular disease, and other
circulating marker concentrations, on the risk of adverse cardiovascular outcome.
As indicated previously CAM concentrations measured in early pregnancy or ideally
pre-pregnancy could be used to assign "risk" to the pregnancy, Increased
surveillance and support of identified 'high risk' pregnancies, which may have a
higher degree of subclinical cardiovascular compromise, may be of therapeutic
value. If CAM assay is not readily available, as indeed it may not be outwith a
research centre, circulating C Reactive Protein (CRP) values may be a useful
alternative prognostic marker. This protein produced by the liver in response to IL-6,
acts as a general down stream marker of inflammation. The circulating concentration
of this protein is readily measured by mainstream hospital laboratories and has been
investigated extensively as a marker of vascular disease progression outwith
pregnancy. A comparison of CRP values to CAM, vWF values and clinical
cardiovascular disease in pregnancy would be of value.
Placental studies in diabetic pregnancy
The use of CAM, or indeed CRP, concentrations to stratify diabetic pregnant women
into groups of differing cardiovascular 'risk' could also aid the study of fetal
outcome, and placental studies. Vascular casting, transmission and scanning electron
microscopy are labour intensive, however targeted comparison of placenta from
pregnancies displaying the highest and the lowest markers of maternal vascular
disease could yield clear specific findings. Such a 'severity classification' of diabetes
could be a superior alternative to White class in future studies of placental structure
and function, aiding comparison of study populations and therefore findings.
Our work focused on the structure of the terminal villi rather than the function. Given
that the structure is grossly conserved, analysis of the function of these villi,
including assessment of fetal endothelial function, has the potential to be more
insightful as to the basis of the continued increased fetal loss rate in diabetic
pregnancies and further studies in this area are required. In-vitro perfusion studies of
villous vascular circuits (placental explants) have been developed (Siman et al 2001,
Sibley et al 2002). This study model may help future studies to determine what we
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need to establish...which are the most critical fetal stresses: hypoxia?, acidosis?,
hyperglycaemia?, hyperinsulinaemia?, or rapid fluxes in each?
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Immunohistochemistry is a widely used technique and essentially is a specialised
stain of tissue sections in which the pivotal reagent is an antibody to a specific tissue
antigen (Mesa-Tejada et al. 1997). The antibody is linked directly or indirectly to an
enzyme i.e. peroxidase or alkaline phosphatase, which when binds to an added
substrate catalyses a reaction to convert the colourless substrate (chromogen) into
coloured end product. Alternatively the antibody can be linked to a fluorescent
marker (Fluroscein, texas red or rhodamine)
8.1.1.1 Antibodies
Antibodies or immunoglobulins are glycoproteins present in the serum and tissue
fluids of all animals. Their production is stimulated when the lymphoid system
comes in contact with immunogenic foreign molecules (antigens) and they bind
specifically to the antigen that induced their formation. They are therefore an
element of the adaptive immune system. A typical antibody molecule has 12
domains arranged in 2 heavy and 2 light chains linked though cystine residues by
disulphide bonds so that their domains lie in pairs. The N terminus domain is the
most variable and contains the antigen-binding site; the other domains are relatively
constant. The constant domains of the heavy chain mediate binding of the antibody
to host tissues including cells of the immune system, phagocytic cells and the first
component (Clq) of the complement cascade, and determine antibody class.
There are five major classes of antibodies: Immunoglobulin (Ig)G, IgA, IgM, IgD,
and IgE. Immunoglobulin G and IgM are the most frequently utilised antibodies in
immunohistochemistry. Immunoglobulin M is the first antibody formed in a humoral
reaction. It is largely confined to the intravascular pool and has a short half-life of 4-
6 days. Immunoglobulin G is the major immunoglobulin in the hyperimmunised
host, accounting for 70-75% of the total immunoglobulin pool. It is evenly
distributed between the intra- and extravascular pools and has a longer survival,
approximately 3 weeks.
For their use in immunohistochemical techniques antibodies may be further
classified as either polyclonal or monoclonal. Polyclonal antibodies are produced by
different cells and are therefore immunochemically dissimilar and react with various
epitopes on the antigen to which they are raised. A number of animals are used to
make polyclonal antibodies, of which the rabbit is the most commonly utilised.
Monoclonal antibodies are produced by cones of plasma cells; therefore antibodies
for a given clone are immunochemically identical. Monoclonal antibodies react with
a specific epitope on the antigen to which they are raised. The main advantage of the
use of monoclonal antibodies, compared to the use of polyclonal antibodies in
immunohistochemistry is their high antigen specificity. Further advantages include
their high homogeneity and absence of inter-batch variability. However their antigen
recognition can be more readily disrupted by tissue fixation techniques. The single
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antigen epitope to which they are raised may not survive fixation, where as other
antigen epitopes may survive allowing antigen recognition by polyclonal antibodies.
8.1.1.2 Enzymes and substrates
Enzymes are proteinaceous catalysts peculiar to living matter. One of the most
commonly used enzymes in immunohistochemistry is horseradish peroxidase.
Horseradish peroxidase is a 40 kd molecular weight protein that contains a heme
group at its active site. The heme group complexes with hydrogen peroxide in the
presence of an electron donor, then subsequently dissociates to produce water and
atomic oxygen. The oxygenation of the electron donor (the chromogen) results in a
coloured insoluble end product.
One of the most commonly used chromogens is three, 3'- Dianrinobenzidine
tetrahydrochloride (DAB). Oxygenation of this compound produces a brown
insoluble end product.
8.1.1.3 Staining methods
The simplest form of immunohistochemistry is the direct method. In this method an
enzyme labeled antibody reacts directly with an antigen in the tissue. The subsequent
addition of a substrate/chromogen concludes the reaction sequence.
More involved methods include the 2 step and 3 step indirect methods, where an
unconjugated primary antibody binds to the tissue antigen. An enzyme labeled
secondary antibody is then directed against the primary antibody (2-step method).
Subsequently an enzyme labeled tertiary antibody may be directed against the
secondary antibody (3-step method). More enzyme can therefore located to the
antigen site, thereby amplifying the staining and improving the sensitivity of the
staining procedure. Further improvement in sensitivity can be made by using the
avidin biotin method (Marty et al 1982) in which a biotinlyated secondary antibody
binds both the primary antibody and to added enzyme labeled avidin or a preformed
avidin biotin enzyme complex. The strong affinity of avidin for biotin at its multiple
biotin binding sites concentrates enzyme at the antigen site.
8.1.2 Enzyme linked immunosorbent assay
Enzyme linked immunosorbent assays (ELISAs) employ similar staining principles
to that described for immunohistochemistry. The aim of the assay is to detect and
quantify the presence of a soluble antigen in biological fluid, rather than to detect
and locate an antigen in a solid tissue specimen.
An antibody is raised to the circulating antigen and is then coated onto the walls of a
microtitre well plate. A further antibody to the antigen is conjugated to an enzyme.
Any antigen in the biological specimen will then form a bridge between the two
antibodies thereby binding the enzyme to the microtitre plate in proportional
quantities to the amount of antigen present. Any unbound enzyme conjugated
antibody is removed by aspiration and washing steps. The amount of conjugate in the
well is detected by a reaction with an added substrate specific for the enzyme, which
during a given limited time period yields a coloured product proportionate to the
amount of the conjugate. The coloured sample is then quantified photometrically. By
analysis of "standards" of known antigen concentration and plotting a curve of signal
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versus concentration, the concentration of the antigen in the biological specimen can
be determined.
8.1.3 Transmission electron microscopy
The best resolution obtainable using light microscopy is 2 um. By the end of the 19th
century scientists recognised that this 2um barrier was inherent to the wavelength
(4um) of visible light. It was subsequently recognised that a beam of electrons
travelling in a vacuum was associated with wave properties. Using this principle
along with the ability to focus a beam of electrons in a magnetic field, Ruska - Knoll
developed the first transmission electron microscope in 1931. Refinements to this
design allow present day electron microscopes to achieve a resolution of 0.2 nm (2 x
10-4 um) with non-biological specimens and 1-2 nm with biological specimens.
Transmission electron microscopy works along the same principles as light
microscopy (Agar et al 1974, Robinson et al). In electron microscopy the "light"
equivalent source is a beam of electrons. Electrons are formed from a heated
tungsten filament enclosed in a cathode plate and are accelerated away from the
filament towards an anode plate, producing the electron beam. The condenser "lens"
assembly is a magnetic coil that focuses the beam of electrons onto the plane of the
specimen. This tissue specimen is cut sufficiently thin to allow the majority of the
electrons to pass through the specimen. This emergent beam is focused by an
objector magnetic coil and then passes through several projector magnetic coils
which form a magnified two dimensional image of the specimen. The viewing screen
of the transmission electron microscope is coated with a fluorescent material which
when bombarded by the projected electrons fluoresces at the visible range. Due to
the grain size of the fluorescent material resolution on the viewing screen is limited
however improved detail may be recorded on fine grain photographic plates when
exposed from beneath the fluorescent plate.
Due to the high magnification only small areas of tissue specimen (< 0.5 mm2) can
be examined at any one time. Multiple samples from tissues that display significant
heterogeneity, such as placental cotyledons should be analysed to ensure adequate
structural representation (Habashi, Burton & Steven 1983).
8.1.4 Scanning electron microscopy
The scanning electron microscope produces topographical images of specimens. It is
similar to the transmission electron microscope in the use of electrons as a source of
short-wave radiation and electromagnetic coils as lenses, however differs in design
and operating mode (Black 1974). In transmission electron microscopy the specimen
image is obtained from transmitted electrons, in scanning electron microscopy when
the electron beam strikes the specimen it interacts with atoms in the surface layer and
a variety of signals are produced. Electrons from the electron beam strike the
specimen and resulting in both elastic collisions (electron-nucleus interactions) and
inelastic collisions (electron-electron interactions) with the atoms of the specimen.
Secondary electrons (resulting from inelastic collision) have low energy and are
detected by a scintillator, which moves closely over the specimen in parallel with the
electron beam, producing a light emission. Less secondary electrons are detected
from depressions than peaks in the specimen and therefore appear as dark spots on
the monitor as opposed to the light spots made by the peaks. Presently scanning
electron microscopes can produce magnification of specimens in the order of
100,000 x and are capable of resolving topographical details of 5 to lOnm.
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8.1.5 Preparation of tissue for electron microscopy
8.1.5.1 Tissue fixation
Due to the high resolution achievable with electron microscopy it is essential that
tissue specimens are tixed in a manner to minimise artifactual changes. Material for
transmission electron microscopy is fixed in gluteraldehyde or paraformaldehyde,
which form strong covalent bond between tissue proteins, preserving structure.
Perfusion fixation of biological specimens speeds fixation of the tissue thereby
reducing hypoxic degradation of the tissue and allows preservation of vessel
dimensions (Kaufmann 1985). Scanning electron microscopy requires that tissue is
dried in a specialised manner as soft tissues readily undergo artifactual changes due
to the properties of liquids as they expend at the tissue surface when evaporating into
gas.
8.1.5.2 Sputter coating
Fixed and dried tissues for analysis by scanning electron microscopy require coating
with a thin layer of conductive material to stop electrons accumulating on their
surface during analysis and thereby reducing obtainable resolution. Sputter coating
uses ionised gas plasma (usually argon) which impinges on a suitable metal target
(e.g. gold) and atoms of that target are subsequently deposited on the tissue
specimen. The coating material is laid down in an even layer and penetrates well into
tissue crevices.
8.2 Clinical subjects
8.2.1.1 Diabetic pregnant subjects
The diabetic women were recruited from the specialised combined diabetic-
antenatal clinic at Glasgow Royal Maternity Hospital over an eighteen-month period
from August 1994. It was a requisite of recruitment that diabetic subjects were
diagnosed as type 1 insulin dependent diabetic prior to pregnancy. Insulin dependent
diabetes was defined as a random blood glucose greater than 11.1 mmol/L or a
fasting blood glucose greater than 7.8 mmol/1. Informed consent was obtained for
maternal blood sampling and post delivery collection of the placentae. Blood was
sampled when clinic attendance corresponded with 12, 18, 28, 32 and 36 weeks'
gestation. To improve sample numbers women advanced further than 12 weeks
gestation were included in the recruitment and sampled at the relevant advancing
gestations, providing relevant retrospective data could be collected from their
hospital records.
8.2.1.2 Management of diabetic pregnant women.
Diabetic pregnant women were referred to the diabetic clinic as soon as pregnancy
was diagnosed. They were then seen fortnightly at this clinic until 32-34 weeks
gestation, thereafter they were reviewed weekly. At each visit they were reviewed by
a diabetologist, an experienced midwife and a dietician. A named obstetric
consultant with a special interest in diabetes was available to review the diabetic
women as needed. At each visit a routine antenatal check was performed, including
the measurement of maternal blood pressure and urinalysis. Fundoscopy was




8.2.1.3 Assessment of glycaemic control
Insulin requirements were adjusted on the basis of twice weekly 4 and 7 point blood
glucose measurements. Diabetic control was also assessed by HbAlc determination
at each clinic visit. Episodes of poor glycaemic control required patient admission to
hospital for stabilisation. During labour glycaemic control was maintained using a
glucose potassium intravenous infusion along with an intravenous insulin infusion.
The rate of the latter was adjusted on the basis of two hourly blood glucose readings.
8.2.1.4 Assessment of fetal complications
Fetal well being was assessed by AFP screening (primarily for neural tube defects) at
15 weeks gestation. A detailed ultrasound scan for fetal anomalies was routinely
performed at 18 weeks gestation. In the third trimester fetal biometry scans were
performed at least fortnightly.
Elective delivery of diabetic women was planned for 38 to 39 weeks' gestation.
Induction of labour was the preferred protocol for this. During labour fetal
monitoring was assessed by a continuous cardiotocograph tracing. Following
delivery the infants were routinely admitted to the special care unit for several hours
to monitor for hypoglycaemia and then reviewed daily by the hospital paedialric
staff. Fetal weight at delivery was related to birth weight centiles obtained from a
local database (Small and Forbes 1983).
8.2.2 Non-diabetic pregnant subjects
Non-diabetic pregnant women to serve as a control population were recruited
randomly from the low risk antenatal clinics held at the same hospital over a similar
time scale from August 1994. Recruited non-diabetic pregnant women had no
current or past medical illness. Parous women had previously uncomplicated
pregnancies.
Recruitment of diabetic and non-diabetic women required that their pregnancies had
been adequately dated with an estimated date of delivery determined by ultrasound
scan before 16 weeks gestation.
8.2.3 Non-pregnant subjects
Type 1 insulin dependent non-pregnant women were recruited from the diabetic
clinic at Glasgow Royal Infirmary. A hospital located within a mile of the maternity
hospital in an attempt to recruit control subjects from the same geographical
population. It is known however that only a third of pregnant diabetic women
attending Glasgow Royal Maternity hospital attend this hospital's diabetic clinic-
prior to pregnancy.
Non-pregnant non-diabetic women were recruited from the staff of Glasgow Royal
Infirmary and Glasgow Royal Maternity Hospital, providing they had no relevant
current or past medical history.
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8.3 Non- clinical materials
8.3.1 General biochemicals
The following chemical were purchased from BDH (Poole, England); acetic acid,
buffer tablets (pH 4, 7.4 and 9.2), decon 75, formaldehyde, hydrochloric acid,
sodium chloride, sodium citrate, calcium chloride, potassium hydroxide pellets,
sodium hydroxide pellets and cupric sulphate (Anala R)(copper sulphate
pentahydrate).
The following reagents were purchased from the Sigma Chemical Company (Dorset,
England); 30% w/v hydrogen peroxide, Harris haematoxylin, 2% silane and tris
chloride.
Ethanol, methanol and acetone (Anala R quality) were purchased from Hayman
Limited (Essex, England).




Glasgow Royal Infirmary: MSE Mistral 4L was purchased from Fisons (Sussex,
England) and the Damon CRU 5000 from Life Sciences (Hampshire, England).
Glasgow Royal Maternity Hospital: The Damon Clini-cool centrifuge was purchased
from Life Sciences (Hampshire, England).
8.3.2.2 Refrigeration and Freezers
The Scandinova (SLF 111) fridge and the Blomberg (-20) freezer were purchased
from Comet (Glasgow, Scotland). The -70 freezer was purchased from Scotlab
(Coatbridge, Scotland).
8.3.2.3 Ovens
The proline power wave 800 microwave was obtained from Comet (Glasgow,
Scotland). Gallenkamp Prelude incubator (Scotlab, Lanarkshire, Scotland)
8.3.2.4 Pipettes
Volumes of solutions in the range of l-25ul were transferred accurately using digital
pipettes from Scotlab (Coatbridge, Glasgow). Volumes of solutions in the range of
10- lOOOul were transferred using Finn-pipettes purchased from Labsystems





Measurement of weighted reagents was performed on the Stanton fine balance,
Fisons (Sussex, England) and on the Sartorius balance BDH (Poole, England).
8.3.2.6 pH measurement
Measurements of pH were carried out using a Kent 7020 pH meter purchased from
BDH (Poole, England). This apparatus was regularly standardised using a solution of
pH 4, pH 7 or pH 9.2 buffer tablets.
8.3.2.7 Miscellaneous
Glassware was purchased from BDH (Poole, England). Plastic syringes and
disposable 21G needles were obtained from Becton-Dickinson (Madrid, Spain).
Glass microscope slides, coverslips and DPX mountanl were purchased from BDH
(Poole, England). The Corning magnetic stirrer and the whirlimixer were obtained
from BDH (Poole, England)
8.3.3 General solutions and buffers
Distilled Deionised Water (ddH20)
All solutions and buffers were prepared using ddh20, obtained from a Milli 0 Plus
water purification system purchased from Millipore S.A. (Molsheim, France).
Volumes approximating 500ml were autoclaved and stored at 4oC.
0.9% Sodium Chloride
9g of NaCl was dissolved into 1L ddH20. Volumes approximating 500ml were
autoclaved and stored at 4oC.
Tris buffered saline (TBS) buffer
10M Hydrochloric acid was added to 25ml 0.2M tris until a pH of 7.4 was obtained.
This was made up to a final volume of 100ml with ddH20. The Tris HC1 was added
to 900ml 0.9% sodium chloride to give the final solution.
Citrate Buffer
2. lg of anhydrous citric acid was dissolved in ddH20. The pH was titrated to pH 6.0
with 2M NaOH.
0.1% Trypsin solution
0.3g of trypsin (type 111 from bovine pancreas), obtained from Sigma Chemicals Co.
(USA) and 0.3g of CaCl were added to 300ml heated tris buffered saline. This
solution was prepared immediately prior to use.
0.5% Copper sulphate solution
2g CuS04 was dissolved in 400 ml tris buffered saline.
Phosphate buffer(PBS)
0.2M solution of disodium hydrogen orthophosphate (DHO) was prepared by
dissolving 2.83g of DHO in lOOmls ddH20 [Sol A], 2.81g of citric acid was
dissolved in 100ml ddH20 to make 0.1M solution of citric acid [SolB]. Neutral
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phosphate buffer was prepared by adding 86ml of solution A to 17.7 ml of solution
B. The buffer was stored at 4oC until use.
4% neutral buffered formalin
80 mis of 10 % formalin (containing 4% formaldehyde) was added to 120 mis
phosphate buffer.
8.3.4.1 ELISA reagents and disposable apparatus
The VCAM-1, ICAM-1 and E-Selectin ELISA Kits were purchased from R+D
Systems (Oxon, England). Microcentrifuge tubes, sterile pastettes and pipette tips
were purchases from Alpha Laboratories (Hamphire, England). Rabbit anti-human
vWf polyclonal antibody, HPR-conjugated rabbit anti-human vWF polyclonal
antibody and ortho-phenylenedione (OPD) chomogen were all obtained from Dako
Ltd, (High Wycombe). vWF (5th British standard for blood coagulation factors) was
obtained from NIBSC (London).
8.3.4.2 ELISA non-disposable equipment
Microplate reader: Dynatech MR5000, Dynatech medical products (Guernsey,
Channel Isles)
8.3.5.1 Immunohistochemistry reagents and disposable apparatus
Rabbit anti-human ki-67 (MIB-1) antibody, mouse anti- human macrophage (CD68)
antibody, rabbit immunoglobulin fraction, mouse IgG negative control, biotinylated
goat anti-mouse immunoglobulins, 3,3'-diaminodenzidinetetrachloride (DAB),
peroxidase conjugated steptavidin and the wax pen were purchased from DAKO Ltd
(High Wycombe, England) Biotinlyated goat anti-rabbit antibody was obtained from
the Vector Elite ABC rabbit kit, Vector laboratories (Peterborough, England) Highly
purified anti-goat collagen type I and collagen type IV from Europath Ltd
(Cornwall, UK), purified anti-rabbit collagen type III from biogenesis(Bournemouth
UK). Anti-laminin and anti-fibronectin from DAKO Ltd. (Buckinghamshire, UK).
Goat Serum was obtained from the Scottish Antibody Production unit (SAPU):
Carluke, Scotland). Normal human serum was obtained from Sigma (St Louis USA).
3-aminopropyl-triethoxy-silane was obtained from Sigma (St Louis, USA). Xylene
(Anala R) was purchased from BDH
8.3.5.2 Immunohistochemistry non-disposable equipment
The Grant waterbath was obtained from Scotlab (Coatbridge, Scotland). Slide trays
and racks were purchased from Philip Harris LTD (Aberdeen, Scotland)
The pressure cooker was purchased from Lakeland Plastics (UK)
Histokinette 2000 was purchased from Medical Laboratory Equipment services. The
tissue Tek 3 and green uni-cassettes (to be used with this machine) were purchased
from Bayer Diagnostics (Basingstoke, England). The microtome was purchased from




8.3.6.1 Scanning Electron microscopy reagents and disposable
apparatus
Methyl methacrlylate and hydrogen peroxide pellets were purchased from BDH
Suppliers Ltd. (Poole, England). Baxter (Norfolk, England) supplied 250ml bags of
0.9% saline. Mercox® and catalyst were purchased from Japan Vilene Hospital
(Hamburg, Germany). Stubs and storage boxes were purchased from Agar Scientific
Ltd. (Essex, UK). Mounting glue was obtained from Neubauer Chemikalien
(Munster, Germany). Venflons (21G) were purchased from Viggo Spectramed
(Helsingburg, Sweden). Sutures (2/0 Chromic catgut were obtained from Ethicon
(Edinburgh Scotland). Photographic film (Ilford Pan F50) was obtained from HA
west (Clydebank, Scotland)
8.3.6.2 Scanning electron microscopy general apparatus
Critical point drier (CPD 750) was purchased from Biorad Microscience Division
(Hertforshire, England). The Edwards coating unit was obtained from VG Scientific
(Crowley, England). The Gallenkamp Prelude incubator was obtained from Scotlab
(Lanarkshire, Scotland). The digital scanning electron microscope (DSM-940) and
the stereomicroscope were purchased from Zeiss (Switzerland).The light microscope
was obtained from Leitz-Labovert (Wetzler, Germany)
8.3.7.1 Transmission electron microscopy reagents and disposable
apparatus
The following were purchased from Agar Scientific Ltd; Araldite, 25% EM grade
gluteraldehyde, Kodak D19 solution, Rapid fix solutions A&B, dodecenyl succinic
anhydride (DDSA), Kodak 4489 EM grade film, tri-dimethylaminomethyl phenol
(DMP30) and Kodak 4489 thick base EM film. Lead nitrate and uranyl acetate were
purchased from Sigma. Osmium tetroxide, glass strips, disposable vials and trufs
were purchased from Leica (UK) Ltd. (Milton Keynes, England). Disposable blades
were purchased from Bayer Diagnostics (Hampshire, England).
8.3.7.2 Transmission electron microscopy general apparatus
The LKB ultramicrotome was obtained from Leica (UK) Ltd. (Milton Keynes, UK).
The plate degasser was obtained from VG Scientific (Crawly, England. The
transmission electron microscope was obtained from Philips (UK).
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Complexes of streptavidin and
biotinylated enzyme
Biotin-labelled secondary antibody (anti
primary antibody)
Unlabelied primary antibody
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Circulating Cell Adhesion Molecule
Concentrations in Diabetic Women During
Pregnancy
JANICE L. GIBSON, MB, ChB, FIONA FYALL, PhD, FIONA BOSWELL, ANNE YOUNG,
ANGUS C. MACCUISH, MD, FRCP, AND IANA. GREER, MD, MRCOG, FRCP, MFFP
Objective: To determine whether circulating concentrations
of defined cell adhesion molecules, which are thought to
reflect endothelial expression, are increased in insulin-
dependent diabetic women during pregnancy.
Methods: Pregnant diabetic women demonstrating good
glycemic control and without major complications before
pregnancy were studied at 8-12 (n = 15), 18 (n = 15), 28 (n =
16), 32 (n = 16), and 36 (n = 16) weeks' gestation. A subgroup
of ten diabetic women was sampled longitudinally through
all five gestational ages. The diabetic women were compared
with healthy nondiabetic women sampled cross sectionally
at 12 (ti = 20), 28 (n = 19), and 36 (« = 19) weeks' gestation.
Nonpregnant diabetic (n = 22) and nonpregnant nondiabetic
women (n = 28) also were studied. Plasma concentrations of
the cell adhesion molecules E-selectin, intercellular adhe¬
sion molecule-1 (ICAM-1), and vascular endothelial cell
adhesion molecule-1 (VCAM-1) were measured by enzyme-
linked immunosorbent assay.
Results: Significantly higher median (range) concentra¬
tions of E-selectin (63.0 [20.2-107.0] ng/mL) and ICAM-1
(281.5 [171.6-778.4] ng/mL) but not VCAM-1 (459.7 [301.0-
909.7] ng/mL) were found in nonpregnant diabetic women
compared with nonpregnant nondiabetic women (43.5 [18.1—
93.2], 243.6 [174.4-329.2], and 476.0 [253.8-929.4] ng/mL,
respectively). During pregnancy these significant differences
between diabetic and control groups were lost. The median
(range) concentration of E-selectin (50.0 [21.2-96.3] ng/mL)
was significantly lower in pregnant compared with nonpreg¬
nant diabetic women. The plasma concentrations of E-
selectin and ICAM-1 did not change significantly with
gestation in either diabetic or nondiabetic pregnant groups.
Vascular endothelial cell adhesion molecule-1 concentration
changed significantly with gestation in the diabetic pregnant
group only.
Conclusion: Circulating concentrations of defined vascular
cell adhesion molecules are not increased abnormally in
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diabetic women with good glycemic control during other¬
wise uncomplicated pregnancy. (Obstet Gynecol 1997;90:
874-9. © 1997 by The American College of Obstetricians
and Gynecologists.)
Despite recent major advances in both obstetric care
and medical management of diabetes, women with this
disease remain at greater risk for morbidity during their
pregnancy than nondiabetic women. Two factors con¬
tributing to this maternal morbidity are preeclampsia1
and progression of microvascular disease, in particular,
retinopathy.2"4 The pregnancy-related mechanisms be¬
hind these conditions are unknown but are associated
with vascular damage and dysfunction.
It is well recognized that the endothelium itself can
play a key role in such vascular pathology by a variety
of mechanisms. One such mechanism is through the
expression of an array of leukocyte-specific cell adhe¬
sion molecules, each of which is induced by a variety of
stimuli and will recognize specific ligands on various
subsets of leukocytes, promoting leukocyte attachment
and activation.5 Once activated, leukocytes can be pow¬
erful mediators of vascular damage and inflammation.
Activation of neutrophils has been demonstrated to
occur in diabetic and preeclamptic pregnancy and in
nonpregnant diabetic women.6,7 Neutrophils are acute
mediators of vascular damage that release a variety of
toxic agents, including elastase and other proteases,
toxic oxygen radicals, and leukotrienes, on activation.8,9
Three of the main endothelial-expressed cell adhesion
molecules associated with leukocyte activation are E-
selectin, a member of the selectin family of cell adhesion
molecules; and intercellular cell adhesion molecule-1
(ICAM-1) and vascular endothelial cell adhesion mole¬
cule-1 (VCAM-1) from the immunoglobulin superfam-




leukocytes, including neutrophils. E-selectin provokes
the initial loose attachment of the leukocyte to the
endothelium and, in the presence of fluid sheer stress,
the subsequent rolling of the leukocyte along the endo¬
thelial surface. Intercellular cell adhesion molecule-1
mediates firm adherence and leukocyte activation. Vas¬
cular endothelial cell adhesion molecule-1 supports the
adhesion of lymphocytes, monocytes, and eosinophils
to the endothelium.
Surface expression of these cell adhesion molecules is
associated with their shedding into the peripheral cir¬
culation. The exact mechanism of this process and the
physiologic function of these shed molecules remain
unclear; however, circulating adhesion molecule con¬
centrations have been shown to be increased in a
number of disease states, including diabetes10,11 and
preeclampsia.12
We hypothesized that in diabetic women, pregnancy
is associated with an increased endothelial expression
and shedding of cell adhesion molecules. If endothelial
expression of cell adhesion molecules is increased, this
may be associated with both the leukocyte activation
and the increased incidence of vascular pathology pre¬
viously documented to occur in diabetic women during
pregnancy.1-4 The aim of this work was to determine
the circulating concentrations of three endothelial cell
adhesion molecules—E-selectin, ICAM-1, and VCAM-
1—throughout diabetic pregnancy, to compare these
with the concentrations found throughout nondiabetic
pregnancy and in nonpregnant diabetic women, and to
correlate our findings with clinical outcome.
Materials and Methods
Sample size was calculated on the basis of 90% power
with significance set at the 5% level. This indicated a
minimal sample size of 12 women in each group, based
on data from a previous report12 of cell adhesion
molecule concentrations in pregnant and nonpregnant
women. Pregnant women with type 1 insulin-dependent
diabetes attending the combined antenatal-diabetic
clinic at Glasgow Royal Maternity Hospital were re¬
cruited into the study during an 18-month period.
Blood samples were drawn when attendance coincided
with the following gestational ages: 8-12 in = 15), 18
(n = 15), 28 (11 = 16), 32 (n = 16), and 36 (n = 15) weeks'
gestation. Ten women were sampled longitudinally
throughout all five designated gestations of pregnancy.
At each time point studied, additional blood was drawn
to assess glycemic control by glycated hemoglobin
measurement.
Healthy nondiabetic women attending a low-risk
antenatal clinic were studied as controls and were
sampled cross sectionally at 12 in = 20), 28 (n = 19), and
36 (n = 19) weeks' gestation. Nondiabetic women
incurring complications during pregnancy were ex¬
cluded from the study. Nonpregnant diabetic and non¬
pregnant nondiabetic women also were studied in = 22
and n = 28, respectively). Glycated hemoglobin was
measured at the time of sampling in the diabetic group.
All subjects gave informed consent. The study was
approved by the local ethics committee.
Peripheral venous blood was collected into prechilled
tubes containing lithium heparin as anticoagulant.
Plasma was prepared by centrifugation at 2000 X g at
4 C within 5 minutes of blood sample collection. Ali-
quots of plasma were stored at — 70 C until use. The cell
adhesion molecules were measured by enzyme-linked
immunosorbent assay (R&D Systems Europe Ltd.,
Abingdon, Oxon, UK).
Cell adhesion molecule concentrations approximated
normal distribution in pregnant but not nonpregnant
groups. Data from nonpregnant diabetic and nondia¬
betic subjects were analyzed by the Mann-Whitney U
test. During pregnancy, change relative to gestation
within the diabetic subgroup in = 10) was assessed by
multiple-measures analysis of variance and within the
control group by simple analysis of variance. Subse¬
quent comparison between the pregnant diabetic and
nondiabetic groups was assessed by Student t test and
used all data available from diabetic subjects. The
Mann-Whitney U test was used to compare pregnant
and nonpregnant women.
The effect of gestation on glycated hemoglobin values
was assessed by multiple-measures analysis of vari¬
ance. Subsequent comparison of pregnant and nonpreg¬
nant glycated hemoglobin values was assessed by Stu¬
dent f test. Maternal age of studied groups was
compared by Student t test. Parity, smoking habit, and
White class (for diabetic groups)13 were compared by y2
analysis.
Residts
There was no significant difference between the groups
in terms of parity, smoking habit, or White class (Table
1). Diabetic women were younger than nondiabetic
controls. One diabetic woman had progressive retinop¬
athy during pregnancy and required laser photocoagu¬
lation for proliferative disease and early delivery (at 36
weeks' gestation). No diabetic woman developed pre¬
eclampsia or gestational hypertension. Diabetic control
as assessed by glycated hemoglobin determination im¬
proved significantly with gestation. By 18 weeks' ges¬
tation, glycated hemoglobin measurements were re¬
duced significantly compared with those seen in
nonpregnant diabetic women and remained so for the
remainder of pregnancy (Table 1).
VOL. 90, NO. 6, DECEMBER 1997 Gibson et al Adhesion Molecules in Diabetes 875















Diabetic Nonpregnant 22 27.5 (6.9)' 10 4 2B, 11C, 8D, 1R 8.5 (2.3)
Diabetic 12 15 24.5 (5.3)' 4 1 6C, 6D, IB 7.6 (1.4)
Diabetic 18 15 24.7 (5.6) 5 1 6C, 7D, 2B 6.5 (1.2)'
Diabetic 28 16 24.0 (5.0) 7 2 9C,7D 6.3 (0.7)®
Diabetic 32 16 25.0 (4.7) 4 3 8C, 6D, IB, 1R 6.3 (0.8)®
Diabetic 36 15 24.7 (4.5)' 7 3 9C, 5D, 1R 6.4 (0.7)"
Diabetic Subgroup 10 24.3 (5.4) 4 1 5C,5D
Control Nonpregnant 28 30.7 (4.2)' 11 4
Control 12 20 28.8 (5.8)' 9 7
Control 28 19 27.1 (5.6) 10 4
Control 36 19 28.4 (4.7)' 11 5
Data are presented as mean (standard deviation).
•Glycated hemoglobin values changed significantly with gestation in the diabetic subgroup (P < .002, data not shown). Comparison of
gestational with nonpregnant glycated hemoglobin values was assessed by Student f test. Normal reference range 3.4-5.2%.
'Comparison of maternal age between study groups at corresponding gestations was assessed by Student f test (P < .05).
* P < .02.
- 5 P = .002.
! P < .05.
All cell adhesion molecule concentrations were above
the detection limit of the applied assay. Comparison of
the nonpregnant groups (Figure 1) demonstrated sig¬
nificantly increased median (range) concentrations of
the cell adhesion molecules E-selectin (63.0 [20.2-107.0]
ng/mL) and ICAM-1 (281.5 [171.6-778.4] ng/mL) but
not VCAM-1 (459.7 [301.0-909.7] ng/mL) in diabetic
women compared with those found in nondiabetic
women (43.5 [18.1-93.2], 243.6 [174.4-329.2], and 476.0
[253.8-929.4] ng/mL, respectively).
In pregnancy, there was no significant change in the
measured concentrations of the cell adhesion molecules
E-selectin and ICAM-1 with respect to gestation in
either the diabetic or control group (mean values
throughout gestation for both groups are shown in
Table 2). The latter observation allowed pregnancy to be
assessed as a single time point in subsequent analysis of
this data. For any woman sampled more than once
during her pregnancy, one of the available values was
selected randomly to represent pregnancy. (Available
values were printed separately, folded to conceal the
printed value, and then placed and mixed in a vessel,
from which one was drawn by a nonauthor.) Subse¬
quent comparisons also included the data available
from the diabetic women not sampled longitudinally
throughout pregnancy. Therefore, a total of 26 diabetic
and 58 control "pregnancy" values were available for
analysis. No significant difference was found between
mean (standard deviation) diabetic pregnant E-selectin
and ICAM-1 concentrations (50.2 [16.0] and 274.5
1107.5] ng/mL, respectively) and nondiabetic preg¬
nancy cell adhesion molecule concentrations (46.5 [17.6]
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Figure 1. Box plots (median, 25th and 75th percentile, tenth and 90th
percentile) of plasma cell adhesion molecule concentrations in non¬
pregnant diabetic women and controls. The Mann-Whitney U test was
used to compare diabetic and control data. ICAM = intercellular cell
adhesion molecule; VCAM = vascular endothelial cell adhesion
molecule.
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Table 2. Gestational Plasma Cell Adhesion Molecule Concentrations
Study Weeks' E-selectin ICAM-1 VCAM-1
group gestation No. (ng/mL) (ng/mL) (ng/mL)
Diabetic 12 10 55.1 (16.2) 261.9 (44.8) 422.0 (132.0)'
Diabetic 18 10 54.4 (13.9) 274.8 (61.8) 390.2 (79.3)*
Diabetic 28 10 55.1 (16.4) 263.5(41.2) 400.8 (113.2)'
Diabetic 32 10 57.9 (20.0) 271.6 (87.1) 494.1 (144.2)'
Diabetic 36 10 55.1 (13.2) 248.7 (44.7) 560.8 (129.3)'
Control 12 20 44.7 (9.8) 268.6 (102.7) 446.8 (117.1)
Control 28 19 48.8 (20.9) 293.9 (89.2) 420.1 (134.9)
Control 36 19 45.8 (19.7) 293.6 (101.6) 502.6 (139.2)
ICAM = intracellular cell adhesion molecule; VCAM = vascular endothelial cell adhesion molecule.
Data are presented as mean (standard deviation). Change in concentration with respect to gestation in the diabetic group was assessed by
multiple-measures analysis of variance. Change relative to gestation in the control group was assessed by simple analysis of variance. Vascular
endothelial cell adhesion molecule-1 concentration changed significantly with gestation in the diabetic population.
* P < .05.
values in pregnant and nonpregnant women revealed
that the median (range) circulating concentration of
E-selectin was significantly lower (P < .05) in pregnant
diabetic women (50.0 [21.2-96.3] ng/mL) than in non¬
pregnant diabetic women (63.0 [20.2-107.0] ng/mL).
There was no significant difference in the concentration
of ICAM-1 between diabetic groups or of both mea¬
sured cell adhesion molecules between nondiabetic
pregnant and nonpregnant groups.
The circulating concentration of VCAM-1 changed
significantly with respect to gestation in the diabetic
pregnant subgroup but not the nondiabetic pregnant
group. Mean values throughout gestation for both
groups are given in Table 2. However, there was no
significant difference in VCAM-1 concentrations be¬
tween diabetic and nondiabetic women at any corre¬
sponding gestation. (All available diabetic data were
used in this analysis and the following analyses.) Com¬
parison of values in pregnant and nonpregnant diabetic
women revealed a significant difference (P < .02) be¬
tween diabetic women sampled at 36 weeks' gestation
(n = 15) (median [range] 582.8 [387.0-848.6] ng/mL)
and nonpregnant diabetic women (n = 22) (459.7
[301.0-909.7] ng/mL) but not between any other gesta¬
tional or nonpregnant data. There was no significant
difference between control pregnant and nonpregnant
VCAM-1 data.
Discussion
Our finding that circulating concentrations of E-selectin
and ICAM-1 are elevated selectively in nonpregnant
diabetic women compared with those measured in
nonpregnant nondiabetic women corresponds with
findings of previous studies10,11 in the general diabetic
population. Increased endothelial expression of these
cell adhesion molecules, reflected by increased circulat¬
ing concentrations, provides a mechanism for the neu¬
trophil activation and the vascular damage demon¬
strated to occur in diabetes.
Clinical studies'"4 have demonstrated an increased
incidence of vascular pathology in diabetic women as a
consequence of pregnancy. Based on these studies, we
hypothesized that pregnancy in diabetic women would
be associated with further increased circulating concen¬
trations of cell adhesion molecules. However, we found
no such increase in the circulating concentrations of
E-selectin and ICAM-1 in the pregnant diabetic group
compared with the nonpregnant diabetic group or with
increasing gestation. The concentration of E-selectin
actually decreased from that seen in the nonpregnant
diabetic women as a consequence of pregnancy.
Altered shedding, dilution, or excretion of cell adhe¬
sion molecules may occur as a result of pregnancy and
therefore the circulating concentrations of these mole¬
cules may no longer represent their endothelial expres¬
sion. However, the finding of constant circulating con¬
centrations of these cell adhesion molecules throughout
nondiabetic pregnancy and in nondiabetic pregnant
and nondiabetic nonpregnant groups suggests that this
is not the case, because we would not expect any change
in the endothelial expression of cell adhesion molecules
during uncomplicated pregnancy in this group of
women. Therefore, although the possibility of altered
renal clearance in pregnant diabetic women cannot be
excluded, the circulating concentrations of E-selectin
and ICAM-1 measured in the present population of
diabetic women suggest that pregnancy per se is not
associated with increased endothelial expression of
these cell adhesion molecules.
The specific population of diabetic women participat¬
ing in the present study may account for apparent
discrepancy between these findings and the outcome of
the referred clinical studies. Studies specifically deter¬
mining the effect of pregnancy on retinopathy, such as
that by Klein et al4 and the large diabetes in early
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pregnancy study,14 have stressed the importance of
poor glycemic control at the onset of pregnancy, rapid
improvement of glycemic control during pregnancy,
and advanced retinopathy before pregnancy as the
major risk factors for progression of retinopathy.
Clearly, such factors have been proven to be pivotal to
progression of retinopathy on the short-term introduc¬
tion of tight glycemic control in the nonpregnant
state.15-18 The women in the present study demon¬
strated reasonable glycemic control at the onset of
pregnancy, and although their control improved signif¬
icantly during pregnancy, this may not have been so
abrupt as to provoke increased endothelial expression
of cell adhesion molecules, vascular damage, and reti¬
nal pathology.
A clinical study1 demonstrating an increased inci¬
dence in preeclampsia in pregnancies in diabetic
women has shown that, as for progressive microvascu¬
lar disease, the incidence of this complication is in¬
creased in women with advanced diabetic disease as
classified by White class. The limited number of dia¬
betic women participating in our study and the lack of
women with advanced diabetic disease may explain
why no woman in the present study developed this
complication. We cannot assess from this study
whether women with more advanced diabetes would
demonstrate increased endothelial expression of cell
adhesion molecules during pregnancy that could in
turn be associated with vascular complications, and this
requires further investigation. Only one woman with
proliferative retinopathy during pregnancy was sam¬
pled during this study. The concentrations of cell adhe¬
sion molecules found within the plasma from this
woman (E-selectin 48.1 ng/mL and ICAM-1 263.6
ng/mL at 36 weeks' gestation) were not outside the
range of concentrations measured in diabetic women
without complication.
It is tempting to speculate that the decreased circu¬
lating concentration of E-selectin found in our popula¬
tion of diabetic women during pregnancy reflected their
improved glycemic control as a consequence of this
event. Hyperglycemia has been proved to cause vascu¬
lar damage in animal models,19 and improved glycemic
control is associated universally with delayed onset and
progression of microvascular disease in both animal
and clinical studies when maintained over the long
term.20 The introduction of improved glycemic control
over a short period, such as during pregnancy, has a
more complex relationship with vascular pathology. It
is possible that the small but significant improvement in
glycemic control in our population of women, who
demonstrated good glycemic control before the onset of
pregnancy, was of a magnitude to provoke only a
positive effect on the endothelial environment. We did
not correlate this short-term improvement in glycemic
control, as assessed by glycated hemoglobin measure¬
ments, with E-selectin concentrations, because of this
complex relationship and because part of the reduction
in glycated hemoglobin values may be explained by a
physiologic increased flux of red blood cells into the
circulation during pregnancy.21
No difference in the circulating concentration of
VCAM-1 was found between nonpregnant diabetic and
nondiabetic women. The ligand recognized by VCAM-1,
very late antigen-4, is expressed not on neutrophils but
on other leukocytes important in the later stages of
inflammation. A selective increased endothelial expres¬
sion of E-selectin and ICAM-1 in diabetic subjects may
emphasize that the vascular endothelial damage occur¬
ring in this disease is an ongoing acute process reflect¬
ing short-term fluctuations in glycemic control, em¬
phasizing the need for improved control, such as that
demonstrated on a daily basis during pregnancy, in the
general diabetic population.
The significance of the change in VCAM-1 concentra¬
tion during diabetic pregnancy is unclear. A similar
pattern of circulating VCAM-1 concentration was seen
throughout nondiabetic pregnancy but did not attain
statistical significance. This pattern, an initial decrease
and then progressive increase, resembles the physio¬
logic change in blood pressure during pregnancy and
hence could be a response to, or an altered shedding
due to, this characteristic. The circulating concentration
of VCAM-1 has been demonstrated to be increased in
preeclampsia.12 However, if increased endothelial ex¬
pression of VCAM-1 provides a mechanism for vascular
dysfunction, this dysfunction obviously is not primarily
neutrophil mediated.
In conclusion, our findings do not support the hy¬
pothesis that increased endothelial expression and
shedding of cell adhesion molecules occur in diabetic
women as a consequence of pregnancy. Rather, our
findings suggest that the endothelial stimulus to neu¬
trophil activation and, hence, vascular damage may
decline in these women during pregnancy, possibly as a
consequence of their improved glycemic control during
this period, a feature that may be reassuring to patient
and physician alike.
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